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Résumé 
 
 
Rôle du répresseur transcriptionnel ICER dans la pathogenèse moléculaire du diabète de 
type 2 
 
Dimitri Favre, Service de médecine interne, Centre Hospitalier Universitaire Vaudois 
 
Le diabète de type 2 (DT2) est une maladie métabolique qui affecte plus de 200 millions de personnes 
dans le monde. La progression de cette affection atteint aujourd’hui des proportions épidémiques 
imputables à l’augmentation rapide dans les fréquences du surpoids, de l’obésité et de la sédentarité. La 
pathogenèse du DT2 se caractérise par une diminution de l’action de l’insuline sur ses tissus cibles – un 
processus nommé insulino-résistance – ainsi qu’une dysfonction des cellules β pancréatiques sécrétrices 
d’insuline. Cette dernière détérioration se définit par une réduction de la capacité de synthèse et de 
sécrétion de l’insuline et mène finalement à une perte de la masse de cellules β par apoptose. Des facteurs 
environnementaux fréquemment associés au DT2, tels l’élévation chronique des taux plasmatiques de 
glucose et d’acides gras libres, les cytokines pro-inflammatoires et les lipoprotéines de faible densité 
(LDL) oxydées, contribuent à la perte de fonction des cellules β pancréatiques. 
 
Dans cette étude, nous avons démontré que le facteur de transcription « Inducible Cyclic AMP Early 
Repressor » (ICER) participe à la progression de la dysfonction des cellules β pancréatiques et au 
développement de l’insulino-résistance. Son expression étant gouvernée par un promoteur alternatif, la 
protéine d’ICER représente un produit tronqué de la famille des « Cyclic AMP Response Element 
Modulator » (CREM), sans domaine de transactivation. Par conséquent, le facteur ICER agit comme un 
répresseur passif qui réduit l’expression des gènes contrôlés par la voie de l’AMP cyclique et des « Cyclic 
AMP Response Element Binding protein » (CREB).  
 
Dans les cellules sécrétrices d’insuline, l’accumulation de radicaux d’oxygène libres, soutenue par les 
facteurs environnementaux et notamment les LDL oxydées – un processus appelé stress oxydatif – induit 
de manière ininterrompue le facteur de transcription ICER. Ainsi activé, ce répresseur transcriptionnel 
altère la capacité sécrétoire des cellules β en bloquant l’expression de gènes clés de la machinerie 
d’exocytose. En outre, le facteur ICER favorise l’activation de la cascade de signalisation « c-Jun N-
terminal Kinase » (JNK) en réduisant l’expression de la protéine « Islet Brain 1 » (IB1), altérant ainsi les 
fonctions de biosynthèse de l’insuline et de survie des cellules β pancréatiques. 
 
Dans le tissu adipeux des souris et des sujets humains souffrant d’obésité, le facteur de transcription ICER 
contribue à l’altération de la réponse à l’insuline. La disparition de la protéine ICER dans ces tissus 
entraîne une activation persistante de la voie de signalisation des CREB et une induction du facteur de 
transcription « Activating Transcription Factor 3 » (ATF3). A son tour, le répresseur ATF3 inhibe 
l’expression du transporteur de glucose GLUT4 et du peptide adipocytaire insulino-sensibilisateur 
adiponectine, contribuant ainsi à la diminution de l’action de l’insuline en conditions d’obésité. 
 
En conclusion, à la lumière de ces résultats, le répresseur transcriptionnel ICER apparaît comme un 
facteur important dans la pathogenèse du DT2, en participant à la perte de fonction des cellules β 
pancréatiques et à l’aggravation de l’insulino-résistance. Par conséquent, l’étude des mécanismes 
moléculaires responsables de l’altération des niveaux du facteur ICER pourrait permettre le 
développement de nouvelles stratégies de traitement du DT2. 
 
Abstract 
 
 
A role for the transcriptional repressor ICER in the molecular pathogenesis of type 2 
diabetes 
 
Dimitri Favre, Service de médecine interne, Centre Hospitalier Universitaire Vaudois 
 
Type 2 diabetes (T2D) is a metabolic disease which affects more than 200 millions people worldwide. The 
progression of this affection reaches nowadays epidemic proportions, owing to the constant augmentation 
in the frequency of overweight, obesity and sedentary. The pathogenesis of T2D is characterized by 
reduction in the action of insulin on its target tissues – an alteration referred as insulin resistance – and 
pancreatic β-cell dysfunction. This latter deterioration is defined by impairment in insulin biosynthesis and 
secretion, and a loss of β-cell mass by apoptosis. Environmental factors related to T2D, such as chronic 
elevation in glucose and free fatty acids levels, inflammatory cytokines and pro-atherogenic oxidized low-
density lipoproteins (LDL), contribute to the loss of pancreatic β-cell function. 
 
In this study, we have demonstrated that the transcription factor Inducible Cyclic AMP Early Repressor 
(ICER) participates to the progression of both β-cell dysfunction and insulin resistance. The expression of 
this factor is driven by an alternative promoter and ICER protein represents therefore a truncated product 
of the Cyclic AMP Response Element Modulator (CREM) family which lacks transactivation domain. 
Consequently, the transcription factor ICER acts as a passive repressor which reduces expression of genes 
controlled by the cyclic AMP and Cyclic AMP Response Element Binding protein (CREB) pathway. 
 
In insulin-secreting cells, the accumulation of reactive oxygen species caused by environmental factors 
and notably oxidized LDL – a process known as oxidative stress – induces the transcription factor ICER. 
This transcriptional repressor hampers the secretory capacity of β-cells by silencing key genes of the 
exocytotic machinery. In addition, the factor ICER reduces the expression of the scaffold protein Islet 
Brain 1 (IB1), thereby favouring the activation of the c-Jun N-terminal Kinase (JNK) pathway. This 
triggering alters in turn insulin biosynthesis and survival capacities of pancreatic β-cells. 
 
In the adipose tissue of mice and human subjects suffering from obesity, the transcription factor ICER 
contributes to the alteration in insulin action. The loss in ICER protein in these tissues induces a constant 
activation of the CREB pathway and the subsequent expression of the Activating Transcription Factor 3 
(ATF3). In turn, this repressor reduces the transcript levels of the glucose transporter GLUT4 and the 
insulin-sensitizer peptide adiponectin, thereby contributing to the diminution in insulin action. 
 
In conclusion, these data shed light on the important role of the transcriptional repressor ICER in the 
pathogenesis of T2D, which contributes to both alteration in β-cell function and aggravation of insulin 
resistance. Consequently, a better understanding of the molecular mechanisms responsible for the 
alterations in ICER levels is required and could lead to develop new therapeutic strategies for the 
treatment of T2D. 
 
 
 
 
 
 
 
Résumé didactique 
 
 
Rôle du répresseur transcriptionnel ICER dans la pathogenèse moléculaire du diabète de 
type 2 
 
Dimitri Favre, Service de médecine interne, Centre Hospitalier Universitaire Vaudois 
 
L’énergie nécessaire au bon fonctionnement de l’organisme est fournie par l’alimentation, notamment 
sous forme de sucres (glucides). Ceux-ci sont dégradés en glucose, lequel sera distribué aux différents 
organes par la circulation sanguine. Après un repas, le niveau de glucose sanguin, nommé glycémie, 
s’élève et favorise la sécrétion d’une hormone appelée insuline par les cellules β du pancréas. L’insuline 
permet, à son tour, aux organes, tels le foie, les muscles et le tissu adipeux de capter et d’utiliser le 
glucose ; la glycémie retrouve ainsi son niveau basal. 
 
Le diabète de type 2 (DT2) est une maladie métabolique qui affecte plus de 200 millions de personnes 
dans le monde. Le développement de cette affection est causée par deux processus pathologiques. D’une 
part, les quantités d’insuline secrétée par les cellules β pancréatiques, ainsi que la survie de ces cellules 
sont réduites, un phénomène connu sous le nom de dysfonction des cellules β. D’autre part, la sensibilité 
des tissus à l’insuline se trouve diminuée. Cette dernière altération, l’insulino-résistance, empêche le 
transport et l’utilisation du glucose par les tissus et mène à une accumulation de ce sucre dans le sang. 
Cette stagnation de glucose dans le compartiment sanguin est appelée hyperglycémie et favorise 
l’apparition des complications secondaires du diabète, telles que les maladies cardiovasculaires, 
l’insuffisance rénale, la cécité et la perte de sensibilité des extremités. 
 
Dans cette étude, nous avons démontré que le facteur ICER qui contrôle spécifiquement l’expression de 
certains gènes, contribue non seulement à la dysfonction des cellules β, mais aussi au développement de 
l’insulino-résistance. En effet, dans les cellules β pancréatiques en conditions diabétiques, l’activation du 
facteur ICER altère la capacité de synthèse et de sécrétion d’insuline et réduit la survie ces cellules.  
 
Dans le tissu adipeux des souris et des sujets humains souffrant d’obésité, le facteur ICER contribue à la 
perte de sensibilité à l’insuline. La disparition d’ICER altère l’expression de la protéine qui capte le 
glucose, le transoprteur GLUT4, et l’hormone adipocytaire favorisant la sensibilité à l’insuline, nommée 
adiponectine. Ainsi, la perte d’ICER participe à la réduction de la captation de glucose par le tissue 
adipeux et au développement de l’insulino-résistance au cours de l’obésité. 
 
En conclusion, à la lumière de ces résultats, le facteur ICER apparaît comme un contributeur important à 
la progression du DT2, en soutenant la dysfonction des cellules β pancréatiques et l’aggravation de 
l’insulino-résistance. Par conséquent, l’étude des mécanismes responsables de la dérégulation du facteur 
ICER pourraît permettre le développement de nouvelles stratégies de traitement du DT2. 
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I Introduction 
 
A Glucose homeostasis 
Glucose represents a major source of energy for the body and is an indispensable fuel for 
neuronal tissues. Consequently, the maintenance of blood glucose levels in a narrow range – a 
process referred as glucose homeostasis – is of primordial importance and relies on a complex 
interaction between neurological and humoral pathways, where insulin possesses a dominant 
position. After a meal ingestion, blood glucose level raises and triggers insulin secretion from 
pancreatic β-cells. The elevation in insulinemia favors glucose uptake and utilization 
predominantly by the muscle, liver and adipose tissue, thereby restoring basal glycemia. 
 
A.1 Insulin secretion 
 
  A.1.1 β-cell of the islet of Langerhans 
The endocrine pancreas consists of small group of cells scattered among the exocrine part of the 
organ. The endocrine unit is known as the pancreatic islets, or the islets of Langerhans, and 
contains approximately 2000 cells, subdivided in five types. The centre of the islet is composed 
mainly of β-cells that produce and secrete insulin; at the periphery, α, δ, and PP cells release 
glucagon, somatostatin and pancreatic polypeptide, respectively. Recently, 1% of islets cells have 
been unveiled to secrete the ghrelin hormone, thus constituting fifth type of cells (1). 
 
Insulin plays a unique role in the maintenance of energy homeostasis and is therefore tightly 
controlled in order to maintain blood glucose in a physiological range. Short-term regulation of 
- 2 - 
insulin occurs mainly at the level of the secretory process, whereas maintenance of proper insulin 
stocks relies on the transcriptional and translational control of insulin synthesis. 
 
A.1.2 Control of synthesis 
The insulin gene encodes the precursor of the insulin polypeptide (proinsulin) chain and is 
composed of a single or two distinct genes, according to the species. Glucose increases 
preproinsulin mRNA through positive effects on its transcription rate and inhibition of its 
degradation. Insulin gene expression is mainly regulated by a 340 base pair region upstream of 
the transcription start site. This region contains cis-acting sequence motifs, including A3, E1 and 
C1 sites to which the transcription factors Pdx-1 (pancreatic and duodenal homeobox-1), 
NeuroD1 (neurogenic differentiation 1) and MafA (V-maf musculoaponeurotic fibrosarcoma 
oncogene homologue A) bind, respectively. These three factors act coordinately to stimulate 
insulin gene expression in response to elevated blood glucose (2). In addition, the velocity of 
preproinsulin translation is controlled by glycemia at multiple levels. Once expressed in the 
endoplasmic reticulum, the precursor undergoes post-translational proteolysis of the NH2-
terminal signal peptide. Proinsulin is converted into insulin by the proconvertases PC2 and PC3 
in its journey along the secretory apparatus. The mature hormone is then packed into secretory 
granules or large dense-core vesicles dispersed throughout the cytosol or docked to the plasma 
membrane. 
 
A.1.3 Control of secretion 
The most important physiological regulator of insulin secretion is glucose. A mechanistic 
whereby glucose elicits insulin secretion has been referred as the triggering pathway (Fig. 1). 
Glucose enters the β-cell via the high Km glucose transporter GLUT2 and is rapidly trapped into 
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glucose-6-phosphate by the β-cell-specific hexokinase, namely glucokinase. Phosphorylated 
glucose can then enter the glycolytic pathway, before going through the Krebs cycle and the 
electron transport chain. Glucose metabolism leads to the production of energy and increases the 
cellular ATP/ADP ratio. The unbalanced ATP/ADP ratio provokes the closure of the K+ATP 
channels and the subsequent depolarization of the plasma membrane. The loss of membrane 
potential triggers the opening of the voltage-dependent Ca++ channels (VDCC). The influx of 
calcium sets into motion the events leading to the exocytosis of secretory granules and the release 
of insulin into the extracellular milieu (Fig 1). 
 
 
Fig1: Insulin secretion 
Insulin secretion is triggered by a rise in glucose 
concentration. Glucose enters the cell via the glucose 
transporter GLUT2 and is phoshorylated by the 
hexokinase glucokinase, before being metabolized 
through glycolysis, the Krebs cycle and the respiratory 
chain. This results in an increased ATP/ADP ratio, 
leading to the closure of the K+ATP channels and 
membrane depolarization. The opening of the VDCC 
is favored by the change in membrane potential, 
ensuing in a net influx of calcium into the β-cell which 
triggers secretory granules fusion and insulin release 
(Adapted from the Beta-Cell Biology Consortium). 
 
Under conditions of prolonged physiological glucose stimulation, the insulin secretion curve is 
biphasic. The release of insulin augments rapidly to a peak at 2-4 minutes, decreases between 10 
and 15 minutes, and then progressively increases to reach a pseudo-plateau at 2-3 hours. The 
initial peak corresponds to the release of granules already docked to the membrane, referred as 
the first phase of insulin secretion or the “readily releasable pool”. The following increase of 
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insulin secretion is considered to represent the second phase and reflects the slow recruitment of a 
reserve pool of secretory granules and their transportation towards the plasma membrane. 
Although the triggering pathway is required to promote the two phases of secretion, a K+ATP 
independent pathway, also referred as an “amplifying pathway” has been highlighted to be 
further needed for the second phase. The exact mechanism of the pathway is still subject to 
debate, while several metabolites including, glutamate, NADPH, long chain acyl-CoA, Malonyl-
CoA and GTP resulting from glucose and mitochondria metabolism, may serve as enhancing 
factors coupling glucose to insulin secretion (3). 
 
A.2 Insulin action 
The effects of insulin on its target organs are aimed at increasing glucose transport and restoring 
basal levels of circulating glucose and rely on the triggering of a complex signaling cascade (4).  
 
The insulin receptor belongs to a family of tyrosine kinases and is composed of two α- and β-
subunits. Binding of insulin by the α-subunits induces the tyrosine kinase activity of the β-
subunits in the intracellular compartment and favors its autophosphorylation. Activated insulin 
receptor attracts and phosphorylates the family of insulin-receptor substrate (IRS 1-4) on tyrosine 
residues. 
 
The enzyme phosphatidylinositol-3-kinase (PI(3)K) plays a central role in the metabolic actions 
of insulin. PI(3)K possesses SH2 domains in its p85 regulatory subunit which interact with 
phosphorylated tyrosine residues of the IRS proteins. The p110 catalytic subunit of the PI(3)K 
catalyses the phosphorylation of  phosphatidylinositol-(4,5)-diphosphates (PI(4,5)P2) into 
PI(3,4,5)P3. PI(3,4,5)P3 which interact with the pleckstrin homology (PH) domain of signaling 
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proteins, including IRS proteins and Akt/PKB, and activates the serine/threonine kinase 
phosphoinositide-dependent kinase 1 (PDK1). In turn, PDK1 induces Akt/PKB by 
phosphorylation, thereby leading to the regulation of a variety of enzymes involved in the 
metabolism of glucose and synthesis of glycogen, proteins and lipids (Fig 2). 
 
Two additional pathways are activated upon binding of insulin. First, the adapter protein Grb2 
binds to phosphotyrosine residues of the IRS proteins. This interaction leads to the stepwise 
activation of Ras, Raf, MEK and the extracellular signal-regulated kinase (ERK), which induces 
a transcriptional programme enhancing cell growth and differentiation. Second, the tyrosine 
kinase domain of the insulin receptor activates the Cbl/CAP protein complex which interacts with 
proteins present in lipid rafts and potentiates mechanisms responsible for the uptake of glucose 
(Fig 2). 
 
 
Fig 2: Insulin signaling 
The insulin receptor possesses a tyrosine 
kinase domain which autophosphorylates 
upon binding of insulin. Activated insulin 
receptor catalyses the phosphorylation of 
signal proteins such as the IRS family and 
Cbl. In turn, these proteins recruit and 
activate diverse cascades, such as 
PI(3)K/Akt, Cbl/CAP complex and 
Grb2/Ras/Raf/MEK/ERK. These pathways 
coordinate the regulation of the metabolic 
and mitogenic effects of insulin (Adapted 
from (4)). 
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A.2.1 Liver 
In hepatocytes, insulin favors glucose utilization and storage as fatty acids and glycogen, while 
inhibiting hepatic glucose production. The hormone induces the production of glycogen by 
activating the enzyme glycogen synthase (GS). This relies on the dephosphorylation of GS 
through inhibition of the glycogen synthase kinase-3 (GSK-3) by phosphorylated Akt and 
recruitment of the protein phosphatase 1 (PP1). In addition, insulin promotes the expression of 
key enzymes of the glycolytic pathway, such as glucokinase (GK), phospho-fructokinase-1 
(PFK1) and pyruvate kinase (PK), thereby enhancing glucose degradation through glycolysis. 
Insulin also stimulates the synthesis of free fatty acids (FFA) via expression of the fatty acid 
synthase (FAS) and the acetyl-coA-carboxylase (ACC). This induction in glycolytic and 
lipogenic gene expression is regulated by an increased activity of the steroid regulatory element-
binding protein (SREBP-1c). 
 
On the other hand, insulin decreases the production of glucose by the liver. Indeed, the hormone 
diminishes the activity of enzymes implicated in gluconeogenesis by reducing the levels of the 
second messenger 3'-5'-cyclic adenosine monophosphate (cAMP). Additionally, the expression of 
gluconeogenetic enzymes phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-
bisphosphatase and glucose-6-phosphatase is decreased in states of hyperinsulinemia. This 
inhibition is mediated by a series of transcription factors including hepatic nuclear factor-4 
(HNF-4), the forkhead protein family (Fox) and PPARγ co-activator 1 (PGC-1). Finally, insulin 
indirectly slows down hepatic glucose production by suppressing the systemic availability of 
gluconeogenic substrates, such as free fatty acids (4). 
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A.2.2 Muscle 
Skeletal muscle is the main tissue responsible for insulin-stimulated glucose disposal (5). In 
myocytes, insulin promotes glucose captation, utilization and storage as glycogen. 
 
The stimulation of glucose transport by insulin relies on the translocation of glucose transporter 
proteins from intracellular sites to the plasma membrane (6). The glucose transporter family is 
composed of different isoforms which exhibit a specific tissue distribution. The GLUT4 isoform 
accounts for the majority of insulin-stimulated glucose transport in muscle and adipose tissue (7). 
In basal conditions, GLUT4 is located on vesicles recycling between intracellular stores and the 
plasma membrane. Upon insulin stimulation, the mobility of GLUT4 vesicles along 
microfilament tracks is increased, plasma membrane architecture is modified and fusion of 
GLUT4 vesicles with the membrane is favored. This supports the exocytosis of GLUT4 vesicles 
and increases the presence of the transporter protein in the plasma membrane and the subsequent 
uptake of glucose (4). The translocation of GLUT4 is controlled by different signaling proteins. 
The protein kinase Akt, the atypical protein kinase C (PKC) λ and ζ and the Cbl/CAP protein 
complex are involved in the stimulation of GLUT4 exocytosis by insulin (4;8-10). 
Similarly to its effects in hepatocytes, insulin stimulates glucose utilization and storage in 
myocytes via induction of glycogen synthase activity and glycolytic enzymes expression. 
 
  A.2.3 Adipose tissue 
An increase in the circulating levels of insulin induces glucose uptake by adipocytes and lipid 
synthesis, and inhibits lipolysis. The mechanisms responsible for the augmentation of glucose 
captation by adipose tissue upon insulin stimulation are similar to those in skeletal muscle and 
rely on the translocation of GLUT4 vesicles to the plasma membrane (4;11). 
- 8 - 
The major inducers of lipolysis in adipocytes are the catecholamines which increase intracellular 
levels of cAMP upon binding to their membrane receptors. Up-regulation of the second 
messenger cAMP induces the protein kinase A (PKA) which in turn activates the hormone-
sensitive lipase (HSL). Insulin potently inhibits lipolysis in adipocytes by decreasing cAMP 
levels, through activation of the enzyme phosphodiesterase-3 (PDE-3) (4;11). Additionally, this 
repression of FFA release has an indirect inhibitory effect on the production of glucose by the 
liver. Indeed, the reduced concentration of FFA in the plasma diminishes the delivery of 
gluconeogenic substrates to the liver and represses therefore the hepatic glucose production. 
 
Similarly to its effect in the liver, insulin supports the synthesis of fatty acids in adipose tissue via 
increased activity and expression of the steroid regulatory element-binding protein-1c (SREBP-
1c). This transcription factor controls the expression of lipid synthetic enzymes, including acetyl-
CoA-carboxylase (ACC) and fatty acid synthase (FAS). Furthermore, incorporation of fatty acids 
into triglycerides is ameliorated by insulin via activation of the enzyme glycerol-3-phosphate-
acyltransferase (12). 
 
B Type 2 diabetes 
  
B.1 Definition and etiology 
Diabetes mellitus represents a group of metabolic diseases of heterogeneous etiology 
characterized by one common manifestation: hyperglycemia. In June 1997, an international 
expert committee has released a report with new recommendations for the classification and 
diagnosis of diabetes mellitus (13). Thus, in clinical practice, diabetes diagnosis is based 
primarily on fasting plasma glucose (FPG) concentration ≥ 7 mmol/l on two separate occasions. 
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Other options for diagnosis include a 2 h post-glucose load (75g glucose) or random postprandial 
plasma glucose level of ≥ 11.1 mmol/l. After a long duration of the metabolic imbalance, diabetic 
complications, such as neuropathy, retinopathy, nephropathy and atherosclerosis, may 
additionally develop. In the turn of this century 171 million individuals were estimated to have 
diabetes worldwide, and this is expected to increase over 350 millions by 2030. The prevalence 
of diabetes and its related complications constitute therefore a social and economic burden for 
our modern society. The etiological classification of diabetes includes mainly type 1, type 2, 
“other specific types” and gestational diabetes. Amongst them, type 2 diabetes (T2D) is the most 
common form, representing 90% of all diabetes cases. 
 
The alteration in the glycemic control in case of type 2 diabetes ensues from two pathogenic 
processes: insulin resistance and β-cell dysfunction. In the context of sustained fuel supply and 
associated obesity, insulin resistance develops when target organs of insulin, such as liver, 
muscle and adipose tissue become less sensitive to the action of this hormone. Normal pancreatic 
β-cells respond to this impairment in insulin sensitivity by a compensatory hypersecretion of 
hormone, in order to maintain normal glucose tolerance. At some point however, pancreatic β-
cells malfunction and fail to compensate for insulin resistance, leading to persistent 
hyperglycemia and overt type 2 diabetes (14). 
 
 B.2 Impairment in insulin action: insulin resistance 
The term insulin resistance applies to the decline in the effects of insulin on glucose uptake and 
utilization in target organs. Physiological variations in insulin sensitivity occur during the normal 
life cycle, with insulin resistance being observed during puberty (15), pregnancy (16) and ageing 
(17). On the other hand, insulin sensitivity can be improved by lifestyle modifications, such as 
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enhanced physical activity (18) and carbohydrate intake (19). Importantly, insulin resistance is 
the initial measurable defect in patients who are destined to develop T2D. This alteration is 
present in the majority of patients with glucose intolerance or overt T2D and is strongly 
associated with obesity (20;21). 
 
Loss of insulin responsiveness dramatically affects glucose homeostasis by impairing glucose 
disposal by muscle and adipose tissue and insulin suppression of hepatic glucose production. 
However, normoglycemia is, in the beginning maintained by a compensatory hypersecretion of 
insulin by the pancreatic β-cells. Sustained hyperglycemia and overt T2D only develop when 
these cells suffer from dysfunction and fail to meet the metabolic demand of insulin (14). 
   
B.2.1 Liver 
Because of its important contribution to glucose homeostasis, development of insulin resistance 
in the liver strongly impacts on glycemic control and progression of T2D. 
 
The main consequence of hepatic insulin resistance is the impaired suppression of glucose 
production by this hormone (22). Indeed, insulin-insensitive hepatocytes exhibit increased 
gluconeogenesis and glycogen degradation. Since the liver is the major source of glucose after an 
overnight fast, loss of hepatic insulin sensitivity strongly participates to the development of 
fasting hyperglycemia in T2D. Various alterations in the cascade of insulin signaling could 
account for the loss of hepatic insulin responsiveness (23). Reduced expression and inhibitory 
serine phosphorylation of signaling proteins, such as the family of IRS proteins and induction of 
phosphatases enzymes may impair transmission of the insulin signal. 
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In addition to the elevation in hepatic glucose production, the insulin-resistant liver is 
characterized by an excessive accumulation of triglycerides – a process referred as hepatic 
steatosis. The mechanisms responsible for the exaggerated deposit of fat are linked to an 
increased delivery of FFA from insulin-insensitive adipose tissue and de novo lipid synthesis in 
the liver itself (24). This disruption could ultimately lead to the emergence of nonalcoholic fatty 
liver disease (NAFLD), which represents the most common cause of liver abnormality in 
westernized societies. 
 
  B.2.2 Muscle 
Since skeletal muscle is the principal tissue responsible for insulin-induced glucose uptake (5), 
the loss of insulin responsiveness in this organ strongly contributes to impaired glucose 
homeostasis in T2D. Indeed, insulin-resistant myocytes exhibit a reduced transport of glucose 
upon insulin stimulation (25) and an alteration in glycogen synthesis (26). 
 
The reduction in glucose uptake in insulin-insensitive skeletal muscle ensues from alterations in 
the insulin signaling cascade and impairment in GLUT4-mediated glucose transport. The 
deterioration in insulin signaling relies on the reduced phosphorylation of insulin receptor, IRS 
proteins and perturbed activity of PI(3)K, as observed in the skeletal muscle of T2D (27). The 
defect in GLUT4-mediated glucose uptake is the consequence of reduced presence of the glucose 
transporter at the plasma membrane. This decline in GLUT4 at the membrane issues from an 
impaired translocation of GLUT4 vesicles but not from a reduced expression of the transporter 
protein (28).  
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Similarly to the liver in T2D, insulin-resistant skeletal muscle presents an elevation in 
triglycerides accumulation (29). This augmentation in intramuscular lipid is associated with a 
deterioration in the capacity of oxidative and glycolytic enzymes (27). 
 
B.2.3 Adipose tissue 
The adipose tissue of T2D is characterized by a diminution in glucose uptake and an absence of  
suppression of FFA release by insulin. Similarly to its transport in myocytes, glucose entry in the 
insulin-resistant adipocytes is decreased as a consequence of a perturbation in insulin signaling 
(30). Adipocytes in T2D have a marked reduction in the insulin-stimulated IRS proteins 
phosphorylation and PI(3)K activity. However, on the contrary to muscle, adipose tissue 
demonstrates a decline in the expression of the glucose transporter GLUT4 which contributes to 
the loss of glucose uptake by adipocyte (30).  
 
Furthermore, insulin-insensitive fat cells are less susceptible to the inhibition of HSL activity by 
insulin. This mechanism leads to an enhanced release of FFA in plasma from triglyceride stocks, 
which in turn contributes to the worsening of glycemic control in T2D. The excess of circulating 
FFA stimulates gluconeogenesis and glucose release by the liver, thereby further increasing 
blood glucose levels. In parallel, the plasma FFA accumulate outside the adipose depots, 
including skeletal muscle and liver, where they aggravate insulin resistance (14). 
 
Beside their role as storage depot for lipids, fat cells produce and secrete number of hormones, 
collectively referred as adipokines. For instance, leptin, adiponectin, resistin and others are 
released by the adipose tissue and could profoundly influence metabolism and energy 
expenditure (4). Importantly, in insulin resistant conditions and associated obesity, the pattern of 
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secretion of these hormones is perturbed; an alteration which is thought to promote the 
impairment in insulin sensitivity and glycemic control. 
 
B.2.4 Genetic factors 
T2D is a polygenic disorder in which multiple genes contribute to a general predisposition to 
develop the disease. Genome-wide analyses have so far identified 23 loci associated with T2D 
(31;32). The majority of these susceptibility loci can be directly mapped to protein of the 
pancreatic β-cell. Interestingly, only few of them were associated with increased risk for insulin 
resistance. For instance, PPARγ, IRS1, Glucokinase Regulator (GCKR) and Insulin-like Growth 
factor 1 (IGF1) are related with insulin action, and functional studies have demonstrated that 
some of them influence insulin sensitivity (33). 
 
  B.2.5 Environmental factors 
Whereas limited numbers of genes have been associated with increased susceptibility to insulin 
resistance, numerous metabolic alterations have been correlated with the obesity-related loss of 
insulin sensitivity. 
 
B.2.5.1 Hyperinsulinemia 
As previously mentioned, pancreatic β-cells counterbalance the loss of insulin responsiveness in 
target tissues by a hypersecretion of hormone, thereby maintaining normoglycemia. However, 
this condition of compensation is not without consequence and the subsequent hyperinsulinemia 
exacerbates the insulin resistant state. Elevated insulinemia further decreases insulin sensitivity 
by down-regulating insulin receptor protein, IRS proteins and other insulin signaling molecules 
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(23). In addition, hyperinsulinemia worsens hepatic steatosis via stimulation of de novo 
lipogenesis in the liver through activation of the transcription factor SREBP-1c (23). 
 
   B.2.5.2 Fatty acids 
As a consequence to the loss of insulin-mediated suppression of HSL activity, insulin-resistant 
adipose tissue releases abnormally elevated levels of FFA into the plasma. These circulating fatty 
acids accumulate outside the fat depots such as in the liver and skeletal muscle, where they 
perturbate the action of insulin. 
 
In the liver, the excess of FFA is redirected into cytosolic lipid species such as triglycerides (TG), 
diacylglycerol (DAG) and cermides, as a result of the reduction in fatty acids β-oxidation. This 
alteration is thought to be regulated by the glucose-induced increase in malonyl-CoA, which 
inhibits the import of fatty acids into the mitochondria via the carnitine palmitoyltransferase-1 
(CPT-1) protein. Such accumulation of lipid species sets the stage for the development of hepatic 
steatosis and associated loss of insulin sensitivity (34). In contrast in skeletal muscle, the surplus 
lipids not only accumulate in cytosol as TG, DAG and ceramides but are transferred to 
mitochondria for β-oxidation. However, in absence of exercise, this augmentation in fatty acid 
oxidation is not matched by an elevation in Krebs cycle activity. As a consequence, lipid 
derivatives concentrate in the mitochondria engendering mitochondrial stress and contributing to 
impaired insulin responsiveness (14). 
 
   B.2.5.3 Inflammatory cytokines 
The adipose tissue of obese subjects is characterized by a low-grade inflammation and 
recruitment of macrophages (35). Whereas the adipose production of inflammatory cytokines is 
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under debate, the recruited macrophages release TNF-α and IL-6, thereby establishing a state of 
systemic low-grade inflammation. The enhanced circulating levels of inflammatory cytokines 
contribute to the loss of insulin sensitivity in target tissues via activation of the transcription 
factor Nuclear Factor-κB (NF-κB) (14). 
    
B.2.5.4 Adipokines 
In addition to their capacity to store lipids, adipocytes have the ability to produce and release 
numerous bioactive peptides, known as adipokines. These molecules encompass the retinol-
binding protein-4 (RBP4), resistin, leptin, adiponectin and others. Obesity-related expansion of 
adipose tissue is associated with an alteration of the production of adipokines, which can 
profoundly affect the ability of organs to respond to insulin (14). For instance, the release of the 
adipose tissue-specific collagen-like protein adiponectin is reduced in obesity – a decrease which 
correlates with the degree of insulin resistance (36). Adiponectin is categorized as an “anti-
diabetogenic” molecule, based on its capacity to reduce triglyceride synthesis, stimulate β-
oxidation and enhance insulin action in both skeletal muscle and liver (14). It is therefore not 
surprising that mice knock-out for adiponectin develop severe insulin resistance upon 
administration of a high fat diet (37). The insulin-sensitizing property of this adipokine relies on 
its ability to activate 5’-AMP-activated protein kinase (AMPK), an enzyme that responds to a 
decrease in ATP/AMP ratio by activating both glucose and fatty acid oxidation (14). 
 
B.3 Impairment in insulin secretion: β-cell dysfunction 
Healthy β-cells are able to counter loss of insulin sensitivity by a compensatory hypersecretion of 
the hormone, as a result of increased β-cell mass and insulin release capacity. This process is so 
efficient that normal glucose tolerance can be maintained for a long time. At some point, 
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however, β-cells fail to compensate for insulin resistance and glucose intolerance and to the 
extreme T2D develop. Consequently, β-cell dysfunction represents a key step in the progression 
of the disease, allowing for transition between an asymptomatic state to overt diabetes (14).  
 
Evidence for an early alteration of β-cell secretory capacity in patients with glucose intolerance 
and T2D has accumulated over years. Indeed, both phases of insulin release have been 
demonstrated to be reduced in glucose intolerant individuals in response to intravenous glucose 
infusion. Whereas the non-glucose secretagogue arginine is able to elicit insulin release in 
diabetic patients, the magnitude of secretion is however lower than in healthy individuals (38). In 
addition, pancreatic islets from cadaveric donors with type 2 diabetes are unable to augment 
insulin secretion during an in vitro hyperglycemic stimulation (39). This defect of insulin 
secretion is associated with damaged secretory machinery and impaired glucose metabolism. 
Such observations are reproduced in some animal models that mimic human T2D such as the 
Goto-Kakizaki (GK) rats (40). 
 
In addition to the functional defects of the β-cells, reduction in their mass has been suggested to 
contribute to the progression of β-cell dysfunction. Control of the β-cell mass relies on the 
balance between β-cell replication and apoptosis, as well as differentiation of new islets from 
pancreatic ducts. Perturbation of the pathways of β-cell generation or increased β-cell death could 
reduce β-cell mass. Because of the difficulties to obtain pancreatic tissue from humans, there are 
only few studies of β-cell mass in diabetic patients. Morphometrical analyses of islets from T2D 
reported a 63% loss of β-cell volume compared with weight-matched controls. Moreover, this 
reduced β-cell volume is not the consequence of a decreased cell proliferation, but is associated 
with an increased β-cell apoptosis (41). However, although the number of β-cells is clearly 
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reduced, this degree of β-cell loss is not sufficient to fully account for the change in secretory 
function. In vitro and in vivo functional assessments of living islets show a marked decrease in 
secretion of insulin compared to islets from non diabetic individuals. 
  
  B.3.1 Genetic factors 
While several rare monogenic forms of diabetes, including maturity-onset diabetes of the young 
(MODY), have been described, the genetic basis of T2D appears to be much more complex. T2D 
is viewed as a disease of polygenic origin in which multiple different genes contribute to a 
general predisposition to develop the disease. However, emergence of high-throughput 
genotyping sequencing methods and systemic screening of cohorts of thousands of patients have 
allowed the identification of several candidate genes for β-cell failure in T2D. Compelling all the 
data from the literature, 23 loci are associated with T2D so far. Amongst them, Peroxisome 
proliferator-activated receptor gamma (PPARγ), KCNJ11 (Kir6.2), transcription factor 7–like 2 
(TCF7L2), insulin-like growth factor 2 mRNA binding protein 2(IGF2BP2), CDK5 regulatory 
subunit associated protein 1-like 1 (CDKAL1), hematopoietically expressed homeobox (HHEX) 
and Zinc transporter 8 (SLC30A8) are expressed in β-cells, and at present, functional studies 
have shown some of them playing a key role in β-cell function (31;32). 
 
B.3.2 Environmental factors 
The diabetic genotype is typically responsible for a part of the vulnerability of islets and for a 
predisposition for insulin resistance and T2D. However, pancreatic β-cell dysfunction and overt 
diabetes only develop once susceptible individuals have been recurrently exposed to 
environmental stressors. 
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B.3.2.1 Gluco- and glucolipo- toxicity 
The term “gluco-toxicity” refers to the adverse effects of chronic exposure of pancreatic β-cells 
to elevated blood glucose. The piece of evidence that supports the detrimental effects of chronic 
elevation of glucose on insulin secretion comes from an investigation that has been realized in 
humans. Consecutive administrations of glucose by intraveinous injection in healthy individuals 
elicit a loss of glucose-induced insulin secretion (42). This observation suggests that chronic 
hyperglycemia, which could result from a combination of glucose intolerance and postprandial 
glucose excursions, would promote and/or worsen T2D development. 
 
The molecular mechanisms through which chronic elevation of glucose exerts adverse effects on 
β-cells have been deciphered. Chronic hyperglycemia evokes impairment in both insulin 
synthesis and secretion. Alteration of insulin expression is caused by a reduced activity of the two 
major β-cell transcription factors, pancreatic-duodenum homeobox-1 (PDX-1) and rat insulin 
promoter element 3b1 (RIPE 3b1/MafA) (43). Reduction in the activity of these factors and loss 
of the β-cells secretory capacity is depicted to the generation of reactive oxygen species (ROS) 
(Fig. 3, (44)). Treatment with the antioxidant N-acetylcysteine (NAC) protects β-cells against the 
harmful effects of high glucose. This process which is referred to as oxidative stress is, at least 
partially, responsible for the modification in the transcriptional factors (43). Finally, it has been 
repeatedly reported that the prolonged exposure of rodent and human islets to elevated glucose 
induces β-cell apoptosis and could contribute to the loss of β-cell mass observed in islets from 
T2D patients (45). 
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Fig 3: Six biochemical pathways along which 
glucose metabolism can form ROS  
Under physiologic conditions, glucose primarily 
undergoes glycolysis and oxidative phosphorylation. 
Under pathologic conditions of hyperglycemia, 
excessive glucose levels can swamp the glycolytic 
process and inhibit glyceraldehyde catabolism, 
which cause glucose, fructose-1,6-bisphosphate, and 
glyceraldehyde-3-P to be shunted to other pathways: 
1, enolization and ketoaldehyde formation; 2, PKC 
activation; 3, dicarbonyl formation and glycation; 4, 
sorbitol metabolism; 5, hexosamine metabolism; and 
6, oxidative phosphorylation. DAG, diacylglycerol 
(Adapted from (44)). 
 
By analogy to the paradoxically adverse effects of chronic hyperglycemia, free fatty acids (FFA), 
which are vital nutrients for β-cells, hamper their physiology when chronically administered. A 
four days infusion of intra-lipids in individuals with a family history of diabetes elicits loss of 
glucose-induced insulin secretion (46). In vitro, the sustained exposure of pancreatic β-cells to 
FFA reduces glucose-induced insulin secretion and affects insulin gene expression, together with 
a reduction in PDX-1 activity (43). Finally, excess in FFA provokes β-cell death by apoptosis 
(47) and generates oxidative stress (48). 
 
Interestingly, lipid-induced alterations in β-cell function can be potentiated by supraphysiological 
concentrations of glucose. In contrast, at low glucose levels, the excess of FFA is efficiently 
metabolized and does not harm the β-cell. The synergistic impairment of β-cell function by 
glucose and FFA is referred to as the “glucolipotoxicity” and has been verified in both in vitro 
and in vivo systems. The simultaneous presence of elevated levels of glucose and FFA catalyzes 
the accumulation of malonyl-CoA, a potent negative regulator of the carnitine-palmitoyl-
transferase-1 (CPT-1). Inhibition of FFA transport into the mitochondria via CPT-1 results in the 
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cytosolic accumulation of long-chain fatty acyl-CoAs (LC-CoA), which are proposed as 
mediators of the adverse effects of persistent elevations of FFA (43). 
 
   B.3.2.2 Pro-inflammatory cytokines 
Recent studies on the role of inflammation in chronic non-immune diseases, such as obesity and 
atherosclerosis, have shed light onto the close association between inflammatory markers and the 
metabolic alterations in T2D and the contribution of inflammation agents to β-cell dysfunction 
and insulin resistance. The sources of pro-inflammatory cytokines that negatively affect β-cells 
are multiple and encompass adipocytes, macrophages, endothelial cells, as well as pancreatic islet 
cells. The three most deleterious cytokines favoring β-cell death are interleukin-1β (IL-1β), tumor 
necrosis factor α (TNFα) and interferon γ (IFNγ). TNFα is secreted by macrophages and adipose 
tissue and its receptor-mediated recognition triggers the mitogen-activated protein kinases 
(MAPKs) c-Jun N-terminal kinase (JNK, also known as MAPK8) and p38 (MAPK11-14), as 
well as the Nuclear Factor κB (NFκB) pathway. IFNγ is released by T-helper cells and induces 
the Janus tyrosine kinase (JAK)/Signal Transducer and Activator of Translation (STAT) path. 
Finally, IL-1β activates the same effectors pathways as TNFα and is liberated by activated 
macrophages and, paradoxically, under some circumstances by β-cells (45).  
 
B.3.2.3 Modified LDL and HDL: additional environmental stressors 
for β-cells 
Individuals with T2D have an increased risk to develop cardiovascular diseases. This association 
has led to the hypothesis that diabetes and cardiovascular affections share common precursors. 
Low levels of circulating high-density lipoproteins (HDL), associated with augmented 
concentrations of modified low-density lipoprotein particles (LDL), particularly oxidized LDL, 
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are associated with a higher risk for T2D patients to develop atherosclerotic cardiovascular 
disease. Numerous clinical studies reflect this correlation. In the prediabetic stage, during which 
hyperglycemic excursions increase abnormally, the high blood glucose appears as an independent 
risk factor for cardiovascular diseases (49). According to the United Kingdom Prospective 
Diabetes Study, LDL-cholesterol is the most important determinant for development of 
cardiovascular disease in T2D (50). In vitro and in vivo experiments show that hyperglycemia can 
potently modify LDL, particularly by generating glycated LDL, a particle that is more susceptible 
to oxidative modifications. A clear increase in the ratio of oxidized LDL over native is 
systematically observed in plasma of patients with T2D, whereas the total plasma levels of LDL-
cholesterol are often modestly increased (51). HDL and paraoxonase (PON1) play an anti-oxidant 
role, insuring a certain detoxification rate of oxidized LDL. The plasma concentration of HDL 
and PON1 is reduced in diabetes, thus providing an additional mechanism for oxidization of LDL 
(52). A role for oxidized LDL as a risk factor for developing diabetes is further supported by the 
fact that a long term follow-up study, which has prospectively investigated the risk factors of 
people at work (employees of companies) for developing diabetes over 4-10 years, does not 
confirm an association of diabetes with an increased concentration of native LDL (53). Indeed, 
progression of diabetes correlates with a decrease in HDL plasma level while the concentration of 
LDL does not increase with hyperglycemia, suggesting rather that oxidization of LDL plays a 
role in the pathogenesis of β-cell failure (53). The presence of oxidized LDL in plasma of 
patients with T2D is further provided by the identification of auto-antibodies directed against 
oxidized LDL in these patients (54). 
 
Although oxidized LDL levels are clearly increased and HDL low in the plasma of glucose 
intolerant and T2D patients, the firm demonstration of their contribution to the progression of β-
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cell failure and subsequent acceleration of overt diabetes remains to be made. However, several 
lines of evidence have been accumulated in favor of the participation of lipoproteins in β-cell 
failure. First, once oxidized in the subendothelial space of the vessel wall, a portion of 
lipoproteins are released in the blood flow. These particles possess a size able to diffuse into the 
pancreatic islets via fenestrated capillaries. Secondly, effective expression of receptors dedicated 
to cellular uptake of LDL particles, such as LDL receptor (LDLR) and LDLR-related protein 
(LRP) is observed in mouse islets and β-cells, as well as the HDL-binding Scavenger Receptor BI 
(SR-BI) and Apolipoprotein E Receptor 2 (ApoER2) (55). The scavenger receptor CD36 for 
oxidatively modified LDL is present on the plasma membrane of insulin-secreting and rat islets 
cells (56). In line with the expression of their affiliated receptors, LDL and HDL are effectively 
recognized and endocyted by human and rodent islets, as well as by mouse insulin-secreting cells 
(55;57). In addition, binding and internalization of oxidized lipoproteins by β-cells has been 
reported (56). Chronic exposure of the insulin-producing HIT-T15 β-cell line to physiological 
cholesterol concentration of oxidized LDL (< 2.6 mM), but not native particles reduces insulin 
biosynthesis and secretion (56). Adverse effects of unmodified lipoproteins only become 
apparent at supraphysiological dosages or after serum starvation-induced LDLR up-regulation 
(55;58). 
 
B.4 Role of the transcription factors modulated by cAMP in β-cell failure and insulin 
resistance  
To adapt to environmental cues such as hormonal or nutrients changes, most of cells are equipped 
with receptors and signaling cascades that rapidly transduce signals, thereby triggering changes in 
gene expression and cellular functions. To achieve efficient coupling of extracellular stimulus to 
cellular outcomes, several second messengers are particularly crucial. Amongst them is cyclic 
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adenosine monophosphate (cAMP) that plays a role in a considerable number of physiological 
processes, including energy metabolism, cellular proliferation and neuronal signaling (59;60). 
 
Adenylate cyclase is the main enzyme responsible for the regulation of intracellular levels of 
cAMP. This enzyme is modulated by various extracellular signals and their affiliated receptors 
and G-proteins. cAMP interacts with the two regulatory subunits of PKA, releasing the catalytic 
parts of the enzyme. The activated catalytic entities ultimately phosphorylate and stimulate a 
specific set of transcription factors responsible for the control of genes expression through 
cAMP-inducible promoter elements. These promoter responsive sequences are referred as cAMP 
Responsive Element (CRE) and the first factor identified to bind these elements was the CRE-
Binding Protein (CREB). The PKA favors the transcriptional activity of CREB by 
phosphorylation on a serine residue at position 133. Two additional members of the CREB 
family were subsequently discovered: the Activating Transcription Factor-1 (ATF1) and the CRE 
Modulator (CREM). These three classes of transcription factors contain consensus PKA 
phosphorylation sites and interact with DNA as dimers via a basic leucine zipper motif. Finally, 
the termination of the cAMP signal involves an atypical member of the CREM family. The 
Inducible Cyclic AMP Early Repressor (ICER) is up-regulated by cAMP itself through an 
alternative promoter within the CREM gene which contains four CRE sites (61). ICER contains 
the basic leucine zipper domain of the CREM, but lacks the activating domain. Consequently, 
ICER can bind the CRE but it is unable to transactivate gene expression. As a passive repressor 
ICER will compete with the activating transcription factors of the CREB, CREM and ATF1 
family and will therefore facilitate the restoration of basal expression levels of cAMP-responsive 
genes (59;60). 
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The interplay between ICER and the CREB, CREM and ATF1 transcriptional activators is 
critical for the regulation of the production and release of neurotransmitters and hormones 
including, β-endorphin, growth hormone (GH), prolactin (PRL) or adenocorticotropic hormone 
(ACTH) produced by anterior pituitary cells (62). This hormonal release plays a pivotal role in 
coordinating the physiologic adaptation of the hypothalamo-pituitary-adrenal axis to stress. In 
this case, stress is defined as physiological changes that accompany increased physical and 
psychological demands. Increasing evidence suggests that ICER plays a regulatory role in 
hormone release in pituitary cells. Consistently, targeted suppression of the CREM gene in mice, 
leading to the loss of ICER expression, results in a chronic increase in plasma β-endorphin (63). 
A model of pituitary corticotroph AtT20 cell line overexpressing ICER has been developed to 
measure the effects of this transcriptional repressor on hormone secretion (64). Ectopic 
expression of ICER blocks the synthesis of ACTH at post-translational levels and alters stimulus-
induced secretion of this hormone (64). The role of CREB and ICER is critical for glucose 
homeostasis. In β-cells, the cAMP pathway contributes to the potentiation of glucose-stimulated 
insulin gene expression by incretin hormones (65). In liver, the CREB/ICER network promotes 
glucose homeostasis during fasting. This is achieved by regulating the expression of genes from 
the neoglucogenic program (66). In adipocytes, the cAMP signalling controls the production of 
the insulin sensitizer adiponectin (67).  
 
B.4.1 Dysregulation of CREB in response to diabetic environmental stressors  
The CREB activators play a critical role in tissues involved in pathogenesis of diabetes. Because 
they are rapidly activated by changes in extracellular environment and devoted to trigger cellular 
outcomes, dysregulation in their function was suggested to be involved in β-cell failure. The 
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dysfunction of pancreatic β-cells evoked by the chronic exposure to elevated concentrations of 
glucose is associated with a reduction in CREB activity, due to exacerbated proteosomal 
degradation of these transcription factors. Restoration of CREB levels protects β-cell from the 
adverse effects of chronic hyperglycemia (68). Accordingly, mice engineered to overexpress a 
dominant negative mutant of CREB specifically in the β-cell develop diabetes, as a consequence 
of a massive loss of β-cell mass by apoptosis (69). The molecular mechanism responsible for the 
alteration in CREB activity under diabetic conditions has been brought to light and relies on the 
transcriptional repressor ICER. Indeed, augmented expression of this transcription factor is 
observed in pancreatic β-cells chronically exposed to elevated concentrations of glucose or 
palmitate and in the islets of rat with T2D (70;71). Importantly, mice with a forced expression of 
ICER in β-cells suffer from severe diabetes (72). The dramatic loss of glucose homeostasis in 
these mice is associated with a failure of insulin biosynthesis and reduced β-cell mass (72). 
Finally, the contribution of ICER to the impairment in insulin secretion evoked by chronic high 
glucose levels or palmitate has been documented to involve the capacity of the transcriptional 
repressor to silence the expression of the exocytotic genes Rab3a, Rab27a and their effectors Slp4 
and Noc2 (73), as well as the gap-junction protein connexin 36 (74). These observations 
emphasize therefore the role of the CREB pathway in the proper function pancreatic β-cells and 
the implication of the transcriptional repressor ICER in the progression of β-cell dysfunction in 
T2D. 
 
B.4.2 Role of CREB in insulin resistance 
The cAMP signaling is, in addition, involved in the progressive loss of insulin sensitivity. In fact, 
the invalidation of CREB in the liver protects from hepatic steatosis and insulin resistance in 
diabetic rodent models, such as the ZDF rats, the streptozotocin-treated and high fat diet (HFD)-
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fed rats, as well as the ob/ob mice. (75). Furthermore, CREB activity in the adipose tissue has 
been reported to influence whole body insulin responsiveness. The CREB pathway is 
constitutively stimulated in fat cells of HFD-fed mice and db/db mice, where it contributes to 
insulin resistance by inducing the Activating Transcription Factor-3 (ATF3). In turn, this 
repressor suppresses the expression of the glucose transporter 4 (GLUT4) and the insulin-
sensitizer hormone adiponectin (76). Transgenic overexpression of a dominant-negative CREB in 
adipocytes under obese conditions restores insulin sensitivity and blocks hepatic steatosis and 
adipose tissue inflammation (76). 
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II Objectives 
 
A Unveiling and deciphering the role of oxidized LDL and HDL in β-cell failure 
A role for oxidized LDL-cholesterol particles in the progression and pathogenesis of diabetes is 
more and more clear. Several lines of evidence indicate a potential effect of these particles in β-
cells. These cells can internalize oxidized as well as native LDL and HDL particles through 
scavenger receptors. Additionally, experiments in an insulin-producing cell line show the 
deleterious effects of oxidized LDL on β-cell function. Consequently, the first aim of the present 
thesis is to better understand the molecular mechanisms of lipoproteins in β-cell dysfunction. 
Precisely, the contribution of the diabetogenic transcriptional repressor ICER and the generation 
of oxidative stress to the alteration of β-cell function evoked by modified lipoproteins will be 
assessed. 
 
B Dissecting the molecular mechanism responsible for adipose tissue dysfunction elicited by 
CREB 
The CREB pathway is involved in the deterioration of glucose homeostasis in T2D and 
particularly in the loss of insulin sensitivity. The activity of these factors is up-regulated in the 
adipocytes under obese conditions, where it favors the silencing of GLUT4 and adiponectin via 
activation of the transcription factor ATF3. As a consequence, the second aim of this thesis is to 
clarify the causes of the abnormal CREB activity in obesity and to elucidate the potential 
contribution of the transcriptional repressor ICER in this pathological process. 
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III Results 
 
A A role for JNK pathway in β-cell dysfunction evoked by oxidized LDL 
 
 A.1 Introduction 
Frank hyperglycemia and T2D develop in patients whose pancreatic β-cells fail to secrete enough 
insulin to compensate for insulin resistance (14). β-cell dysfunction is characterized by a decline 
in the number of β-cells and their capacity to produce and release insulin. Environmental 
stressors, such as chronic elevation of glucose and FFA contribute to β-cell insult by persistently 
increasing intracellular levels of ROS – a process termed oxidative stress. The main mitogen-
activated protein kinase associated with the generation of oxidative stress is the JNK kinases, 
which lead to the activation of the Activator Protein-1 (AP-1) transcriptional complex and 
subsequent loss of preproinsulin gene expression and β-cell survival (77). The scaffold protein 
Islet Brain 1 (IB1) is an important regulator of the JNK pathway which prevents the activation of 
c-Jun, a member of the AP-1 transcription complex. Interestingly, reduction in IB1 content 
contributes to the loss of insulin expression and β-cell survival under diabetic conditions (78;79). 
 
Patients with T2D have a perturbed lipid profile, with elevated plasma levels of oxidized LDL 
(oxLDL) over native LDL. This augmentation is associated with reduced concentrations of HDL 
and is considered as a major risk factor for patients to develop atherosclerotic cardiovascular 
diseases. In addition to their pro-atherogenic properties, several lines of evidence support the 
implication of oxLDL in the progression of β-cell dysfunction and development of T2D. The 
prolonged exposure of insulin-secreting cells to modified lipoproteins causes a decline in insulin 
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production and secretion and triggers β-cell apoptosis (56;80). Noteworthy, in others tissues, 
oxLDL can induce oxidative stress and activate JNK pathway and AP-1 transcriptional activity – 
a mechanism that ultimately leads to cellular apoptosis (81).  
 
In view of these data, we hypothesized that JNK signalling is implicated in the perturbation of 
insulin biosynthesis and β-cell survival caused by oxLDL. 
 
A.2 Results 
The role of lipoproteins in the progression of β-cell dysfunction was first confirmed by 
determinating the effects of oxLDL on insulin biosynthesis and cell survival. To do so, the 
insulin-secreting cell line MIN6 B1 and rat and human isolated islets were cultured in presence of 
2mM cholesterol of copper-oxidized or native LDL for 72h. Modified lipoproteins induced a 
significant reduction in insulin content, which was associated with decreased preproinsulin 
mRNA level and insulin gene promoter activity (Fig 1 and 2a). In the meanwhile, native LDL at 
a similar cholesterol concentration did not affect the insulin production capacity of β-cell (Fig 1). 
In addition, the percentage of β-cell apoptosis – assessed as the number of cell displaying a 
picnotic nucleus – was markedly augmented by the modified lipoproteins, but not by native LDL 
(Fig 6b). This increase in cell death was correlated with the loss of expression of the anti-
apoptotic factor Bcl2 (Fig 6d). 
 
The alteration in β-cell function and survival by oxLDL was associated with an activation of the 
JNK pathway, as reported by increased phosphorylation of the JNK target c-Jun, AP-1 
transcriptional activity and c-Jun and c-Fos expression (Fig 3 and 4). Interestingly, the long-term 
induction of this signalling path was correlated with the disappearance of the scaffold protein IB1 
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(Fig 6a). The contribution of the JNK cascade to the β-cell dysfunction evoked by oxidized LDL 
was confirmed by the restoration of insulin mRNA levels and cell survival by the JNK inhibitor 
JNKi during chronic oxLDL treatment (Fig 5a and 6b-c). Interestingly, the anti-atherogenic 
particles HDL prevented development of β-cell failure by modified LDL. Indeed, insulin gene 
expression, IB1 content were augmented, whereas apoptosis was reduced in MIN6 cells and 
human islets exposed to oxLDL and HDL (Fig 7a, 8 and 9e-f). 
 
In conclusion, these data provide evidence that oxidized, but not native LDL exert deleterious 
effects on insulin levels and β-cell survival by reducing IB1 content and activating the JNK 
pathway. Inhibition of this signalling cascade by the inhibitor JNKi or HDL counteracts the 
adverse consequence of oxLDL exposure on β-cell function. 
 
A.3 Contribution 
In this paper, the student was involved in the experimental data collection, being specifically in 
charge of the AP-1 transcriptional activity assays, the quantification of the mRNA of c-Jun, c-
Fos, Bcl2 and the preparation of the lipoproteins and experimental media. In addition, the student 
took a significant role in the lead of the revision experiments and corrections. He drove the 
statistical analysis of the majority of the data and was implicated in the design of the 
experiments, the preparation of the figures and the writing of the manuscript. 
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Abstract
Aims/hypothesis We explored the potential adverse effects
of pro-atherogenic oxidised LDL-cholesterol particles on
beta cell function.
Materials and methods Isolated human and rat islets and
different insulin-secreting cell lines were incubated with
human oxidised LDL with or without HDL particles. The
insulin level was monitored by ELISA, real-time PCR and a
rat insulin promoter construct linked to luciferase gene
reporter. Cell apoptosis was determined by scoring cells
displaying pycnotic nuclei.
Results Prolonged incubation with human oxidised LDL
particles led to a reduction in preproinsulin expression
levels, whereas the insulin level was preserved in the
presence of native LDL-cholesterol. The loss of insulin
production occurred at the transcriptional levels and was
associated with an increase in activator protein-1 transcrip-
tional activity. The rise in activator protein-1 activity
resulted from activation of c-Jun N-terminal kinases
(JNK, now known as mitogen-activated protein kinase
8 [MAPK8]) due to a subsequent decrease in islet-brain 1
(IB1; now known as MAPK8 interacting protein 1) levels.
Consistent with the pro-apoptotic role of the JNK pathway,
oxidised LDL also induced a twofold increase in the rate of
beta cell apoptosis. Treatment of the cells with JNK
inhibitor peptides or HDL countered the effects mediated
by oxidised LDL.
Conclusions/interpretation These data provide strong evi-
dence that oxidised LDL particles exert deleterious effects
in the progression of beta cell failure in diabetes and that
these effects can be countered by HDL particles.
Keywords Apoptosis . Diabetes . HDL . Insulin . JNK
pathway .MAPK . Oxidised LDL . Pancreatic beta cells
Abbreviations
AP1 activator protein-1
AP1Luc luciferase reporter construct driven by multi-
merised AP1 consensus sequences
Bcl2 B-cell leukaemia/lymphoma 2
GST glutathione S-transferase
IB1 islet brain 1
JNK c-Jun N-terminal kinases
Luc luciferase reporter construct
MAPK8 mitogen-activated protein kinase 8
Rip rat insulin II promoter
RIPE rat insulin promoter element
RipLuc rip linked to the luciferase reporter
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Introduction
A decline in the number of insulin-producing beta cells
and/or their intrinsic ability to produce and/or secrete
insulin contributes to the pathophysiology of type 2
diabetes [1]. It is now accepted that this beta cell
inadequacy results in part from oxidative stress due to
adverse effects of chronic elevation of glucose and free or
non-esterified fatty acids [2–4]. Among the major mecha-
nisms that have been associated with oxidative stress, is
induction of the c-Jun N-terminal kinases (JNK, now
known as mitogen-activated protein kinase 8 [MAPK8])
signalling pathway, leading to activation of activator
protein-1 (AP1) transcriptional factors complex [5, 6].
Suppression of this pathway prevents the loss of preproin-
sulin gene expression and apoptosis [7, 8].
Islet-brain 1/JNK-interacting protein 1 (IB1; now known
as MAPK8 interacting protein 1) is a mammalian scaffold
protein involved in the regulation of the JNK pathway [9–
11]. One of the outcomes of this regulation is to prevent the
activation of c-Jun (now known as JUN or Jun oncogene), a
transcription factor included in the AP1 transcriptional
complex that directly represses production of insulin and
induces beta cell apoptosis [11–14]. Reduction in IB1
content diminishes preproinsulin mRNA levels and renders
the cells more sensitive to stress-induced programmed death
[11, 15, 16]. The importance of IB1 levels in beta cells has
been confirmed in human diabetes. A missense mutation
(S59N) in the gene encoding IB1 has been found to co-
segregate with diabetes in a French family with a monogenic
form of type 2 diabetes. Ex vivo, this mutation reduces the
stability of IB1, leading to decreased insulin promoter
activity and acceleration of the rate of cell apoptosis [11, 17].
Elevated levels of oxidised LDL-cholesterol, together
with low HDL-cholesterol, are typical symptoms of
diabetic dyslipidaemia and risk factors for prediabetic and
diabetic patients to develop cardiovascular diseases [18–
20]. Oxidised LDL is produced in the subendothelial space
and is taken up by resident macrophages via scavenger
receptors [21–23], leading to their transformation into foam
cells. A recent report shows that beta cells express scavenger
receptor class B, member 1 and CD36, two scavenger
receptors for oxidised LDL, and that incubation of beta cells
with oxidised LDL causes a decline in specialised tasks
including insulin synthesis [24]. Oxidised LDL can induce
oxidative stress in several tissues, including activation of
the JNK signalling pathway and AP1 transcriptional
activity [25–27]. In view of these data, we postulated that
JNK signalling is implicated in the alteration of insulin
production and cell survival caused by oxidised LDL.
Herein, we provide evidence that oxidised LDL, but not
native LDL, exerts deleterious effects on insulin levels and
beta cell survival by activating the JNK pathway. Selective
inhibition of this pathway with peptide inhibitors or
incubation with human HDLs countered the effects medi-
ated by oxidised LDL.
Materials and methods
Lipoprotein preparation Blood was collected from healthy
donors. Plasma LDL fractions were isolated by sequential
ultracentrifugation (LDL density, 1.063) and dialysed
against PBS. Samples were analysed by SDS-PAGE to
assess the integrity of apolipoproteins and the purity of the
different fractions. The lipoprotein preparations contained
less than 0.112 units of endotoxin/μmol cholesterol as
determined by the kinetic chromogenic technique (Endotell,
Allschwil, Switzerland). Oxidation of LDL particles (at
1 mg/ml protein concentration in PBS) was performed by
incubation with 5 μmol/l CuSO4 at 37°C for 18 h. The
oxidation reaction was stopped at 4°C for 30 min by adding
300 μmol/l EDTA and by thorough dialysis against PBS
and subsequently against either DMEM or RPMI medium
without fetal calf serum. The oxidation reaction was
verified by determining the lipid peroxide content as
previously described [28].
Preparation and culture of islets Rat islets were isolated
from the pancreas of male Sprague–Dawley rats weighing
250–350 g by ductal injection of collagenase. The
purification of islets was conducted as described [29].
Isolated human islets were obtained from the Cell Isolation
and Transplantation Center (islets for research distribution
programme) of the Geneva University Hospitals. Islets were
cultured in CMRL-1066 supplemented with 10% fetal
bovine serum (Mediatech, Herndon, VA, USA) in a 5%
CO2 humidified atmosphere at 37°C.
Cell culture, transient transfection and plasmids The
insulin-secreting cell lines (MIN6 and INS-1E) and rat
isolated islets were maintained as previously described [30].
Transient transfection experiments were performed using a
kit (Effectene Transfection Reagent kit; Qiagen, Basel,
Switzerland) as reported [30]. The following plasmids were
used for the transfection assays: a 600-base pair sequence
of the rat insulin II promoter (Rip) cloned upstream of the
firefly luciferase gene [11]; rat insulin promoter element
(RIPE)3Luc [11]; and a luciferase reporter construct (Luc)
driven by multimerised AP1 consensus sequences
(AP1Luc). The latter two are firefly luciferase reporter
constructs corresponding to five copies of the (RIPE)3
binding site (containing the E elements) and to four copies
of the canonical AP1-responsive elements inserted up-
stream of the TATA minimal promoter, respectively.
Luciferase activities from the firefly and the renilla from
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the pRL-SV40 vector (Promega, Wallisellen, Switzerland)
were measured using an assay system (Dual-Luciferase
Reporter; Promega).
Measurement of insulin content Cells (5×105) were plated
in 24-well dishes and cultured in the presence of vehicle,
native and oxidised LDL for 72 h. Afterwards, the cells
were washed three times with a modified KRB/bicarbonate-
HEPES buffer (140 mmol/l NaCl, 3.6 mmol/l KCl,
0.5 mmol/l NaH2PO4, 0.5 mmol/l MgSO4, 1.5 mmol/l
CaCl2, 2 mmol/l NaHCO3, 10 mmol/l HEPES, 0.1% bovine
serum albumin) containing 2 mmol/l glucose. Insulin
contents were extracted with acid/ethanol solution and
measured by ELISA (Linco Research, St Charles, MO,
USA) as recommended by the manufacturer’s protocol.
Apoptosis assay Apoptosis was determined by scoring cells
displaying pycnotic nuclei visualised with Hoechst 33342
(Invitrogen, Basel, Switzerland) [28].
Protein kinase assay The preparation of whole-cell protein
extracts and the kinase assays were conducted as previously
described [8]. Briefly, cell extracts were incubated for 1 h at
room temperature with 1 μg glutathione S-transferase
(GST)-Jun (amino acids 1–89) and 10 μl glutathione-
agarose beads (Sigma-Aldrich, St-Gallen, Switzerland).
After several washings, the beads were supplemented with
JNK inhibitor or TAT (control) peptides for 20 min [8]. The
JNK inhibitor peptides used were the JNK binding domain
of IB1, which was coupled covalently to an N-terminal ten-
amino acid carrier peptide derived from the HIV-TAT48–57
sequence [8]. The retro-inverso D-enantiomer TAT and JNK
inhibitor peptides (Auspep PLT, Melbourne, VIC, Australia)
[8] were a gift from C. Bonny (S. A. Xigen, Lausanne,
Switzerland). Phosphorylation of substrate proteins was
examined after overnight exposition of polyacrylamide
gels to autoradiography; gel quantifications were accom-
plished by Phosphor-Imager analysis (Molecular Imager
FX; Bio-Rad Laboratories, Basel, Switzerland).
Nuclear protein extracts preparation and electromobility
shift assays Nuclear protein extracts and binding reaction
were conducted exactly as previously reported [30]. The
primers used as labelled probe were: AP1: sense: 5′-CG
CTTGATGAGTCAGCCGGAA-3′ and antisense 5′-GGC
TGACTCATCAAGCG-3′.
Western blotting, total RNA preparation and real-time
PCR For western blotting, the cell extracts were separated
by SDS-PAGE and blotted on nitrocellulose membranes.
The proteins were detected using specific antibodies and
were visualised by chemiluminescence using horseradish
peroxidase-coupled secondary antibodies. Total RNA from
insulin-secreting cell lines and pancreatic islets was
extracted using an RNA purification kit (Ambion, Austin,
TX, USA) according to the manufacturer’s protocol.
Reverse transcription reactions were performed as previous-
ly described [30]. Real-time PCR assays were carried out on
a real-time PCR detection system (MyiQ Single-Colour;
Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad), with
100 nmol/l primers, 1 μl of template per 20 μl of PCR and
an annealing temperature of 59°C. Melting curve analyses
were performed on all PCRs to rule out non-specific
amplification. Reactions were carried out in triplicate.
Primer sequences for PCR were as follows: mouse and
human insulin, sense 5′-TGGCTTCTTCTACACACCCA-3′,
antisense 5′-TCTAGTTGCAGTAGTTCTCCA-3′; mouse and
human tubulin, sense 5′-GGAGGATGCTGCCAATAACT-3′,
antisense 5′-GGTGGTGAGGATGGAATTGT-3′; rat and
mouse Ib1, sense 5′-AGTGTCCAGCTTCCCTTGTC-3′,
antisense 5′-TTACTGTGGCCCTCTCCTTG-3′; human
IB1, sense 5′-ATCAGCCTGGAGGAGTTTGA-3′, antisense
5′-AGGTCCATCTGCAGCATCTC-3′; human FOS, sense
5′-TGATACACTCCAAGCGGAGAC-3′, antisense 5′-CCC
AGTCTGCTGCATAGAAGG-3′; mouse ribosomal phospho-
protein P0 gene, sense 5′-ACCTCCTTCTTCCAGGCTTT-3′,
antisense 5′-CCACCTTGTCTCCAGTCTTT-3′; mouse B-
cell leukaemia/lymphoma 2 (Bcl2), sense: 5′-CTCCCGATT
CATTGCAAGTT-3′, antisense 5′-TCTACTTCCTCCG
CAATGCT-3′.
Statistical analyses Data are expressed as means±SEM.
Unpaired two-tailed Student’s t test was used to compare
groups.
Results
Oxidised LDL particles reduce insulin expression at the
transcript level We first investigated the effects of oxidised
LDL particles on insulin production. In vitro oxidisation of
LDL-cholesterol particles by copper has been previously
shown to generate similar changes in LDL particles to those
occurring in endothelial cells, including lipid peroxidation
and extensive hydrolysis of phosphatidylcholine [31]. For
this reason, we chose to oxidise LDL particles by copper, as
performed in many reports [24, 32, 33], in order to evaluate
the effects of oxidised LDL on beta cells. Insulin contents
were measured from MIN6 cells cultured with different
concentrations of freshly purified oxidised LDL-cholesterol
particles. The results show that oxidised LDL reduced
insulin content in a dose-dependent manner, whereas native
LDL did not affect insulin expression (Fig. 1a). Similar
results were obtained in INS-1E cells (data not shown) and
are consistent with the data of a previous study showing
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that native LDL at cholesterol concentrations between 1.6
and 3.1 mmol/l has no effect on beta cell survival and
function [28]. To evaluate the effects of modified LDL for
the following experiments, we chose to incubate the cells at
an oxidised LDL concentration of 2 mmol/l. Under these
conditions, as previously reported [24], we found that the
decrease in insulin content was associated with a loss in
preproinsulin mRNA levels (Fig. 1b). These oxidised LDL-
mediated effects also occurred at 48 h (data not shown) of
culture and were observed in isolated human and rat islets
(Fig. 1b), as well as in the insulin-secreting cell lines MIN6
(Fig. 1b) and INS-1 (data not shown).
Oxidised LDL diminishes the expression of insulin at the
promoter level We next assessed the hypothesis that
oxidised LDL-mediated effects on insulin expression
occurs at transcriptional levels. For this purpose, a 600-
base pair fragment of rat insulin II promoter (Rip) linked to
the luciferase reporter (RipLuc) construct was transiently
transfected in INS-1E cells [11]. While culture of the
transfected cells with native LDL did not significantly
modify the luciferase activity of RipLuc, oxidised LDL
caused a drastic decrease in production of the reporter gene
(Fig. 2a). The activity of the Rip is dependent for a large
part on an enhancer region (5′-GCCATCTG-3′), which is
referred to as insulin control element or E element [34, 35].
When multimerised and cloned downstream of a SV40
promoter, this region is capable of enhancing expression of
a luciferase gene from the (RIPE)3Luc construct [11, 13].
To verify whether the E element is responsible for the loss
of insulin expression, INS-1E cells transfected with this
heterologous promoter construct were cultured in the
presence of oxidised LDL. We found that incubation with
oxidised LDL but not with native LDL generated a twofold
decrease in the luciferase activity of (RIPE)3Luc (Fig. 2b).
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Fig. 1 Effects of oxidised LDL on insulin levels. a Insulin content
of MIN6 cells exposed for 72 h to vehicle (−), native LDL and
different concentrations of oxidised LDL-cholesterol particles. Data
(mean ± SEM) are representative of four independent experiments.
b Analysis of representative insulin mRNA levels by real-time PCR.
Total RNAwas isolated from MIN6 cells (grey bars), isolated rat islets
(striped bars) and isolated human islets (black bars) that had been
cultured for 72 h with different LDL preparations. Total RNA was
then subjected to real-time PCR to measure the preproinsulin and
β-tubulin (internal control) mRNA levels. Data from cells cultured
with vehicle (−) were set to 100%. Data are the mean ± SEM of three
independent experiments. ** p<0.01; *** p<0.001
Fig. 2 Effects of oxidised LDL on insulin reporter construct activity
in MIN6 cells. Vehicle (−), native and oxidised LDL-cholesterol
particle preparations were added to culture medium 2 h after
transfection. Exposure of cells to oxidised LDL led to a reduction of
(a) the luciferase activity of a 600-bp fragment of the rat insulin
promoter (RipLuc) and (b) the heterologous promoter activity
containing insulin control element (ICE) (RIPE)3Luc. The empty
pGL3basic (Luc) and the SV40Luc vectors were used as controls for
measuring the promoter activity of RipLuc and (RIPE)3Luc, respec-
tively. All luciferase activities were normalised using pRLSV40
renilla. Each experiment was performed at least three times in
triplicate. All values are expressed as per cent of SV40Luc activity in
cells cultured with vehicle (−). Results are mean ± SEM. *** p<0.001
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Introduction of a mutation in E elements [11] prevented the
loss of luciferase activity mediated by oxidised LDL (data
not shown). This indicates that the E element is responsible
for the loss of insulin expression.
Oxidised LDL induces JNK activity, increases AP1
transcriptional activity and downregulates expression of
Ib1 It is well documented that the E element of Rip binds the
basic helix loop helix transcription factors [34, 35]. Previous
reports have demonstrated that c-Jun, a component of the
AP1 transcriptional complex [36], can inhibit the E47 basic
helix loop helix factor, leading to inhibition of insulin
promoter activity [13, 14]. Interestingly, oxidised LDL led
to oxidative stress in various cell types [25, 27]. This
phenomenon involves activation of the JNK signalling
cascade and culminates in an increase in the activity of
AP1 transcriptional complexes due to an elevation of c-Jun
levels and its activity [25, 37, 38]. Based on these
observations, we hypothesised a possible increase in AP1
activity in cells cultured with oxidised LDL. To test this
assumption, we monitored AP1 activity by transiently trans-
fecting a luciferase reporter construct driven by multimerised
AP1 consensus sequences (AP1Luc). While no changes in
AP1Luc activity were observed in the presence of native LDL,
in cells cultured with 2 mmol/l oxidised LDL-cholesterol a
twofold increase in the luciferase activity of AP1Luc was
detected (Fig. 3). In addition, electromobility shift assay
experiments performed using the AP1 consensus sequence as
labelled probe revealed an increase in AP1 binding pattern in
nuclear extracts from cells cultured with oxidised LDL
(Electronic supplementary material [ESM] Fig. 1).
To determine whether the rise in AP1 activity was the
result of increased JNK activity, we measured JNK-
mediated phosphorylation of the target transcription factor
c-Jun. Total proteins from cells cultured with either
2 mmol/l of oxidised LDL or native LDL were incubated
with the c-Jun recombinant. Using extracts of cells treated
by oxidised LDL, kinase experiments show a time-
dependent increase in c-Jun phosphorylation (Fig. 4a,b).
As expected, the phosphorylation of c-Jun was efficiently
blocked by 5 μmol/l JNK inhibitor peptides [8] or by the
selective JNK inhibitor SP600125 (ESM Fig. 2). Phosphor-
ylation of c-Jun occurred with extracts of cells incubated
for 45 min and 72 h with oxidised LDL, whereas native
LDL did not induce any change in phosphorylation of
c-Jun. Phosphorylation of JNK is required for JNK to
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Fig. 4 Effects of oxidised LDL (oxLDL) on JNK activity. a, bWhole-
cell extracts were prepared from cells incubated with 2 mmol/l
oxidised LDL or native LDL at the indicated times. JNK inhibitor
peptides (JNKi) (b), at a 5 μmol/l concentration, were added in cells
cultured with oxidised LDL (2 mmol/l). JNK solid-phase JNK assays
were performed with the lysates using GST-c-Jun as substrate. The
reaction was loaded on a polyacrylamide gel and γ-33P-phosphorylation
of the substrates (Phospho-c-Jun) was subsequently analysed. The gel
was stained with Coomassie blue to evaluate the loading of substrate
(GST-Jun). The results are representative of three independent experi-
ments. c, d Measurement of c-Jun and Fos expression levels by real-
time PCR. The mRNA levels of these genes were normalised against
β-tubulin and expression levels from cells cultured with vehicle were
set to 100%. Data are the mean ± SEM of four independent experiments.
*** p<0.001
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phosphorylate its substrates. Consistent with this, western
blotting experiments showed an increase in JNK activity in
cells exposed to oxidised LDL (Fig. 4a,b). Thus, these
results confirm that activation of JNK is induced by
oxidised LDL. To validate activation of the JNK signalling
cascade by oxidised LDL, expression of the c-Jun and Fos
genes was then quantified. The transcriptional activity of
the promoters of these two genes is positively regulated by
JNK [8]. Real-time PCR analysis showed a statistically
significant augmentation by 1.5- and threefold in Fos and
c-Jun mRNA levels, respectively, in MIN6 cells cultured
with oxidised LDL (Fig. 4c,d).
We next investigated whether JNK activation is respon-
sible for the loss of insulin production. Insulin-secreting
cells were incubated with oxidised LDL in the presence of
JNK inhibitor. Treatment of the cells with these peptides
prevented the decrease in preproinsulin mRNA and
(RIPE)3Luc promoter activity caused by oxidised LDL
(Fig. 5a,b). Prolonged exposure of cells to various stressors
has been shown to activate the JNK pathway in beta cells.
In some cases, this activation results from the decline of
IB1 levels [15, 16, 39]. This prompted us to evaluate the
expression of Ib1 in cells treated with the oxidised LDL
preparation. Western blotting showed a decrease in IB1
protein contents in MIN6 cells treated with oxidised LDL
for 72 h, whereas the content was unaffected at 45 min of
culture (Fig. 6a). Real-time PCR confirmed the reduction in
IB1 mRNA levels in isolated human and rat islets as well as
in MIN6 cells cultured with oxidised LDL for 72 h (ESM
Fig. 3).
Activation of the JNK pathway has often been associated
with an increase in beta cell programmed death [8, 15, 40].
We therefore tested the viability of insulin-secreting cells in
the presence of LDL-cholesterol preparations. As expected,
the rate of apoptosis of the cells cultured with 2 mmol/l
oxidised LDL-cholesterol for 72 h increased by threefold in
MIN6 cells and rat isolated islets, whereas the viability of
the cells incubated in the presence of native LDL was
unchanged (Fig. 6b). The rate of apoptosis was similar
when MIN6 cells were incubated either at 20 or at
10 mmol/l glucose. This result is in agreement with a
previous report showing that glucose did not render cells
more sensitive to the effects of LDL [28]. Co-treatment
with JNK inhibitors prevented the apoptosis of cells
mediated by oxidised LDL (Fig. 6c). Real-time PCR
experiments showed a reduction of Bcl2 expression
(Fig. 6d). This result is in agreement with the induction of
the apoptotic pathway by oxidised LDL as reported in
endothelial cells [41]. In contrast to early effects of oxidised
LDL on insulin levels, the viability of the cells cultured
with oxidised LDL for 48 h was apparently unchanged
(data not shown). This result indicates that the loss of
insulin expression induced by oxidised LDL probably
precedes programmed cell death.
Taken together, our results indicate that the effects of
oxidised LDL on insulin expression and beta cell survival
are linked to activation of the JNK signalling pathway
resulting from a decrease in IB1 contents.
HDL protects cells from oxidised LDL-induced loss of
insulin expression and death HDL has been described to
protect beta cells from cytokine- and LDL-mediated
apoptosis [28]. To assess the potential protective effects of
HDL on the decline of insulin expression and the induction
of cell death mediated by oxidised LDL, MIN6 cells and
isolated human islets were co-incubated with HDL and
LDL preparations. HDL at 1 mmol/l of cholesterol
concentration protected the cells from apoptosis (Fig. 7a)
Fig. 5 Effects of JNK inhibition on the loss of insulin expression
mediated by oxidised LDL. a JNK inhibitor (filled bars) or D-TAT
(open bars) as control [8] was co-incubated with the different LDL
preparations in MIN6 cells and preproinsulin mRNA levels were
quantified by real-time PCR experiments. Data are the mean ± SEM of
four independent experiments. b Effects of JNK inhibitor on the
activity of the (RIPE)3Luc construct. MIN6 cells were transiently
transfected with (RIPE)3Luc and co-cultured with LDL preparations
and 5 μmol/l of the JNK inhibitor (filled bars) or TAT (open bars) for
48 h. Luciferase activities were normalised using pRLSV40 renilla.
Each experiment was performed at least three times in triplicate. All
values are expressed as per cent of SV40Luc activity. Results are
expressed as mean ± SEM. ** p<0.01
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and prevented the reduction in Bcl2 expression induced by
oxidised LDL (Fig. 7b). In addition, HDL treatment
partially prevented the loss of preproinsulin mRNA and
promoter activity (Fig. 8a,b). The protective effects of HDL
on the activity of RipLuc were also observed at 48 h of
incubation (data not shown). HDL also efficiently pre-
vented oxidised LDL-induced AP1Luc activity (Fig. 9a)
and an increase in Fos expression in MIN6 cells (Fig. 9b)
and human isolated islets (Fig. 9c). The restoration of basal
activity of AP1 by HDL was already observable at 48 h
(data not shown). In line with the loss of AP1 activity,
HDL countered JNK’s effects on c-Jun phosphorylation
(Fig. 9d) and the decline in IB1 expression (Fig. 9e,f).
These data suggest that HDL exerts its protective action by
blocking the effects of oxidised LDL on the JNK signalling
pathway.
Discussion
Several studies have reported expression of receptors for
native and modified forms of LDL, including scavenger
receptor class B, member 1 and CD36 scavenger receptors,
as well as the uptake of these lipoproteins in pancreatic beta
cells [24, 28, 33, 42]. Herein, in agreement with a previous
study, we found that insulin-secreting cells cultured with
oxidised LDL have reduced preproinsulin gene expression
[24]. This perturbed expression was observed at protein and
mRNA levels, both in isolated human and rat islets and in
several insulin-secreting cell lines. The reduced luciferase
activity of RipLuc and the multimerised E elements-
containing promoter (RIPE)3Luc suggests that oxidised
LDL particles exert their action on the preproinsulin gene at
the transcriptional levels. This effect is mediated through
the E elements and is not the result of irreversible cell
damage as can be seen from the fact that mutation of these
elements prevents the changes in luciferase activity of
(RIPE)3Luc triggered by oxidised LDL. Several lines of
evidence support a role for c-Jun, a component of the AP1
transcriptional complex, in the decline of preproinsulin
gene transcription mediated by oxidised LDL [13]. Over-
expression of c-Jun has been shown to indirectly repress
the enhancer activity of the E elements by interfering with
the transactivating capacity of basic helix loop helix
transcription factors, which bind to the former element
[13, 14]. Conversely, induction of insulin expression is
accompanied by a decrease in c-Jun expression [43]. In line
with these observations, we found that the impaired
preproinsulin expression is associated with an increase in
AP1 transcriptional activity and c-Jun expression.
AP1 activity and c-Jun expression are induced by an
unusually broad range of environmental stressors [44].
Many of these stimuli activate JNKs, leading to enhanced
AP1 transcriptional activity. In cultured human fibroblasts
and human aortic endothelial cells, oxidised LDL has been
reported to increase the activity of AP1 and JNK,
respectively [25, 26, 45]. Moreover, activation of the JNK
pathway by overexpressing mitogen activated protein
kinase kinase kinase 1 in insulin-secreting cells reduces
the luciferase activity of (RIPE)3Luc [11]. For this reason,
we presumed that activation of JNK by oxidised LDL was
responsible for augmenting AP1 activity and therefore for
reducing preproinsulin gene expression. Consistent with
this, inhibition of JNK with JNK inhibitors prevented the
loss of (RIPE)3Luc activity and the decrease in preproinsu-
lin mRNA levels mediated by oxidised LDL. This finding
furnishes new evidence for the possible involvement of the
JNK pathway in impaired preproinsulin expression through
the E element.
Increased JNK activity and c-Jun expression have been
reported in many scenarios in which cells undergo
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apoptosis [46, 47]. As expected, oxidised LDL induced a
rise in the rate of apoptosis and JNK inhibitors protected
cells against this deleterious effect. The reduction of Bcl2
expression confirms activation of the apoptotic pathway
induced by oxidised LDL. In contrast, native LDL at
2 mmol/l cholesterol concentration did not induce apopto-
sis. This result is in agreement with previous studies
showing that native LDL-cholesterol at concentrations
lower than 3.1 mmol/l cholesterol does not cause apoptosis
[24, 28]. Some reports found no effects of oxidised LDL on
apoptosis [24, 33]. The discrepancy between the latter
studies and our data could be due to the length of exposure
to oxidised LDL. Indeed, we observed that 48 h incubation
with oxidised LDL is sufficient to initiate a slight decrease
in insulin levels but not to affect the rate of apoptosis (data
not shown). Thus, these data confirm that the loss of insulin
levels caused by oxidised LDL is not a consequence of cell
death and might precede the apoptotic events.
IB1 is a key modulator of the JNK pathway and is
required for cell survival and insulin expression [11, 15].
Long-term exposure of cells to proapoptotic stimuli
diminishes expression of Ib1 [15, 16]. Such a decrease
induces the JNK pathway and the subsequent activation of
AP1, thereby leading to impaired insulin synthesis and
increased apoptosis [11, 15, 16]. As expected, IB1 levels
were reduced in cells treated with oxidised LDL for
72 h. In contrast, these levels were unchanged after
45 min of treatment, although JNK activity occurred at
that time point. Therefore, the data show that the early
effects of oxidised LDL on induction of JNK activity do
not require downregulation of IB1. However, the latter
event can be responsible for maintaining prolonged acti-
vation of JNK.
In patients with diabetes and metabolic syndrome, low
serum HDL levels and elevated oxidised LDL concen-
trations are risk factors for the the development of
cardiovascular diseases [18–20]. While oxidised LDL has
pro-atherogenic effects, HDL is known to be anti-athero-
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by oxidised LDL. a The preproinsulin mRNA levels were quantified
by real-time PCR experiments in cells incubated for 72 h in the
presence (filled bars) or absence (open bars) of 1 mmol/l of HDL and
2 mmol/l of LDL preparation. Results are expressed as the mean ±
SEM of at least three independent experiments measured in triplicate.
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ments measured in triplicate. *** p<0.001
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genic and cardioprotective. Besides its role in the reverse
transport of cholesterol, HDL has been shown in vitro to
exert its effects by inhibiting LDL oxidation and cell
signalling mediated by oxidised LDL; it also counters
several adverse biological effects, such as cytotoxicity and
inflammatory responses triggered by oxidised LDL [19, 48,
49]. In this report, we establish that HDL efficiently
counters the effects of oxidised LDL on apoptosis by
restoring expression of Bcl2. One possible mechanism is
the depletion by HDL of LDL from lipid peroxides through
enzymatic hydrolysis of phospholipid hydroperoxides, a
process effected by the HDL-bound enzyme paraoxonase.
This has been shown to reduce cytokine production
stimulated by oxidised LDL [50]. In addition, the idea that
HDL mediates its action by preventing activation of the
JNK pathway is supported by the fact that JNK and AP1
activities were not induced and that IB1 and FOS levels
were unaltered in cells co-cultured with oxidised LDL and
HDL. This hypothesis is supported by the fact that HDL
protects insulin-secreting cells from apoptosis induced by
VLDL [28]. As is the case here for oxidised LDL, VLDL-
mediated apoptosis was linked to impaired Ib1 expression
and an increase in JNK activity [28].
Our data also show that HDL exerted its effects on insulin
levels and AP1 activity as early as the 48-h time point. At that
incubation time, downregulation of Ib1 and apoptosis did not
occur. Thus, HDL counters the oxidised LDL-mediated
activation of JNK in a manner that is both dependent and
independent of IB1. More than 20 proteins are associated
with HDL. These include apolipoproteins that serve as
Fig. 9 HDL prevents induction
of the JNK pathway mediated
by oxidised LDL. a MIN6 cells
were transiently transfected with
the AP1Luc construct and incu-
bated with vehicle, native and
oxidised LDL with (closed bars)
or without (open bars) 1 mmol/l
HDL. b Fos mRNA levels
were measured in MIN6 cells
and (c) in human islets co-
cultured with LDL preparations
and with (filled bars) or without
(open bars) 1 mmol/l HDL-
cholesterol for 72 h. d JNK
activity was measured in whole-
protein extracts from MIN6 cells
cultured with vehicle (−), native
and oxidised LDL plus or minus
1 mmol/l HDL. e The effects of
HDL on Ib1 mRNA levels were
assessed in MIN6 cells and f in
human isolated islets exposed to
LDL preparations and HDL
(filled bars) for 72 h. The
mRNA level was normalised
against β-tubulin. Expression
levels from cells cultured with
native LDL were set to 100%.
Data in all panels are the
mean ± SEM of five independent
experiments. * p<0.05,
** p<0.01, *** p<0.001
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structural components, cofactors or inhibitors of enzymes, as
well as ligands of receptors. Future studies will have to clarify
which of these components mediate the protective effects of
HDL, which counter those of oxidised LDL, on beta cells.
Finally, this study highlights the biological consequences
and the relationship between the levels of the modified
lipoproteins and HDL for beta cell function. Reductions in
the concentration of HDL could potentiate the effects of
oxidised LDL, thereby contributing to beta cell dysfunc-
tion. Therefore, like hyperglycaemia and NEFA, modified
LDL could contribute to the development of diabetes. A
better understanding of the mechanisms underlying the
effects of oxidised LDL and HDL will help elucidate the
causes of human type 2 diabetes and may lead to novel
strategies for treatment or prevention of diabetes.
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B Oxidative stress and ICER mediate the harmful effects of oxLDL on β-cell function 
 
B.1 Introduction 
Pancreatic β-cell dysfunction represents a key step in the pathogenesis of T2D, as this process 
underlies the transition between an asymptomatic state of β-cell compensation and overt diabetes. 
This alteration is characterized by impairment in the biosynthesis and secretory capacities of β-
cells and exacerbated rate of apoptosis. The chronic exposure of pancreatic β-cells to excess of 
metabolic fuels, such as FFA and glucose, contributes to the progressive decline in cellular 
function and glucose homeostasis (14). These environmental stressors chronically elevate 
intracellular ROS which interfere with the proper function of β-cells – a process termed oxidative 
stress (44). As previously mentioned, hyperglycemia and hyperlipidemia stimulate the expression 
of the transcriptional repressor ICER, thereby promoting β-cell dysfunction (71;73;82).  
 
Patients with T2D and glucose intolerance have a higher risk to develop atherosclerosis and 
associated cardiovascular diseases, as a consequence of the elevation in the circulating levels of 
oxidatively modified over native LDL and the reduced concentrations of HDL. Since these 
perturbations in lipid profile occur long before the establishment of frank hyperglycemia, a role 
for these lipoproteins in the pathogenesis of T2D and particularly β-cell dysfunction has been 
postulated. Several data, including the results of the precedent chapter, support the idea that 
oxidized lipoproteins together with low levels of HDL contribute to the impairment in insulin 
biosynthesis and release, and β-cell survival (56;80). These perturbations ensue from the 
activation of the JNK pathway, which is one of the hallmarks of oxidative stress, as demonstrated 
in the previous chapter. 
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These observations led us to hypothesize that oxidized LDL may trigger β-cell failure by 
inducing the transcriptional repressor ICER in a mechanism that involves oxidative stress. 
 
B.2 Results 
In order to study the molecular mechanism underlying the adverse outcomes of oxidized 
lipoproteins, we first determined the expression of the transcription factor ICER in pancreatic β-
cells exposed for 72h in presence of native or oxidized human LDL. Whereas native lipoproteins 
had no effect, modified LDL significantly increased ICER mRNA and protein levels in the 
insulin-secreting cell lines MIN6 B1 and INS-1E, as well as in rat isolated islets (Fig 1). The 
activation of this transcriptional repressor was associated with impairment in the expression of 
the ICER target genes Rab3a, Rab27a, Slp4, Noc2 and IB1, which was significantly restored by 
the silencing of ICER (Fig 2b-f). Importantly, the invalidation of ICER expression was correlated 
with a protection of insulin gene transcription, secretory activity and β-cell survival in presence 
of oxLDL (Fig 2a and 3). 
 
Induction of the transcriptional repressor ICER by modified lipoproteins was paralleled by the 
generation of oxidative stress, as demonstrated by the amplified production of ROS (Fig 4a). 
Oxidative stress proved to be causal in the activation of ICER by oxLDL since the direct ROS 
generator hydrogen peroxide activated expression of the transcriptional repressor, whereas the 
antioxidants N-acetylcysteine (NAC) or HDL particles inhibited ICER induction by modified 
lipoproteins (Fig 4b-e and 6). In agreement with the inhibitory properties of NAC on ICER, 
antioxidant treatment of pancreatic β-cells fully protected insulin gene expression, insulin 
secretion and cell survival against the harmful effects of oxLDL (Fig 5). 
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In conclusion, all these data demonstrate that oxidized LDL contribute to β-cell dysfunction by 
activating the transcriptional repressor ICER in a mechanism involving oxidative stress. 
 
B.3 Contribution 
In this paper, the student was the principal investigator and performed all the experiments. He 
was helped by his colleagues to increase the number of experimenters on key experiments and to 
assess the reproducibility of the results. The student performed the preparation of the figures, the 
statistical analysis of the data and contributed to the redaction of the manuscript. Finally, he 
designed and made the experiments for the correction of the paper with the help of his colleagues. 
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Abstract
Aims/hypothesis Pro-atherogenic and pro-oxidant, oxidised
LDL trigger adverse effects on pancreatic beta cells,
possibly contributing to diabetes progression. Because
oxidised LDL diminish the expression of genes regulated
by the inducible cAMP early repressor (ICER), we
investigated the involvement of this transcription factor
and of oxidative stress in beta cell failure elicited by
oxidised LDL.
Methods Isolated human and rat islets, and insulin-
secreting cells were cultured with human native or oxidised
LDL or with hydrogen peroxide. The expression of genes
was determined by quantitative real-time PCR and western
blotting. Insulin secretion was monitored by EIA kit. Cell
apoptosis was determined by scoring cells displaying
pycnotic nuclei.
Results Exposure of beta cell lines and islets to oxidised
LDL, but not to native LDL raised the abundance of
ICER. Induction of this repressor by the modified LDL
compromised the expression of important beta cell
genes, including insulin and anti-apoptotic islet brain
1, as well as of genes coding for key components of the
secretory machinery. This led to hampering of insulin
production and secretion, and of cell survival. Silencing
of this transcription factor by RNA interference restored
the expression of its target genes and alleviated beta cell
dysfunction and death triggered by oxidised LDL.
Induction of ICER was stimulated by oxidative stress,
whereas antioxidant treatment with N-acetylcysteine or
HDL prevented the rise of ICER elicited by oxidised LDL
and restored beta cell functions.
Conclusions/interpretation Induction of ICER links oxida-
tive stress to beta cell failure caused by oxidised LDL and
can be effectively abrogated by antioxidant treatment.
Keywords Antioxidant . Apoptosis . Diabetes . HDL .
ICER . Insulin . Oxidative stress . Oxidised LDL .
Pancreatic beta cells
Abbreviations
CRE cAMP responsive elements
CREluc Luciferase reporter construct driven by two CRE
sequences linked upstream to a SV40 promoter
hGH Human growth hormone
ICER Inducible cAMP early repressor
JNK c-Jun amino terminal kinase
MAPK Mitogen-activated protein kinase
NAC N-Acetylcysteine
ROS Reactive oxygen species
si Small interfering
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Introduction
A decline in the number of insulin-producing beta cells
and/or their intrinsic ability to produce and/or secrete
insulin contributes to the pathophysiology of type 2
diabetes [1]. Chronic excess of cholesterol and metabolic
fuels, such as the NEFA palmitate and glucose, conspire
with genetic factors to trigger beta cell dysfunction and
destruction over time [2–6]. Low plasma levels of HDL
together with increased levels of oxidised LDL-cholesterol
are associated with diabetes, thereby elevating risk of
developing atherosclerosis and ultimately cardiovascular
diseases [7, 8]. The fact that perturbations of these
lipoproteins precede development of diabetes has led to
the hypothesis that they could contribute to the progres-
sion of the disease [9–12]. So far, numerous clues
support a role for oxidised LDL in triggering adverse
effects in beta cells and thereby contributing to the
pathophysiology of diabetes. Prolonged exposure of
insulin-producing cell lines, as well as isolated human
and rodents islets to oxidised LDL at physiological
cholesterol concentration compromised insulin produc-
tion and secretion, and increased the rates of apoptosis
[6, 13–15], while native LDL at a similar cholesterol
concentration did not exert such adverse effects. Co-
incubation of cells with HDL permitted abrogation of the
harmful effects of oxidised LDL [13]. Positive effects, as
well as protective properties of this particle against
toxicity generated by chronic hyperglycaemia have also
been shown [15, 16], validating the concept that adequate
levels of HDL are required for beta cell function and
control of glucose homeostasis.
A wealth of data point to oxidative stress as the link
coupling oxidised LDL to cell dysfunction and death
[17, 18]. The hypothesis that oxidative stress can
mediate beta cell dysfunction caused by pro-
atherogenic oxidised LDL is further supported by a
clinical trial investigating the efficiency of an antioxi-
dant in cardiovascular events in patients with acute
coronary diseases [19]. Daily administration of the
antioxidant molecule markedly reduced the occurrence
of new-onset diabetes [19]. Furthermore, in vitro induc-
tion of specific signalling cascades supports involvement
of oxidative stress in beta cell failure evoked by oxidised
LDL. Activation of the mitogen-activated protein kinase
(MAPK) pathways, including MAPK8 (also called c-Jun
amino terminal kinase [JNK]), is one of the hallmarks of
oxidative stress [20, 21]. Activation of JNK signalling in
beta cells leads to programmed cell death and impaired
insulin expression [20, 21]. Induction of JNK activity has
been demonstrated to contribute to beta cell dysfunction
caused by oxidised LDL [13].
Increased JNK activity caused by oxidised LDL
results from reduced levels of MAPK8 interacting
protein-1 (also called JNK interacting protein 1 or islet
brain 1), a potent inhibitor of JNK activity in beta cells
[13, 22]. Islet brain 1 is a target of the inducible cAMP
early repressor (ICER), a member of the cAMP
responsive element (CRE) modulator transcription fac-
tors [23]. ICER is a powerful passive repressor, which
silences expression of genes that contain a CRE within
their promoters [24]. Induction of ICER is in part
responsible for beta cell failure evoked by hyperglycaemia
and fatty acids [25, 26]. This negative role is achieved by
silencing expression of insulin [27] and components of the
secretory machinery, such as the GTPases Rab3a and
Rab27a, and their effectors Slp4 (also known as Sytl4) and
Noc2 (also known as Rph3al) [25]. All these observations
led us to investigate whether oxidised LDL may trigger
beta cell failure by inducing production of ICER in a
mechanism that involves oxidative stress.
Methods
Lipoprotein preparation Blood was collected from healthy
donors. Plasma LDL fractions were isolated by sequential
ultracentrifugation (LDL density 1.063) exactly as de-
scribed [13]. Oxidation of LDL particles was done by
incubating 1 mg LDL protein/ml PBS with 5 μmol/l CuSO4
at 37°C for 6–8 h [13]. The oxidation reaction was verified
as previously described by determining the lipid peroxide
content [13].
Cell culture and preparation of isolated islets The insulin-
secreting cell line (MIN6) was maintained as previously
described [13]. Isolated human islets were obtained from
the Cell Isolation and Transplantation Center (islets for
research distribution programme) of the Geneva University
Hospital (Geneva, Switzerland). Investigations were been
approved by the responsible ethics committee. Islets were
cultured in CMRL-1066 supplemented with 10% (vol./vol.)
fetal bovine serum (Mediatech, Herndon, VA, USA) in 5%
CO2 humidified atmosphere at 37°C. Rat islets were
isolated from the pancreas of male Sprague–Dawley rats
weighing 250–350 g by ductal injection of collagenase P
(Roche Diagnostics, Rotkreuz, Switzerland). Purification
and culture of islets was conducted as described [13].
Experimental protocols were approved by the Cantonal
Veterinary Office.
Small interfering RNA and transfection A pool of two 19-
nucleotide pre-validated small interfering (si) RNA duplexes
that target the mouse and rat Icer (also known as Crem)
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sequence (si-Icer) were chemically synthesised by Mycro-
synth (Balgach, Switzerland). The two target sequences of
Icer were: 5′-CTGGAGATGAAACTGCTGC-3′ and 5′-
CTGGAGATGAAACTGATGA-3′. Transient transfection
experiments were performed using a kit (Lipofectamine
2000 transfection; Invitrogen, Basel, Switzerland) as
reported [23].
Measurement of secretion Cells (5×105) were plated in 24-
well dishes and cultured in the presence of vehicle, native
and oxidised LDL for 72 h. When human growth hormone
(hGH) was used as a reporter for regulated secretion, the
cells were first transiently transfected with a construct
encoding the hGH and 24 h later cultured with lipoproteins
for 72 h. Thereafter, the cells were washed three times with
modified KRB HEPES buffer (10 mmol/l HEPES, 0.1%
[wt/vol.] bovine serum albumin) containing insulin secre-
tagogues (20 mmol/l of glucose or 30 mmol/l KCl). Insulin
released in the supernatant fraction and insulin cellular
contents were measured by EIA (Cayman Chemical, Ann
Arbor, MI, USA) as recommended by the manufacturer’s
protocol. Exocytosis from transfected cells was assessed by
ELISA (Roche Diagnostics, Rotkreuz, Switzerland) that
measured the amount of hGH released into the medium
during the incubation period.
Apoptosis assay Apoptosis was determined by scoring cells
displaying pycnotic nuclei (visualised with Hoechst 33342)
[13]. The counting was performed blind by three different
experimenters.
Measurement of superoxide After treatment, MIN6 cells
were washed twice with PBS 1× and scraped in PBS 1×.
Cells were dispersed by pipetting and then 10 μmol/
l lucigenin and 0.2 mmol/l NADPH were added to the cell
suspension. Emitted luminescence was quantified for 12 s
in a luminometer (Berthold, Bad Wildbad, Germany).
Results were normalised to the DNA content measured
using Hoechst 33258 dye (Sigma-Aldrich Chemie, Buchs,
Switzerland).
Western blotting, total RNA preparation and real-time
PCR For western blotting, nuclear extracts were sepa-
rated by SDS-PAGE and blotted on nitrocellulose
membranes as described [13]. The proteins were detected
using specific antibodies and visualised with IRDye 800
(Rockland, Gilbertsville, PA, USA) as secondary anti-
bodies, and quantified in an imaging system (Odyssey
Infrared; Li-COR, Lincoln, NE, USA). Total RNA from
insulin-secreting cell lines and pancreatic islets was
extracted using phenol/chloroform extractions as described
previously [13]. Reverse transcription reactions were per-
formed as previously described [23]. Real-time PCR assays
were carried out on a real-time PCR detection system (MyiQ
Single-Color; Bio-Rad Laboratories, Hercules, CA, USA)
using the iQ SYBR Green Supermix (Bio-Rad Laboratories)
exactly as previously described by Abderrahmani et al. [13].
Primer sequences of rat/mouse origin for Rab3a, Slp4,
Icer and Rplp0 were those published elsewhere [25].
Otherwise primer sequences are described in the electronic
supplementary material [ESM] Table 1.
Statistical analyses Experiments including more than two
groups were analysed by ANOVA or with the non-
parametric equivalent Kruskal–Wallis test.
Results
Oxidised LDL-cholesterol particles hamper insulin produc-
tion and insulin secretion, as well as beta cell survival by
inducing the activity of Icer We first assessed whether
induction of Icer links oxidised LDL to beta cell failure. In
vitro oxidisation of LDL-cholesterol particles by copper
have been previously shown to generate changes in LDL
particles similar to those occurring in endothelial cells,
including lipid peroxidation and extensive hydrolysis of
phosphatidylcholine [28]. To evaluate the effects of
oxidised LDL on beta cells, LDL particles were oxidised
by copper as performed in many reports [6, 29, 30]. Our
previous study had shown that culture of beta cells for
72 h with oxidised LDL containing 2 mmol/l cholesterol
(physiological concentration), diminished the insulin level
and cell survival [13]. Here, reduction in insulin expression
and cell integrity was already visible in cells exposed for
72 h to 1 and 1.5 mmol/l cholesterol of oxidised LDL, but
the effect was less pronounced than with 2 mmol/l choles-
terol of modified LDL (ESM Fig. 1). As previously shown,
0.5 mmol/l oxidised LDL was not efficient in triggering
harmful effects on the cells (ESM Fig. 1) [13]. The decrease
in insulin expression achieved by oxidised LDL occurred at
a time point at which cell death was not yet apparent (ESM
Fig. 2) [13]. This implies that impaired levels of the
hormone are not merely the consequence of a reduced
number of cells caused by apoptosis. While native LDL can
exert deleterious effects on beta cell secretion and prolifer-
ation above 3 mmol/l (A. Abderrahmani and D. Favre,
unpublished observations) [16], the unmodified lipoproteins
at 2 mmol/l cholesterol triggered no effect on beta cell
function [13, 14]. For these reasons, we chose this
cholesterol concentration to carefully investigate the effects
of oxidised LDL. We found a two- to threefold increase in
levels of ICER isoforms in MIN6 and INS-1 cells, as well
as in isolated rat islets cultured with oxidised LDL
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(Fig. 1a). Two ICER isoforms (ICER and ICER Iγ) that
result from alternative splicing of CREM mRNA have been
described [31]. These two isoforms act as transcriptional
repressors whose abundance varies within cell types and
species [31]. MIN6 cells produce one ICER isoform, while
INS-1E cells contain the two forms of the repressor
(Fig. 1b). An increase in the contents of all ICER isoforms
by oxidised LDL was confirmed at the protein level by
western blotting in the two cell types (Fig. 1b). As
anticipated (Fig. 1a, b), neither the protein nor mRNA
levels of the repressor were augmented in response to
native LDL. ICER is a transcriptional passive repressor,
which inhibits the expression of genes that contain a CRE
in their promoter region [24, 32]. This is achieved by
competing with CREB transcriptional activators for binding
to the CRE sequence [24, 32]. To assess the activity of
ICER in response to oxidised LDL, MIN6 cells were
transfected with the luciferase reporter construct driven by
two CRE sequences linked upstream to a SV40 promoter
(CREluc). While native LDL did not modify luciferase
activity, oxidised LDL treatment strikingly decreased
CREluc activity, suggesting that repressor activity of ICER
was elevated (ESM Fig. 3). The expression of target genes
of ICER was next quantified to confirm the increased ICER
activity in response to oxidised LDL. The insulin gene [27],
IB1 (also known as MAPK8IP1) [23] and four genes of the
secretory machinery, the GTPases Rab3a and Rab27a and
their effectors Slp4 and Noc2 [25], are known targets of
ICER. In line with the increase in ICER abundance,
expression of all these target genes was diminished in cells
cultured with oxidised LDL, but not in those cultured with
native particles (Fig. 2a–f). To clearly establish whether
ICER is responsible for these effects, we blocked expres-
sion of the repressor using siRNAs (si-Icer). The efficacy
and specificity of the si-Icer in beta cells has already been
tested in a former study [25]. The mRNA of Ib1 and insulin
in cells cultured with oxidised LDL was partially restored
upon silencing of Icer (Fig. 2a, b). In contrast, silencing of
Icer was able to fully restore the levels of the four genes of
the secretory machinery (Fig. 2c–f).
We next investigated the causal role of ICER in beta
cell dysfunction and death triggered by oxidised LDL.
The decreased expression of Ib1 caused by oxidised LDL
is responsible for sustained induction of the JNK pathway
[13]. Activation of this signalling cascade by oxidised
LDL leads in isolated rat islets and MIN6 cells to
apoptosis through a mechanism involving reduced expres-
sion of B-cell CLL/lymphoma 2 [13]. Consistent with the
restored mRNA Ib1 expression, blockade of ICER
protected the cells against apoptosis evoked by oxidised
LDL (Fig. 3a). As previously reported [14], we found that
oxidised LDL compromise glucose-induced insulin secre-
tion (ESM Fig. 4). Rab3a, Rab27a, Slp4 and Noc2 play
major role in the control of insulin exocytosis [25]. This
led us to assume that the late steps of insulin exocytosis
were impaired in the presence of modified LDL.
Exogenously produced hGH has previously been shown
to be targeted to secretory granules and to be co-
released with insulin after triggering of exocytosis [33].
As, in contrast to insulin, hGH biosynthesis is not affected
by oxidised LDL, secretion of this hormone was used to
directly monitor the exocytotic process in cells cultured
with the lipoproteins. In addition, the use of hGH as a
reporter for exocytosis allows selective assessment of the
secretory process in the fraction of cells that are co-
transfected with the siRNAs. Potassium chloride (KCl) is a
potent insulin secretagogue that triggers exocytosis of
insulin-containing vesicles through direct depolarisation of
the beta cell membrane [34]. Culture of the cells with
oxidised LDL altered secretion elicited by KCl
(Fig. 3b). This result suggests a defect in the distal
steps of the secretory process, which could be the
consequence of reduced expression of Rab3a, Rab27a,
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Fig. 1 mRNA and protein levels of ICER in response to oxidised
LDL. a The mRNA level of Icer was quantified by quantitative real-
time PCR using total RNA from MIN6, INS-1E and isolated rat islet
cells cultured for 72 h with vehicle (white bars), native LDL (hatched
bars) or oxidised LDL (black bars). mRNAwas normalised against the
housekeeping gene, Rplp0, and expression from cells cultured with
vehicle was set to 100%. Data are mean±SEM of three independent
experiments; *p<0.05, **p<0.01 and ***p<0.001. b Quantification
of ICER content in response to oxidised LDL. Total protein from cells
that were cultured with native or oxidised LDL 2 mmol/l cholesterol
was subjected to western blotting analysis. Blot shows results of a
representative experiment (one of three)
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Slp4 and Noc2. Secretion elicited by KCl was completely
restored when expression of Icer was suppressed
(Fig. 3b), confirming the direct role of the repressor in
perturbation of the late steps of insulin secretion caused
by oxidised LDL.
Antioxidant treatment prevents induction of Icer and
oxidised LDL-mediated beta cell failure Oxidised LDL
are potent inducers of oxidative stress in several cell types
[17, 18]. Oxidative stress is a metabolic process that
consists of formation of reactive oxygen species (ROS).
In physiological concentrations, endogenous ROS help to
maintain homeostasis [35]. However, when ROS accumu-
late in excess for prolonged periods as observed for all the
environmental stressors related to diabetes, they trigger
adverse effects [18, 36–39]. Incubation of MIN6 cells with
oxidised LDL elicited a twofold increase in superoxide
production (Fig. 4a). Similar levels were reached in cells
exposed to hydrogen peroxide for 1 h, indicating that
oxidised LDL are potent inducers of oxidative stress in
insulin-secreting cells (Fig. 4a). We then investigated
whether oxidative stress can induce expression of Icer.
Treatment with hydrogen peroxide resulted in four-, two-
and 1.7-fold induction of the expression of Icer, in MIN6
cells, and isolated islets of rat and humans, respectively
(Fig. 4b). To confirm the role of oxidative stress in
induction of Icer achieved by oxidised LDL, the cells
were co-cultured with the modified lipoproteins and the
antioxidant, N-acetylcysteine (NAC) at 1 mmol/l. NAC is
the acetylated precursor of the amino acid L-cysteine and
reduced glutathione. NAC exerts a powerful antioxidant
action by elevating the level of glutathione. Addition of
NAC abolished induction of Icer caused by oxidised LDL
in MIN6, and in isolated islets of rat and humans (Fig. 4c-
e). Co-treatment with NAC enabled partial protection of
the cells against loss of insulin level (Fig. 5a) and
completely restored glucose-induced insulin secretion
executed by oxidised LDL (Fig. 5b). Restoration of the
secretory capacity was in line with the rise in expression
of the genes of the secretory machinery (ESM Fig. 5). Co-
incubation of the cells with NAC prevented cell death
triggered by oxidised LDL in MIN6 and isolated rat islets
(Fig. 5c, d). HDL-cholesterol particles antagonise the
adverse effects of oxidised LDL in beta cells [13, 15]
and display antioxidant properties [40]. Co-culture of
MIN6 cells in the presence of HDL prevented the
induction of Icer caused by oxidised LDL (Fig. 6),
pointing to the repressor as an important link coupling
oxidative stress to beta cell failure achieved by the
modified LDL.
Discussion
Evidence of adverse effects of pro-atherogenic oxidised
LDL on beta cells [13, 15, 16] is now growing. Several
independent in vitro studies agree in pointing to a
deleterious impact of these modified lipoproteins on
insulin level, glucose-induced insulin secretion and ulti-
mately cell survival in different insulin-secreting and islet
cells [13, 15, 16]. Such harmful effects, which are
potentiated by inadequate levels of and/or inactive HDL,
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Fig. 2 Expression of ICER target genes in the presence of oxidised
LDL. mRNA of (a) insulin, (b) Ib1, (c) Rab3a, (d) Rab27a, (e) Noc2
and (f) Slp4 was quantified in MIN6 cells exposed for 72 h to human
native LDL or oxidised LDL containing 2 mmol/l cholesterol. The
cells were transfected with duplexes of control siRNA (si-Gfp)
(white bars) or siRNA directed specifically against ICER (si-Icer,
black bars). mRNA levels were normalised against Rplp0 and
expression from cells cultured with vehicle were set to 100%. Data
are the mean±SEM of three independent experiments; *p<0.05, **p<
0.01 and ***p<0.001
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are thought to promote and contribute to the progression
of diabetes [13, 15]. Our aim here was to understand the
mechanism through which oxidised LDL leads to beta cell
dysfunction. ICER is a basic leucine zipper transcriptional
factor that negatively regulates expression of numerous
genes containing a CRE sequence within their promoter.
The lack of an activation domain makes ICER into a
passive transcriptional repressor [24]. The inhibitory role
of ICER is achieved at certain levels of abundance.
Thereafter, the repressor acts by competing with transcrip-
tional activators and preventing their binding to the CRE
[24]. Induction of ICER is a physiological process that
permits levels of some hormones in endocrine or neuro-
endocrine cells to return to basal [41]. However, persistent
expression of this repressor can occur in response to a
deleterious milieu [41]. In this study, we found that
abnormal induction of ICER links oxidised LDL to beta
cell dysfunction. Selective reduction of ICER contents
partially prevented the loss of insulin expression and cell
death evoked by oxidised LDL. Loss of specialised beta
cell functions caused by the modified lipoproteins preced-
ed cell death. While ICER is responsible for beta cell
failure and death, our observations imply that beta cell
dysfunction driven by the repressor is established prior to
cell death. Variation in islet brain 1 levels is critical for
maintaining appropriate insulin content and cell survival
[13, 22]. As observed in our former study [13], the islet
brain 1 level was dramatically diminished in the face of
oxidised LDL, confirming that loss of islet brain 1
function mediates at least some of the damages to beta
cells provoked by the modified lipoprotein. Reduction of
islet brain 1 abundance inhibits the insulin level and
increases apoptosis by permitting activation of the JNK
pathway [22]. While ICER can directly target the gene
coding for insulin [42], it could also cause the loss of
insulin expression and cell death indirectly by reducing
islet brain 1 content and stimulating the JNK pathway.
However, restoration of levels of the scaffold protein was
incomplete upon silencing of Icer. This coincided with a
partial recovery in insulin production and survival. This
result could not be attributed to efficacy of silencing,
because si-Icer was able to fully restore the mRNA level
of the two other ICER target genes, Noc2 and Rab27a.
These observations suggest that additional factors that are
independent of ICER could have contributed to the
decreased abundance of islet brain 1 provoked by the
modified particle. However, as observed for chronic
hyperglycaemia [25], it is mostly induction of ICER that
operates dysregulation of genes controlling insulin secre-
tion, and thereby the defective secretory capacity of beta
cells caused by oxidised LDL. We found that silencing of
Icer permitted full protection against impairment of
stimulated secretory capacity triggered by oxidised LDL,
a finding that correlates with fully restored expression of
Noc2 and Rab27a.
The major role of ICER in mediating the adverse effects
of oxidised LDL led us to seek the mechanism responsible
for its induction. Many in vitro studies show that oxidised
LDL favour production of ROS and thus oxidative stress in
various cell types [17, 18]. Furthermore, elevated levels of
oxidised LDL correlate with an increase in certain markers
of oxidative stress, such as heat shock protein 70 in patients
with newly diagnosed and long-standing diabetes [43]. For
these reasons, we investigated the role of oxidative stress in
stimulating production of ICER. In this regard, we first
found that oxidised LDL evoked production of superoxide
in beta cells. Second, culture of cells with hydrogen
peroxide elicited an increase in ICER levels. Finally, NAC
antioxidant treatment abrogated the induction of ICER
caused by oxidised LDL. Consistent with this result,
mRNA expression of ICER target genes Rab3a, Rab27a,
Slp4 and Noc2 was restored. This was further accompanied
by full recovery of glucose-induced insulin secretion.
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Fig. 3 Effect of Icer silencing on secretion and survival. aMIN6 cells
were transfected with a control RNA duplex (si-Gfp) (white bars) or
with si-Icer (black bars). Cells were then cultured for 72 h with native
or oxidised LDL 2 mmol/l cholesterol. The fraction of cells
undergoing apoptosis was determined by scoring the percentage of
cells with picnotic nuclei. bMeasurement of insulin exocytosis. MIN6
cells were transiently transfected with hGH together with the control
siRNA (white bars) or si-Icer (black bars), and cultured as above (a).
Secretion of hGH was elicited by pre-incubating cells for 30 min in
KRB containing 2 mmol/l glucose and then incubating them with KCl
30 mmol/l. The amount of hGH released into the medium during the
incubation period and remaining in the cells was measured by ELISA.
The results are expressed as fold increase of stimulated over basal.
Data (a, b) are the mean±SEM of three independent experiments; *p<
0.05 and ***p<0.001
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However, NAC treatment was partially effective in prevent-
ing the loss of insulin transcript accomplished by oxidised
LDL. This observation leads us to assume that another
mechanism, parallel to oxidative stress, accounts for the
partial reduction of insulin caused by the modified LDL.
Administration of NAC strongly improved survival of
MIN6 cells in the presence of oxidised LDL, supporting
the notion of a cytoprotective role of the antioxidant
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Fig. 5 Counteractive effect of NAC on adverse effects of oxidised
LDL on beta cell functions. a Insulin expression in the presence of
NAC. MIN6 cells were cultured for 72 h with oxidised LDL (oxLDL)
2 mmol/l cholesterol in the presence of vehicle (white bars) or NAC
1 mmol/l (black bars). The insulin mRNA level was determined by
quantitative real-time PCR. mRNA levels were normalised against
Rplp0 and the results obtained in cells cultured with vehicle were set
to 100%. b Assessment of glucose-induced insulin secretion. MIN6
cells were cultured for 72 h with oxidised LDL 2 mmol/l cholesterol
plus vehicle (white bars) or NAC 1 mmol/l (black bars). For
measurement of glucose-induced insulin secretion, the cells were
pre-incubated for 60 min in KRB containing 2 mmol/l glucose (basal)
and successively incubated in the same buffer or in KRB containing
20 mmol/l glucose (stimulated). The amount of insulin release and
cellular contents during the incubation period were measured by EIA.
Results are expressed as the ratio between the amount of insulin
released into the medium under stimulatory and basal conditions over
basal condition. c, d Cell survival in the presence of NAC. MIN6 cells
(c) and dispersed rat islet cells (d) were cultured for 72 h with oxidised
LDL 2 mmol/l cholesterol plus vehicle (white bars) or NAC 1 mmol/
l (black bars). The fraction of cells undergoing apoptosis was
determined by scoring cells with pycnotic nuclei. a–d Data are
expressed as the mean±SEM of three independent experiments; *p<
0.05, **p<0.01 and ***p<0.001
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Fig. 4 Role of oxidative stress in the induction of Icer by oxidised
LDL. a Production of superoxide in response to oxidised LDL.
Extracellular ROS were measured by luminescence. MIN6 cells were
cultured for 1 h with oxidised LDL 2 mmol/l (oxLDL) or hydrogen
peroxide 150 μmol/l (H2O2). Superoxide production in cells cultured
with vehicle condition was set to 100%. b Effects of hydrogen
peroxide on the expression of Icer. The mRNA level of Icer was
quantified by quantitative real-time PCR from MIN6 cells, isolated rat
islets cultured for 4 h and human islets cultured for 0.5 h with
hydrogen peroxide 150 μmol/l (black bars). mRNA levels were
normalised against the Rplp0 and expression from cells cultured with
vehicle was set to 100%. c–e Effects of the antioxidant NAC on
expression of Icer evoked by oxidised LDL. The mRNA level of Icer
was quantified by quantitative real-time PCR using total RNA that
was prepared from (c) MIN6 cells, and isolated rat (d) and human (e)
islets cultured for 4 h with oxidised LDL 2 mmol/l cholesterol. The
cells were co-incubated with vehicle (white bars) or NAC (black bars)
1 mmol/l for MIN6 and isolated rat islets (c, d) or 10 mmol/l for
human islets (e). Results were normalised against RPLP0 and
expression from cells cultured with vehicle was set to 100%. a–e
Data are the mean±SEM of three independent experiments; *p<0.05,
**p<0.01 and ***p<0.001
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against the deleterious effects of the modified lipopro-
tein in beta cells. Even though primary beta cells were
not examined, the protective effect of NAC was almost
complete in isolated islets. Activation of the JNK
pathway and decrease of Bcl2 expression are partially
responsible for apoptosis elicited by oxidised LDL [13].
Generation of oxidative stress could therefore be the
leading upstream cause of activation of JNK pathway
and decrease of B-cell CLL/lymphoma 2 levels, in a
mechanism that could also involve ICER.
HDL particles are potent antioxidants [40] and exert
many beneficial effects in beta cells. They not only
stimulate beta cell function [15], but also counter loss
of beta cell functions and cell survival achieved by
oxidised LDL or chronic hyperglycaemia [13, 15, 16]. In
line with this cytoprotective role, we found that HDL
abolished induction of ICER evoked by oxidised LDL. As
observed for oxidised LDL, chronic excess of glucose
elicits beta cell dysfunction and death by generating
intracellular oxidative stress and elevating ICER levels
[25, 44]. Thus, it is very likely that HDL particles
counteract adverse effects provoked by prolonged expo-
sure to glucose by inhibiting oxidative stress and conse-
quently blocking ICER production. However, the plasma
concentration of HDL particles and their activity are
reduced in patients with diabetes or metabolic syndrome
[7, 8]. For this reason, much is being done to find out
effective therapeutic strategies to elevate plasma HDL. It
has, however, been suggested that loss of HDL activity in
patients with type 2 diabetes might be the consequence of
an oxidised LDL-mediated decrease in lecithin-cholesterol
acyltransferase activity [45]. Therefore it is possible that
oxidised LDL elicit oxidative stress and, consequently,
beta cell failure by directly abolishing the protective
effects of HDL. In this case, as long as oxidised LDL are
present, improvement of HDL levels in patients may not
effectively counteract beta cell failure. If this hypothesis is
correct, then the use of other alternative antioxidant
approaches to counteract oxidative stress in beta cells
may be required. Numerous in vitro and in vivo studies
have shown the efficacy of certain antioxidants in
preventing beta cell failure. For example, administration
of the antioxidant NAC alone or in combination with some
vitamins ameliorated glucose-induced insulin secretion in
Zucker diabetic fatty rats and db/db mice [44, 46]. In
contrast, large clinical trials failed to detect an improve-
ment in insulin secretion in patients with type 2 diabetes in
response to antioxidant vitamins [47, 48]. However some
findings in favour of preventive antioxidant therapy to
combat the decline of beta cell function in diabetes have
been reported, in particular, a clinical study originally
devised with the primary endpoint efficacy of the
antioxidant succinobucol in cardiovascular outcomes in
patients with acute coronary disease [19]. Interestingly,
daily administration of the antioxidant succinobuccol has
been found to reduce occurrence of new-onset diabetes by
almost threefold [19]. Succinobuccol is derived from
probucol, a bisphenol molecule that preserves beta cells
by attenuating oxidative stress [49]. NAC is a potent
antioxidant, which is widely used as an antidote for
hepatotoxicity caused by acetaminophen overdose. At
present, a growing body of data supports many other
clinical benefits from use of this antioxidant. These
include: prevention of chronic obstructive pulmonary
disease exacerbation, attenuation of illness from the
influenza virus, treatment of pulmonary fibrosis and
treatment of infertility in patients with clomifene-
resistant polycystic ovary syndrome [50]. Therefore,
antioxidant supplementation in a subset of patients with
low HDL levels and elevated oxidised LDL could help to
prevent beta cell failure and thereby delay the develop-
ment of diabetes.
Induction of ICER by oxidative stress may represent the
unifying mechanism for beta cell failure provoked by
chronic hyperglycaemia, hyperlipidaemia and oxidised
LDL. For the future design of effective and potent
antioxidant preventive treatment, careful examination of
their ability to counteract adverse effects of diabetes
stressors in beta cells will be required.
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Fig. 6 Effects of HDL on oxidised LDL-induced Icer expression.
MIN6 cells were cultured for 4 h with oxidised LDL (oxLDL)
2 mmol/l cholesterol in the presence of vehicle (white bars) or
1 mmol/l HDL-cholesterol (black bars). Icer mRNA was determined
by quantitative real-time PCR. mRNA levels were normalised against
Rplp0 and the results obtained in cells cultured with vehicle were set
to 100%. Data are the mean±SEM of three independent experiments;
*p<0.05 and **p<0.01
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C.1 Introduction 
Insulin resistance is the initial measurable defect in the pathogenesis of T2D and is correlated 
with the extent of visceral adiposity in obese patients (83). The normal function of adipose tissue 
is perturbed with excessive weight and there is accumulating evidence suggesting that adipocyte 
dysfunction plays a major role in the development and progression of insulin resistance (84). 
Increased visceral adiposity is associated with impaired glucose uptake by the adipocytes, owing 
in part to the reduced expression of GLUT4 (30;85). In addition to the altered glucose disposal, 
adipocytes produce and secrete lower amounts of the insulin-sensitizer adiponectin. The 
subsequent decline in circulating levels of adiponectin is thought to participate to the progressive 
loss of insulin sensitivity in obese individuals (37;86). Interestingly, an important mechanism 
responsible for the impaired expression of GLUT4 and adiponectin in obesity has been revealed 
and involves the CREB proteins (76). The transcriptional activity of the CREB factors is 
abnormally augmented in the adipocytes of obese mice, ensuing in the expression of the 
transcription factor ATF3. Induction of this transcriptional repressor, in turn suppresses the levels 
of its target genes GLUT4 and adiponectin. Accordingly, mice overexpressing a dominant 
negative form of CREB specifically in the adipocytes exhibit an improved insulin sensitivity and 
glucose homeostasis under condition of high fat diet (76). 
 
One of the major controllers of the activity of the CREB factors is the transcription factor ICER. 
This transcriptional repressor represses the expression of genes by competing with the activating 
factors of the CREB family for the binding of CRE sequences (61). All these observations led us 
to question whether the stimulated expression of ATF3 by the CREB factors and the subsequent 
- 35 - 
loss of adiponectin and GLUT4 levels could be the consequence of a decline in ICER in the 
adipose tissue of obese individuals. 
 
C.2 results 
In order to study the potential role of ICER in the adipocyte dysfunction in obesity, we quantified 
the expression of this transcriptional repressor, ATF3, GLUT4 and adiponectin in the white 
adipose tissue (WAT) of mice fed a HFD and in the visceral adipose tissue (VAT) of obese 
human subjects. The transcript levels of ATF3 were massively augmented in the adipose tissue of 
the two obese models, resulting in the loss of GLUT4 and adiponectin expression. This activation 
of ATF3 was accompanied by a marked reduction in the mRNA levels of ICER in the obese 
adipose tissues (Fig 1). Importantly, these modifications were observed in the adipocytes fraction 
of the WAT of obese mice, but absent from the stromal vascular fraction which contains mainly 
pre-adipocytes and macrophages (Fig 2a and b). This observation testifies therefore for the 
adipocyte specificity of the loss of ICER in obesity. The disappearance of ICER was associated 
with an elevation in the activity of the CREB factors, as shown by the augmentation in CREB 
binding in electromobility shift assays (Fig 1c-e). 
 
To demonstrate the ability of ICER to control ATF3 expression in adipocytes, we overexpressed 
the transcriptional repressor in the adipocyte model 3T3-L1 cells by electroporation techniques. 
Exogenous expression of ICER markedly decreased ATF3 mRNA levels in adipocyte and non-
differentiated 3T3-L1 cells (Fig 3a and b). Finally, the knocking out of ICER transcript by RNA 
interference favored an augmentation in the mRNA and protein contents of ATF3 (Fig 4a and b).  
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In conclusion, all these data indicate that the loss of the transcriptional repressor ICER in the 
obese adipose tissue is responsible for the activation of the transcription factor ATF3 by CREB 
and the subsequent impairment in GLUT4 and adiponectin expression. 
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Abstract 
Objective Increase in adipose cAMP response binding proteins (CREB) activity
promotes adipocyte dysfunction and thereby, systemic insulin resistance in obese mice. 
This is achieved by increasing the expression of activating transcription factor 3 (ATF3). 
In this study we investigated whether impaired expression of the inducible cAMP early 
repressor (ICER), a transcriptional antagonist of CREB, is responsible for the increased 
CREB activity in adipocytes of obese mice and humans.  
Research Design and Methods Total RNA and nuclear proteins were prepared 
from visceral adipose tissues (VAT) of human lean or obese subjects, and white adipose 
tissues (WAT) of C57Bl6-Rj mice that were fed with normal or high fat diet for 12 
weeks. The expression of genes was monitored by real-time PCR, western blotting and 
electromobility shift assays. RNA interference was used to silence the expression of Icer. 
Results The expression of ICER was reduced in VAT and WAT of obese humans 
and mice, respectively. Diminution of Icer was restricted to adipocytes and was 
accompanied by a rise in Creb activity and elevation of Atf3, leading to repression of the 
Atf3 target genes Adipoq and Glut4. Overexpression of Icer in 3T3-L1 adipocytes as well 
as fibroblasts decreased the Atf3 content while silencing of Icer increased the expression 
of Atf3, indicating a mechanistic link between the level of the two transcription factors.
Conclusion Impaired expression of Icer contributes to elevation in Creb target 
genes and therefore contributes to the development of insulin resistance in obesity.
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Accumulation of visceral fat in obesity is a strong risk factor for life-threatening 
diseases such as type 2 diabetes, atherosclerosis, polycystic ovary syndrome, non-
alcoholic fatty liver disease and certain types of cancer (1-4). Increased adiposity is 
associated with impairment in glucose uptake in adipocytes, which in part result from the 
diminished expression of GLUT4 (5). Parallel to defective glucose metabolism, 
adipocytes display reduced production of the insulin-sensitizer adiponectin (Adipoq) 
(6;7). This dysregulation is considered as part of a crosstalk linking adiposity to overall 
insulin resistance in obesity (8). An important mechanism responsible for decreased level 
of Glut4 and Adipoq in obesity is now advanced (9). This involves the cAMP response 
element binding proteins (CREB) transcriptional factors (9). Transcriptional activity of 
Creb is abnormally elevated in adipocytes of obese mice fed with a high fat diet (HFD) 
resulting in elevation of the expression of its target gene the activating transcription 
factors 3 (Atf3) (9). In turn, Atf3 suppresses the expression of Glut4 and Adipoq and 
thereby, disrupts insulin action in adipocytes and causes systemic insulin resistance (9). 
Obese mice that express a dominant-negative form of Creb in adipocytes have improved 
whole body-insulin sensitivity and glucose homeostasis (9). Furthermore, the transgenic 
mice are protected against hepatic steatosis and adipocytes inflammation (9).  
The activity of the CREB factors is finely tuned by the level of the inducible 
cAMP early repressor (ICER). ICER is a member of the cAMP-responsive element 
modulator family (CREM). ICER represses genes transcription by binding to the CRE 
sequence within their promoters (10). Typically, ICER plays as a dominant-negative role 
by competing with all cAMP responsive transcriptional activators of the CREB, CREM 
and activating transcription factor families for binding to CRE (11). Induction of ICER is 
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part of an adaptive mechanism that allows production of hormones to return to basal state 
(11). Elevation in the ICER level is normally transient and dysregulation in the 
expression of this repressor leads to diverse pathologies (11-14). In this report, we 
investigated whether a diminished Icer level could be responsible for the increase of 
ATF3 and, consequently, the loss of Adipoq and Glut4 expression in the adipose tissue of 
obese individuals.  
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Research Design and Methods 
Additional information concerning the hyperinsulemic-euglycemic clamps, suppliers of 
chemicals and antibodies as well as for the methods of cell culture, transfection, western 
blotting and electromobility shift assays (EMSA) can be found in the online appendix.
Animal experimentation- All procedures on mice were performed according to the 
Swiss legislation for animal experimentation. Six-week-old C57Bl6-Rj male mice were 
obtained from the Janvier Breeding Centre (Le Genest-Saint-Isle, France). They were 
placed for 12 weeks randomly upon either a standard diet including proteins 28%, 
carbohydrates 60% and fat 12% (SD, Provimi Kliba, Penthalaz, Switzerland) or a fat-
enriched diet with the following composition proteins 21%, carbohydrates 24%, fat 55% 
(Harlan Teckland, Oxon, UK).  
Biopsies and RNA preparation- Approximately 5 cm3 of VAT was obtained at the level 
of the omentum from five obese white women (BMI >35 kg/m2) who were referred
consecutively over a period of 24 months for weight reduction surgery and lean 
individuals (24< BMI <28 kg/m2). The criteria for exclusion and phenotyping are those 
previously described (15). Tissue samples and total RNA were prepared exactly as 
previously described (16). Total RNA was isolated from epididymal visceral adipose 
tissue of mice (immediately frozen in liquid N2 and stored at -80°C after dissection) with 
TriPure isolation reagent (Roche). 
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Real-time quantitative PCR- Preparation of total RNA and real-time PCR were 
conducted exactly as described (12). Primer sets are available upon request. 
Statistical analysis- The experiments including more than two groups were analyzed by 
ANOVA or with the non parametric equivalent Kruskal-Wallis test.
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Results 
Samples of white adipose tissues (WAT) were prepared from obese mice fed with 
a high fat diet (HFD) for 16 weeks. This mice model of obesity mimics metabolic 
disorders observed in human (17;18). As the result of the diet, mice indeed gained 
significantly more body weight (n= 8, 23.1±6.1 vs. 32.1±1 grams, p<0.05), were hyper-
insulinemic (n=8, 15±7 vs. 53±9 µU/ml, p<0.05) and hyperglycaemic (n= 8, 134±13.5 vs. 
168±17 mg/dl, p<0.05) compared to littermates fed with chow diet. The HFD mice were 
insulin resistant as indicated by a marked decrease in glucose infusion rate (GIR, n=8, 
94±19 vs. 33±5 mg/kg/min, p<0.05). In this model, elevation in the transcriptional 
activity of Creb has been shown to promote insulin resistance in adipose tissue (9). The 
defect in insulin sensitivity is caused by the increase in the expression of Atf3, which in 
turn, downregulates the expression of Glut4 (9). In agreement with these data, we found 
an increase in the Atf3 mRNA level whereas the expression of Glut4 decreases in WAT 
of obese mice when compared to control animals (Fig. 1a). Elevation of Atf3 also 
partially accounts for systemic insulin resistance (9). This is achieved by a subsequent 
diminution in the mRNA level of its target gene Adipoq (9). In line with this finding, we 
confirmed reduction in the Adipoq level in WAT of obese mice (Fig.1a). Increase in the 
expression of the Creb target gene Atf3 in WAT was associated with a striking 
diminution in the Icer mRNA level (Fig. 1a), thus supporting a role for Icer in the 
dysregulation of adipose tissues. The drop in Icer level and the subsequent changes in the 
expression of Atf3, Glut4 and Adipoq were observed in WAT of obese animals under 
fasting condition (Fig. 1a). Similar results were found using WAT from animals under 
fed conditions (data not shown), indicating that impaired Icer level in HFD-induced 
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obese mice is independent from the nutritional status. Samples of adipose tissues from 
human lean and obese subjects were prepared to confirm the data obtained in mice. Since 
it is the excess of visceral fat rather than subcutaneous, which is associated with an 
increased risk of developing cardiovascular disease and metabolic syndrome, we chose to 
quantify the expression of genes in visceral adipose tissue (VAT) (19). As observed in 
mice, the ICER mRNA level was decreased in VAT of obese individuals (Fig. 1b). This 
was associated with an increase in the expression of the CREB target gene ATF3 and 
decreased levels of ADIPOQ and GLUT4 (Fig. 1b). EMSA were next done to confirm 
changes in binding activities of Icer and Creb in adipose tissues of obese mice. Nuclear 
proteins from WAT of obese mice were incubated with a labelled oligonucleotide 
corresponding to the cAMP response element (CRE) (12). A fast migrating band was 
observed in WAT of control mice, which was markedly reduced in obese mice (Fig. 1c). 
On the other hand, a slower migrating pattern appeared in WAT of obese mice that is 
almost undetectable in control mice (Fig. 1c). The binding activities were specific to CRE 
as a 100 fold excess of the unlabeled probe, but not of unspecific binding sequences, 
efficiently prevented the formation of the two bands (Fig. 1d and 1e). The lower band 
was identified as Icer because it co-migrates with exogenously expressed ICER-Iγ and 
the formation of this complex was selectively abrogated by the addition of an anti-CREM 
antibody (Fig. 1d). In the presence of the anti-Creb1 antibody, the migration of the upper 
band observed in WAT of obese mice was slower (Fig. 1e). This result indicates that 
nuclear extracts of WAT from obese mice display an increase in Creb binding activity 
with a concomitant reduction in the expression of Icer. Creb activity, and consequently 
the expression of its target genes are required for adipogenic program (20;21). Various 
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stimuli including insulin can elicit Creb activity (20;21). In line with this we found that 
insulin infusion elicited a 16 fold increase in the expression of Icer in control mice 
(supplementary Fig. 1). As anticipated insulin-induced Icer expression was abolished in 
insulin resistant WAT of obese mice, indicating that induction of Icer is also defective in 
obese animals.  
The drop of Icer was only observed in the adipocyte fraction of obese mice, 
whereas the expression of the repressor in the stroma vascular fraction was similar 
between obese and control mice (Fig. 2a). The reduced Icer content in adipocytes 
paralleled the rise in the mRNA level of Atf3 (Fig. 2b) and the diminution in Adipoq and 
Glut4 levels (Fig. 2b).  
We then attempted to confirm the negative regulation of Atf3 by Icer. To this end, 
a plasmid encoding for Icer-Iγ was introduced by electroporation into 3T3-L1 adipocytes. 
Western blotting and EMSA experiments revealed a high expression of Icer 
(supplementary Fig. 2). Overexpression of Icer-Iγ led to reduction in the mRNA level of 
Atf3 (Fig. 3a). IBMX is a phosphodiesterase inhibitor that elicits activation of the 
cAMP/PKA pathway and thereby the activation of CREB. As anticipated, culture of 3T3-
L1 adipocytes with IBMX for 4 h evoked a rise in the level of Atf3 (Fig. 3a). 
Overexpression of Icer-Iγ alleviated IBMX-induced expression of Atf3 (Fig. 3a). Similar 
results were obtained in 3T3-L1 fibroblasts (Fig. 3b), indicating that regulation of Atf3 by 
Icer is conserved in most cell types. On the other hand, we found that silencing of Icer by 
RNA interference elevates the level of Atf3 (Fig. 4a and 4b) confirming the negative 
regulation of Icer on Atf3 expression.  
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Discussion 
Increase in the Atf3 level inhibits the expression of Adipoq and Glut4 in 
adipocytes and thereby promotes systemic insulin resistance of HFD-induced obese mice 
(9). Our data not only validate this observation but also confirmed dysregulation of these 
genes in human adipose tissues of obese individuals. Augmentation of Creb activity has 
been shown to be responsible for the elevation in Atf3 expression (9). The positive 
regulation of Atf3 by Creb is direct as the proximal promoter of Atf3 contains a Cre 
sequence that directly bind CREB (9). Icer contains a DNA binding domain for Cre and, 
consequently, shares similarities with CREB (10;22;23). However, the properties of Icer 
diverge from those of the CREB factors because it lacks the activating domain 
(10;22;23). For this reason, Icer functions as a passive repressor that prevents the 
transcriptional activators CREB from binding to the Cre sequence (10;22;23). In this 
report, we provide evidence that dysregulation of Icer in adipocytes is responsible for 
CREB-induced expression of Atf3 in obesity. First, diminution of Icer correlated with the 
increase in Atf3 expression in adipocytes from HFD-induced obese mice and human 
obese individuals. The drop in the Icer level in adipose tissues elevates the Atf3 
expression by increasing Creb activity. EMSA experiments indeed showed that reduced 
Icer expression was accompanied by an increase in Creb binding activity in adipose 
tissues of obese mice. Second, in vitro manipulation of the level of Icer confirmed Atf3 
as a target gene. On the one hand, overexpression of Icer in 3T3-L1 adipocytes or 
fibroblasts inhibited the expression of Atf3. On the other hand, the level of Atf3 was 
augmented upon silencing of Icer. Based on these findings we propose that reduction in 
the Icer content in adipocytes could permit CREB to occupy the Cre located in the 
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promoter of the Atf3 gene. Induction of the latter gene would in turn silence the 
expression of Adipoq and Glut4.  
Creb activity, and consequently the expression of Icer, can be induced by various 
stimuli including insulin (20;21). With this respect we found that insulin elicited a rise in 
the expression of Icer in control animals whereas insulin-induced expression of the 
repressor was abrogated in insulin resistant WAT of obese mice. The fact that the 
expression of Icer in WAT of obese animals was reduced both in fed and fasting 
conditions, supports a defective induction of Icer, and therefore impaired negative control 
of Creb activity upon stimulation. This dysregulation could be responsible for persistent 
increased CREB activity, which in turn could lead to the constitutive increase in Atf3 
expression and the subsequent decrease in Glut4 and Adipoq levels. Further studies are 
now needed to identify the mechanism leading to impaired expression of Icer in obesity. 
We believe that such investigations may pave the way for the design of novel therapeutic 
strategies or for improvement of existing approaches for recovering normal adipose 
function and insulin sensitivity.  
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Figures legends
Fig. 1: Examination of ICER level in adipose tissues of obese mice and human 
subjects. The mRNA level of ICER was quantified by quantitative real-time PCR in a) 
WAT of control mice fed with a standard diet (C, white bars) and HFD-induced obese 
(H, filled bars) and b) in VAT of human lean (L, white bars) and obese individuals (O, 
filled bars). The expression of the ICER target gene ATF3, ADIPOQ and GLUT4 was 
also monitored in adipose tissues of obese mice and humans. In all cases, the results were 
normalised against the housekeeping acidic ribosomal phosphoprotein P0 gene (RPLP0) 
gene and those of the control mice (C) or lean human (L) cells were set to 100%. Data are 
the mean ± SEM for 10 mice or 5 humans for each groups that were repeated three times 
(***, P<0.001; **, P<0.01). c) Assessment of the CRE-binding activities. Nuclear 
extracts of WAT of obese (H) and control mice (C) were incubated with the radioactive 
probe containing the consensus Cre (CRE). The arrows indicate the major migrating 
bands. Identification of the CRE-binding activity in the WAT of d) control (C) and e) 
obese mice (H). For both d) and e) panels, the nuclear extracts were omitted in the first 
lane (-). Where indicated the incubation was performed in the presence of 100-molar 
excess of unlabeled oligonucleotides corresponding to the consensus CRE sequence 
(CRE) or of the binding sequences for the Sp1 transcription factor (Sp-1). Before the 
addition of the labeled oligonucleotide, the nuclear extracts were pre-incubated with 
antibodies recognizing CREM (CREM) or CREB1 and the unrelated factors Hairy and 
Enhancer of Split-1 (HES-1), RE-1 silencing transcription factor (REST) and histone 
deacetylase 1 (HDAC1) as negative controls (Nsp1, Nsp2 and Nsp3, respectively). Nsp: 
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Non specific. For comparison, nuclear extracts of HEK 293T cells transfected with an 
empty vector (CMV) or with a plasmid producing ICER-Iγ (ICER) were incubated in 
parallel with the probe. The positions of ICER and of the unbound CRE probe are 
indicated. The results are representative of three independent experiments.  
Fig. 2: Expression of ICER and its target genes in adipocytes. The mRNA level of 
Icer was assessed by quantitative PCR in adipocytes or Stroma vascular fraction (SVF) 
that were collected from WAT from either control (C) or HFD-induce obese mice (H). b) 
The expression of Atf3, Adipoq and Glut4 was measured in adipocytes from control (C) 
or obese mice (H). The mRNA levels were normalized against the Rplp0 and the 
expression levels from controls (C) were set to 100%. Data are the mean of ± SEM of 3 
independent experiments (***, P<0.001; **, P<0.01; *, P<0.05).  
Fig. 3: Overexpression of Icer reduces the level Atf3. a) The 3T3-L1 adipocytes and b) 
undifferentiated cells were transfected with either a control plasmid (pcDNA3, white 
bars) or with a plasmid coding for Icer-Iγ (ICER, filled bars). Total RNAs were prepared 
from cells that were incubated for 4 h with vehicle (-) or with IBMX to stimulate the 
expression of Atf3. The levels were normalised against the Rplp0 and the expression 
levels from cells cultured with vehicle were set to 100%. Data are the mean of ± SEM of 
3 independent experiments (***, P<0.001; **, P<0.01; *, P<0.05). 
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Fig. 4: Effect of Icer silencing on Atf3 expression. The 3T3-L1 undifferentiated cells
were transfected with a control RNA duplex (si-GFP, open bar) or with si-ICER (filled 
bar). a) Nuclear proteins were prepared 48 h after transfection and subjected to western 
blotting analysis for the quantification of Icer and Atf3 levels. To control the specificity 
of the silencing the expression of Creb1 is shown. The figure shows the results of a 
representative experiment out of three. b) Quantification of the Atf3 level by quantitative 
real-time PCR. Total RNAs were prepared 48 h after transfection. The mRNA level of 
Atf3 was normalised against the Rplp0 and the expression levels from cells cultured with 
vehicle were set to 100%. Data are the mean of ± SEM of 3 independent experiments (**, 
P<0.01).
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Supplemental Fig. 1: Effect of the insulin on the expression of Icer in WAT. Insulin was
infused in control (upper panel) and obese mice (lower panel) as described in supplemental
methods. The animals were fasted for 10 h before hyperinsulinemic-euglycemic clamp. Total 
RNAs were prepared from WAT of control and obese mice that were infused with insulin (filled
bars). The level of Icer was quantified by quantitative real-time PCR. The mRNA level were 
normalized against the Rplp0 and the expression level from mice that were fasted for 10 h 
(white bars) was set to 100%. Data are the mean of ± SEM  for 4 mice in each groups that were 
repeated 3 times (***, P<0.001). 
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Supplemental Fig. 2: Overexpression of Icer in 3T3-L1 adipocytes.  a) The 3T3-L1 
adipocytes were electroporated with the plasmid coding for Icer-Iγ (ICER) or with the empty
vector (Ctrl). The expression of Icer was detected by Western blotting experiments using the 
anti-Crem antibodies. B) Measurement of Icer activity by EMSA. Nuclear protein extracts (NE) 
were prepared from 3T3-L1 adipocytes with either the empty vector (Ctrl) or ICER. NE were
incubated with the CRE sequence as the labelled probe. To determine the binding activity of 
ICER, NE were pre-incubated with the anti-CREM (CREM) or the anti-HES-1 (Nsp1) antibodies
as a negative control. The figures are representative of three independent experiments.
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IV Discussion 
 
A Deleterious effects of oxidized LDL and protective action of HDL in β-cell: significance 
for β-cell dysfunction in T2D 
Type 2 diabetes reaches nowadays epidemic proportions worldwide and is expected to affect 
more than 300 million people in the next 20 years, according to the World Health Organization. 
This disease become manifest when pancreatic β-cells fail to overcome insulin resistance by a 
compensatory hypersecretion of the hormone (14). Elucidating the mechanisms underlying β-cell 
failure is required to understand the molecular pathophysiology of T2D and to discover specific 
therapeutic strategies to block β-cell decline over time. In this respect, one of the objectives of 
this thesis was dedicated to shed light into the potential involvement of lipoproteins in β-cell 
dysfunction. The data obtained from in vitro experiments using insulin-producing cell lines and 
isolated islets, show that oxidized LDL induce a complete dysfunction of the β-cell, including a 
decrease in insulin expression, secretion and β-cell survival (56;80). On the other hand, as 
reported by several studies, 2mM of native LDL-cholesterol has no negative impact on β-cell 
function (56;80). However, higher doses of unmodified LDL exert adverse effects on β-cell 
survival and insulin release (55;87), revealing that supraphysiological concentrations of 
lipoproteins could hamper β-cell function in absence of oxidative modifications. 
 
In macrophages, the class B scavenger receptors SR-B1 and CD36 are two important acceptors 
for the uptake of oxidized LDL (88;89). Peritoneal macrophages of CD36 null mice have a 
reduction of 70% of oxidized LDL binding, whereas the association of modified lipoproteins with 
cells overexpressing the SR-B1 receptor is massively increased (88;89). Interstingly, the 
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expression of these two scavenger receptors in macrophages is augmented in response to 
hyperglycemia and in diabetic animals (90;91). SR-B1 and CD36, as well as the LDL receptor 
which can recognize the mildly oxidized LDL (92), are present in pancreatic β-cells and could 
thereby mediate the harmful effects of modified lipoproteins ((55;56); Fig 1a and b, Appendix I). 
Other support in favor of a role for scavenger receptors in the harmful effects accomplished by 
oxidized LDL on β-cells could come from studies and observations performed on the glucagon-
producing α-cells. While the α- and β-cells share similar islet environmental cues, cultured α-
cells are, on the contrary, unable to uptake native LDL (57) and the expression of certain 
scavenger receptors such as SR-B1 and the LDL receptor is undetectable in these cells (Fig 1c, 
Appendix I). The notion that α-cells could be insensitive to toxic effects of oxLDL is further 
strengthened by the fact that hyperglucagonemia prevails with relative or absolute insulinopenia 
in plasma of patient with diabetes (93). 
 
Another finding of our study is the protective role played by HDL-cholesterol. In line with this, 
we demonstrated that HDL particles efficiently counteract harmful outcomes on insulin synthesis 
and β-cell survival caused by oxidized LDL. Anti-apoptotic features of HDL have also been 
described on starvation-, cytokines- and hyperglycemia-mediated β-cell death, as well as on 
macrophage apoptosis evoked by oxidized LDL (55;87;94). Beneficial properties of HDL 
encompass efflux of cholesterol and oxysterol, antioxidant activity, oxidized phospholipids 
detoxification and anti-inflammatory capacity. Thus, all these observations strengthen the idea 
that low plasma levels of HDL might indirectly participate to β-cell failure by two mechanisms. 
The first one is the inefficiency of low levels of HDL in diabetes to counteract the effects of 
oxidized LDL, high glucose levels and cytokines on pancreatic β-cells. The second is the possible 
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incrimination of diminished antioxidant activity of HDL in the generation of oxidized LDL. 
Hyperglycemia generates glycated LDL that are sensitive to oxidization. Therefore low levels of 
HDL could decrease antioxidant activity and thereby, favor oxidization of LDL in diabetes. In 
turn, the modified particles would be responsible for the progressive decline of β-cells and 
development of atherosclerosis (Fig 4).  
 
 
Fig 4: Deleterious effects of oxidized LDL and beneficial action of HDL in β-cell dysfunction and atherosclerosis 
 
 
Future studies are needed to clarify whether HDL particles can exert their protective effect 
through receptor-mediated entry into the cells and/or by antagonizing process of stressors. The 
capacity of HDL particles to decrease both basal and IL-1β-induced pancreatic β-cell apoptosis 
supports the possible implication of these two mechanisms in HDL protection (87). 
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B Oxidative stress and ICER: two major players in β-cell dysfunction 
Oxidized LDL have negative incidences on β-cells. Consequently, this prompted us to seek the 
molecular mechanisms involved. Activation of the JNK pathway has often been associated with 
the dysfunction of β-cells evoked by diabetic environmental factors, such as chronic 
hyperglycemia, elevated FFA and pro-inflammatory cytokines (78;95;96). Furthermore, modified 
lipoproteins trigger JNK pathway and AP-1 transcriptional activity in other cell types, ensuing in 
cellular apoptosis (81). The transcription factor c-Jun which constitutes part of the AP-1 
complex, is activated by JNK and mediates the adverse effects of this signaling cascade on 
insulin expression and β-cell survival (97). In synergy with the activation of c-Jun, the decrease 
in the transcriptional activity of PDX-1 caused by the JNK pathway mediates loss of β-cell tasks 
in the face of chronic hyperglycemia (77). Induction of the JNK pathway elicits the export of the 
PDX-1 nuclear factor to cytosol and thereby, induces loss of insulin expression and cell survival 
(77). For these reasons, we therefore hypothesized a potential role for JNK pathway in the 
progression of β-cell dysfunction secondary to oxidized lipoproteins exposure. In agreement with 
this assumption we found an increase in JNK activity and c-Jun levels in β-cells cultured with 
oxidized LDL. The implication of this pathway in the alteration of β-cell function was illustrated 
by the restoration of insulin synthesis and cell survival by the JNK inhibitor peptide JNKi. We 
also found that the long-term JNK activity is inversely correlated with the expression of the JNK-
interacting protein IB1. IB1 is an important negative regulator of JNK activity and is required for 
proper biosynthesis of insulin and β-cell survival (78;79). We speculate that the reduction in IB1 
content permits the sustained induction of the JNK pathway by modified lipoproteins, the 
impairment in insulin biosynthesis and the initiation of programmed cell death. On the other 
hand, IB1 is not involved in the rapid activation of this signaling cascade, since the expression 
level of this protein is not affected after 45 minutes of exposure to oxidized LDL. This result 
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suggests that another process regulates the short-term triggering of JNK by modified lipoproteins. 
The mechanism accountable for the diminution in IB1 content is now elucidated and involves the 
transcriptional repressor ICER.  
 
The expression of ICER is induced in response to the major environmental stressors related to 
T2D, including chronic hyperglycemia, hyperlipidemia and pro-inflammatory cytokines ((71); 
Fig 2, Appendix I). ICER is a basic leucine zipper transcription factor that negatively regulates 
the expression of numerous genes containing CRE sequences within their promoter (60;98). The 
lack of a transactivation domain makes ICER playing as a passive transcriptional repressor (61). 
Induction of this negative transcription factor by diabetic stressors has been reported to 
participate to the deterioration in insulin biosynthesis and secretion, and initiation of β-cell death 
(72-74). Similarly, we hypothesize that the transcriptional repressor ICER drives the adverse 
outcomes of the modified lipoproteins on pancreatic β-cells. Several data of the present thesis 
support this assumption. First, we found an induction of ICER in β-cells chronically exposed to 
oxidized LDL which was associated with dysfunction of these cells. Secondly, the selective 
reduction in ICER content prevented the impairment in insulin biosynthesis and secretion, and 
cell survival evoked by modified LDL. 
 
On the one hand, the capacity of the transcriptional repressor ICER to inhibit the expression of 
the CRE-containing IB1 gene (Fig 6e, Appendix II) interferes with insulin production and β-cell 
survival. Indeed, reduction in IB1 content has been shown in this thesis to contribute to the loss 
of insulin biosynthesis and cell survival evoked by oxLDL. In addition, ICER could directly 
repress the transcription of insulin, owing to the presence of a CRE sequence in the promoter of 
this hormone (99). On the other hand, the sustained activation of ICER drives defects in glucose-
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induced insulin secretion elicited by chronic hyperglycemia (73). In this context, impaired insulin 
release is in part linked to drop in the expression of at least four key genes governing insulin 
exocytosis, the GTPases Rab3a, Rab27a and their effectors Slp4 and Noc2, respectively (73). 
Similarly we observed a reduction in the levels of these four exocytotic genes in presence of 
oxidized LDL which was prevented by the deletion of the transcriptional repressor ICER. This 
illustrates the central role of the factor ICER in the insult of insulin secretion by various diabetic 
stressors. 
 
It is worth mentioning that beside their ability to stimulate the expression of ICER, the majority 
of the environmental factors associated with T2D, such as elevated levels of glucose, FFA and 
cytokines, generate oxidative stress in pancreatic β-cells (43;48;100). Regarding oxidized LDL, 
many in vitro studies report production of ROS and oxidative stress in various cell types exposed 
to modified lipoproteins (81;101). Our data confirm the role of oxidative stress in the induction of 
ICER in pancreatic β-cells. First, oxidized lipoproteins triggered activation of the JNK pathway, a 
fact that represents a hallmark of oxidative stress (77). Second, incubation of β-cells with 
hydrogen peroxide, which directly generates oxidative stress, mimicked the effects of oxidized 
LDL and led to the induction of ICER. Last, modified lipoproteins markedly increased 
production of ROS in β-cells and the antioxidant NAC prevented the rise in ICER expression 
evoked by these particles. In endothelial and smooth muscle cells, oxidized LDL evoke 
production of ROS in a mechanism that involves some redox enzymes, such as NADPH oxidases 
(NOXs), endothelial nitric oxide synthase (eNOS) and complexes of the respiratory chain 
(102;103). Interestingly, in pancreatic β-cells, NOXs and enzymes of the electron transport chain 
have been reported to participate to the exacerbated production of ROS by diabetic stressors, such 
as high glucose, palmitate and cytokines (104;105). Future experiments are required to examine 
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the contribution of these enzymes in the generation of oxidative stress by oxidized LDL in β-
cells. 
 
Oxidative stress links oxidized LDL to induction in the expression of ICER. Under physiological 
conditions, the expression of this transcription factor is regulated by two mechanisms. The first 
one involves the transcriptional activators CREB. The alternative intronic promoter driving ICER 
transcription contains a cluster of four CRE elements, making this transcription factor a target 
gene of the CREB and CREM pathways (61). The hypothesis that increased CREB activity is 
involved in the induction of ICER provoked by oxLDL is unlikely because this activity is itself 
repressed by an elevated constitutive expression of the repressor. In addition, exposure of insulin-
secreting cells to hydrogen peroxide resulted in the up-regulation of ICER transcript in absence 
of an increase in CREB phosphorylation (Fig 3a, Appendix I). The other mechanism that could 
participate to the augmented expression of ICER by the modified LDL engages the histone 
deacetylases (HDAC) activity. While HDAC promote inhibition of genes expression in most 
cases, they can stimulate transcription of certain genes, such as ICER. This positive regulation 
organized by HDAC requires the assembly of the preinitiation complex on ICER promoter, thus 
favoring the expression of the gene (106). Preliminary experiments performed in our laboratory 
suggest that oxidative stress promotes induction of the transcription factor ICER in a mechanism 
that necessitates HDAC activity. Elevation in ICER expression elicited by oxidative stress was 
completely blocked by the HDAC inhibitor trichostatin (Fig 3b, Appendix I). Further 
experiments are required to determine whether induction of ICER observed in cells challenged 
with most of diabetes stressors such as oxLDL, glucose, FFA and cytokines, correlates with an 
increase in HDAC activity.  The expression of ICER is normally transient. After reaching a 
certain level, ICER inhibits its own expression through the CRE contained within its promoter. 
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The persistent elevated expression of ICER in response to oxLDL also suggests that the 
inhibitory feedback loop is defective. The role of the HDAC activity on such dysregulation will 
also be investigated in the future. 
 
C A role for ICER in the sustained adipose CREB activity in obesity 
The critical role of ICER in β-cells has prompted us to investigate an implication of this repressor 
in other cell dysfunction involved in the pathogenesis of diabetes. A reduced expression of 
GLUT4 and adiponectin in adipocytes accounts for loss of insulin sensitivity. Mice lacking 
expression of one of these genes specifically in the adipocyte exhibit development of systemic 
insulin resistance (37;107). The expression of GLUT4 and adiponectin are regulated by the 
transcription factor ATF3, which is a target of the CREB factors. ATF3 reduces the expression of 
GLUT4 and adiponectin probably by acting as a transcriptional repressor within the promoter of 
these two genes (76). In adipocytes of insulin-resistant and obese mice, the CREB activity and 
the abundance of ATF3 are increased (76). For this reason, we suggested that loss of ICER 
expression could cause the increase in CREB activity and subsequent loss of adipose function. In 
line with this hypothesis, we observed that altered expression of ATF3, GLUT4 and adiponectin 
was associated with a decrease in the abundance of ICER in adipose tissues of obese human and 
mice. In vitro experiments further confirmed the regulation of ATF3 by ICER. Overexpression of 
ICER in adipocytes lowered the mRNA content of ATF3, and consequently elevated the 
expression of GLUT4 and adiponectin (Fig 4a, Appendix I). Conversely, reduction in the ICER 
content by RNA interference augmented the transcript and protein levels of ATF3, and 
subsequently decreased the expression of GLUT4 and adiponectin (Fig 4b, Appendix I). These 
data therefore support the following model; Reduction in ICER content in obese adipocytes could 
permit CREB to occupy the CRE element located in the promoter of the ATF3 gene. Induction of 
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this transcription factor would, in turn, silence the expression of the glucose transporter GLUT4 
and the insulin-sensitizer adiponectin. Future investigations will have to clarify the mechanism 
leading to impaired expression of ICER in obesity. Chronic hyperinsulinemia, pro-inflammatory 
cytokines and fatty acids contribute to defects in insulin signaling, glucose uptake and the 
expression of adipokines in adipocytes (14;23). Next experiments will be to determine whether 
these environmental stressors may diminish the expression of ICER.  
 
The CREB and CREM activators regulate the expression of ICER. Diminution in ICER level is 
expected to elicit an increase in the transcriptional activity of the CREB and CREM activators. 
Involvement of this mechanism in the defective expression of ICER seems therefore very 
unlikely. A role for HDAC activity in the dysregulation of ICER is rather assumed. In support of 
this hypothesis, we observed that inhibition of HDAC activity in adipocytes by trichostatin 
hampers the expression of ICER (Fig 5a, Appendix I). This result led us to quantify the overall 
activity of HDAC in adipose tissue of obese human and mice. Measurements revealed that defect 
in ICER content is associated with a major reduction in HDAC activity (Fig 5b, Appendix I). A 
mechanism for adipose dysregulation of ICER in obesity should therefore consider involvement 
of HDAC activity.  
 
Our work emphasizes that variations in the expression of ICER could contribute to pancreatic β-
cell and adipocyte dysfunction in a mechanism involving HDAC activity (Fig 5). We think that 
counteracting the dysregulation of ICER could be proposed as a therapeutic target to combat 
development of diabetes 
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Fig 5: Role of the transcriptional repressor ICER in the molecular pathogenesis of type 2 diabetes 
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Fig 1: Expression of scavenger receptors in pancreatic α- and β-cells
(a) CD36, LOX-1, SR-A, SR-B1, LDL-R and RPLP0 transcripts were amplified by PCR 
using cDNA that was prepared from MIN6, β-TC3 and RAW cells, and mouse small 
intestine and brain. (b) SR-B1 and CD36 proteins were detected in total protein prepared 
from MIN6 cells and mouse small intestine and liver by immunoblotting. (c) SR-B1, LDL-R
and RPLP0 transcripts were amplified by PCR using cDNA that was prepared from FACS-
purified mouse α-cells, MIN6, β-TC3 and RAW cells, and mouse brain. 
Fig 2: Role of oxidative stress in the activation of ICER by IL1-β
The mRNA level of ICER was quantified by quantitative real-time PCR using total RNA that 
was prepared from MIN6 cultured for 24h with 10ng/ml of IL-1β in the presence of vehicle 
(open bars) or NAC 1mM (filled bars). The mRNA levels were normalized against the Rplp0
and the expression level from cells cultured with control (CTL) was set to 100% (***, 
P<0.001; **, P<0.01).
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Fig 3: Role of histone deacetylase in the activation of ICER by oxidative stress
(a) Phosphorylated (P-CREB) and total CREB proteins were detected by immunoblotting in
total protein prepared from MIN6 cells treated for 0 to 120 min in presence of 150µM of 
hydrogen peroxide (H2O2) or 100µM IBMX and 10µM Forskolin (IBMX/FSK). (b) The 
mRNA level of ICER was quantified by quantitative real-time PCR using total RNA that was 
prepared from MIN6 cultured for 2h with 150µM of H2O2 in the presence of vehicle (open 
bars) or trichostatin 10nM (TSA: filled bars). The mRNA levels were normalized against the 
Rplp0 and the expression level from cells cultured with vehicle was set to 100% (***, 
P<0.001; **, P<0.01).
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Fig 4: Effect of ICER on GLUT4 and adiponectin expression
(a) The mRNA level of GLUT4 and adiponectin (Adipoq) were quantified by quantitative 
real-time PCR using total RNA that was prepared from 3T3-L1 adipocytes 4 days after 
electroporation with the empty vector (pcDNA3) or the plasmid coding for ICER .The mRNA 
levels were normalized against the Rplp0 and the expression level from cells electroporated
with pcDNA3 was set to 100% (***, P<0.001; **, P<0.01). (b) The mRNA level of GLUT4 
and adiponectin (Adipoq) were quantified by quantitative real-time PCR using total RNA 
that was prepared from 3T3-L1 fibroblastes 4 days after transfection with the control siRNA
(siGFP) or the siRNA specific for ICER (siICER). The mRNA levels were normalized 
against the Rplp0 and the expression level from cells transfected with siGFP was set to 
100% (***, P<0.001).
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Fig 5: Role of histone deacetylase in the loss of ICER in obesity
(a) The mRNA level of ICER was quantified by quantitative real-time PCR using total RNA 
that was prepared from 3T3-L1 adipocytes cultured for 6h with 100µM IBMX in the 
presence of vehicle (open bars) or TSA 10nM (filled bars). The mRNA levels were 
normalized against the Rplp0 and the expression level from cells cultured in control 
condition was set to 100% (***, P<0.001). (b) The total HDAC activity was quantified by 
ELISA using nuclear extracts prepared from white adipose tissue of control (CTL) and high 
fat diet-fed (obese) mice and visceral adipose tissue from lean (CTL) and obese human 
subjects. The HDAC activity levels were normalized against the protein content. (**, 
P<0.01; *, P<0.05).
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Exendin-4 Protects -Cells From Interleukin-1–Induced
Apoptosis by Interfering With the c-Jun NH2-Terminal
Kinase Pathway
Mourad Ferdaoussi,1,2 Saida Abdelli,1,2 Jiang-Yan Yang,2,3 Marion Cornu,3,4 Guy Niederhauser,1,2
Dimitri Favre,1,2 Christian Widmann,2,3 Romano Regazzi,2 Bernard Thorens,3,4 Ge´rard Waeber,1 and
Amar Abderrahmani1,2
OBJECTIVE—The pro-inflammatory cytokine interleukin-1
(IL-1) generates pancreatic -cells apoptosis mainly through
activation of the c-Jun NH2-terminal kinase (JNK) pathway. This
study was designed to investigate whether the long-acting ago-
nist of the hormone glucagon-like peptide 1 (GLP-1) receptor
exendin-4 (ex-4), which mediates protective effects against cyto-
kine-induced -cell apoptosis, could interfere with the JNK
pathway.
RESEARCH DESIGN AND METHODS—Isolated human, rat,
and mouse islets and the rat insulin-secreting INS-1E cells were
incubated with ex-4 in the presence or absence of IL-1. JNK
activity was assessed by solid-phase JNK kinase assay and
quantification of c-Jun expression. Cell apoptosis was deter-
mined by scoring cells displaying pycnotic nuclei.
RESULTS—Ex-4 inhibited induction of the JNK pathway elic-
ited by IL-1. This effect was mimicked with the use of cAMP-
raising agents isobutylmethylxanthine and forskolin and required
activation of the protein kinase A. Inhibition of the JNK pathway
by ex-4 or IBMX and forskolin was concomitant with a rise in the
levels of islet-brain 1 (IB1), a potent blocker of the stress-induced
JNK pathway. In fact, ex-4 as well as IBMX and forskolin induced
expression of IB1 at the promoter level through cAMP response
element binding transcription factor 1. Suppression of IB1 levels
with the use of RNA interference strategy impaired the protective
effects of ex-4 against apoptosis induced by IL-1.
CONCLUSIONS—The data establish the requirement of IB1 in
the protective action of ex-4 against apoptosis elicited by IL-1
and highlight the GLP-1 mimetics as new potent inhibitors of the
JNK signaling induced by cytokines. Diabetes 57:1205–1215,
2008
Type 2 diabetes is characterized by a progressivedecline in the number of insulin-producing-cells and/or their intrinsic ability to produceand/or secrete insulin. With the classical treat-
ment options of type 2 diabetes, a steady decline of -cell
function is observed, because none of the current treat-
ment is aimed at the amelioration of -cell deterioration.
Toward the long-term improvement of -cell mass, a new
class of hypoglycemic mimetic agents and analogs of the
glucoincretin glucagon-like peptide 1 (GLP-1) (1–5) offer a
promising feature for patients with type 2 diabetes.
The anti-apoptotic role of GLP-1 has been determined in
different -cell models. GLP-1 and its long-acting receptor
agonist, exendin-4 (ex-4) (6,7), increase the survival of
immortalized rodent -cell lines and purified rat -cells
when challenged with various pro-apoptotic stimuli, in-
cluding the pro-inflammatory cytokine interleukin-1 (IL-
1) (8–13). The latter is thought to be implicated in the
pathogenesis of type 2 diabetes. Increased levels of IL-1
and reduction in IL-1–receptor antagonist content have
been observed in pancreatic islets of patients with type 2
diabetes (14,15).
The GLP-1 promotes -cell survival by interaction with
GLP-1 receptor (GLP-1R), a member of the Gs-protein–
coupled receptor superfamily (16). The mice with homozy-
gous disruption for GLP-1R exhibit increased -cell
apoptosis in response to stress (12). Activation of GLP-1R,
in turn, elevates cAMP levels and activates the protein
kinase A (PKA) signal transduction system (9). PKA-
dependent phosphorylation of the cAMP response element
(CRE)-binding protein (CREB) stimulates the expression
of various genes required for insulin secretion and cell
survival (17,18). Disrupting CREB activity in islets causes
-cell apoptosis and diabetes in mice (18). Among the
targets of CREB important for cell survival is the insulin
receptor substrate 2 (18). The latter promotes islet-cell
survival by mediating phosphorylation of Akt, also known
as protein kinase B (PKB), in response to insulin and IGF-I
signaling (19). The blockade of the PKB signaling partly
prevents the protective effects of GLP-1 against cytokine-
induced apoptosis (11).
Activation of the c-Jun NH2-terminal kinase (JNK) path-
way, a class of mitogen-activated protein kinases (MAPKs)
also known as MAPK8, contribute largely to apoptosis of
-cells exposed to a stressful environment, such as cyto-
From the 1Service of Internal Medicine, Centre Hospitalier Universitaire
Vaudois and University of Lausanne, Lausanne, Switzerland; the 2Department
of Cellular Biology and Morphology, University of Lausanne, Lausanne,
Switzerland; the 3Department of Physiology, University of Lausanne, Lau-
sanne, Switzerland; and the 4Center for Integrative Genomics, University of
Lausanne, Lausanne, Switzerland.
Corresponding author: Dr. Amar Abderrahmani, Privat-Docent, Department
of Cellular Biology and Morphology, Rue du Bugnon 9, 1005 Lausanne,
Switzerland. E-mail: amar.abderrahmani@unil.ch.
Received for publication 29 August 2007 and accepted in revised form 30
January 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 5 Febru-
ary 2008. DOI: 10.2337/db07-1214.
ChIP, chromatin immunoprecipitation; CRE, cAMP response element;
CREB, CRE–binding protein; EMSA, electromobility shift assay; ex-4,
exendin-4; GFP, green fluorescent protein; GLP-1, glucagon-like peptide 1;
GLP-1R, GLP-1 receptor; GST, glutathione S-transferase; HES-1, hairy and
enhancer of split-1; IB1, islet-brain 1; IBMX, isobutylmethylxanthine; ICER,
inducible cAMP early repressor; IL, interleukin; JBD, c-Jun NH2-terminal
kinase binding domain; JNK, c-Jun NH2-terminal kinase; JNKi, JBD of IB1;
MAPK, mitogen-activated protein kinase; PI 3-kinase, phosphatidylinositol
3-kinase; PKA, protein kinase A; PKB, protein kinase B; RNAi, RNA interfer-
ence; shIB1, target-specific shRNA directed against IB1; shRNA, short hairpin
RNA; siRNA, small interfering RNA.
© 2008 by the American Diabetes Association.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
DIABETES, VOL. 57, MAY 2008 1205
kines (20). In most cases, activation of the JNK pathway is
favored by the decline in expression of islet-brain 1/JNK-
interacting protein 1 (IB1, now known as MAPK8 interact-
ing protein 1), a scaffold protein that tethers components
of the JNK pathway (21,22). The involvement of IB1 in the
control of JNK activity and -cell apoptosis is now well
documented. A missense mutation (S59N) in the gene
encoding IB1 (23) has been found in a French family with
type 2 diabetes (23). Ex vivo, this mutation reduces the
stability of IB1 leading to acceleration of the rate of cell
apoptosis (23,24). Reduction in IB1 levels with the use of
an adenovirus-mediated antisense cDNA leads to a con-
comitant increase in JNK activity and apoptotic rate (25).
In contrast, overexpression of IB1 prevents IL-1–medi-
ated activation of JNK and renders the cells more resistant
to apoptosis (25). IB1 interacts with JNK through JNK
binding domain (JBD) (26,27). The delivery of a derivative
peptide of the JBD linked to a HIV TAT is able to block
JNK activation and fully protect -cells against apoptosis
induced by cytokines and oxidized LDL (21,26).
In this report, we demonstrate that ex-4 inhibits IL-1–
induced JNK signaling by stimulating the IB1 expression at
the transcriptional levels. Suppressing the levels of IB1
with the use of RNA interference (RNAi) prevented the
protective effects of ex-4 on -cell apoptosis elicited by
IL-1. We provide evidence that the anti-apoptotic action
of ex-4 against IL-1–induced apoptosis involves inhibition
of the JNK pathway.
RESEARCH DESIGN AND METHODS
Cell culture and preparation of pancreatic islets. Isolated human islets
were from the Cell Isolation and Transplantation Center (islets for research
distribution program) of the Geneva University Hospital. Islets were cultured
in CMRL-1066 supplemented with 10% fetal bovine serum (Mediatech, Hern-
don, VA) in 5% CO2 humidified atmosphere at 37°C. The rat insulin-secreting
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FIG. 1. Inhibition of IL-1–induced phosphorylation and expression of c-Jun by ex-4. A: Effects of ex-4 on c-Jun phosphorylation. INS-1E cells
were pretreated with ex-4 at indicated concentrations for 8 h. Thereafter the cells were exposed to 10 ng/ml IL-1 for 16 h. Solid-phase JNK
assays were performed with the whole-cell lysates using GST–c-Jun as substrate. The reaction was loaded on a polyacrylamide gel, and -33P
phosphorylation of the substrates (P-c-Jun) was subsequently analyzed. The gel was stained with Coomassie blue to evaluate the loading of
substrate (GST-Jun). The corresponding quantitation is depicted below the blots. The values correspond to the ratio in band intensities of
phospho–c-Jun (P-c-Jun) over GST–c-Jun. Data are the means  SE of four independent experiments. *P < 0.05; ***P < 0.001. The mRNA levels
of c-Jun was quantified in INS-1E cells (B) and isolated rat islets (C) treated with ex-4 at indicated concentrations (or 100 nmol/l when not
indicated) for 8 h followed by incubation with IL-1 for 16 h. The levels were normalized against L10E, and those of the untreated cells (Ctrl)
were set to 100%. Data are the means  SE of five independent experiments. *P < 0.05; ***P < 0.001. D: Effects of the PKA and PI 3-kinase/PKB
inhibitors on the c-Jun expression. Total RNA was prepared from INS-1E cells that were cocultured with ex-4 (100 nmol/l) and IL-1 (10 ng/ml)
in the presence of 10 nmol/l wortmannin (Wort) or 10 mol/l H89. The expression of c-Jun mRNA was measured by real-time PCR and normalized
against the housekeeping acidic ribosomal phosphoprotein P0 gene (L10E) gene. Data are the means SE of five independent experiments. **P<
0.01, ***P < 0.001.
PROTECTIVE EFFECTS OF Ex-4 REQUIRE IB1
1206 DIABETES, VOL. 57, MAY 2008
cell line INS-1E was cultured as previously described (28). Rat and mouse
islets were isolated by hand-picking after collagenase digestion of pancreas as
described previously (29) and were maintained overnight in RPMI-1640
supplemented with 10% FCS, 10 mmol/l HEPES, pH 7.4, 1 mmol/l sodium
pyruvate, 100 units/ml penicillin-streptomycin, 50 mol/l -mercaptoethanol,
and 11 mmol/l glucose.
Western blotting. The cells were scrapped into the PBS and lysed using a
passive lysis buffer (Promega). The cell protein extracts (20 g) were
separated on 10% SDS–polyacrylamide gel and electrically blotted to nitrocel-
lulose membrane. The proteins were detected using a buffer containing 0.1%
Tween 20 and 5% milk and incubated overnight at 4°C specific with primary
antibodies (mouse IB1 antibodies [BD Transduction Laboratories] or mouse
-tubulin antibodies [Sigma]) and were visualized with IRDye 800 (Rockland)
as secondary antibodies and quantified in an Odyssey Infrared Imaging System
(Li-Cor). For quantification of IB1, we took the sum of the two band intensities
and normalized against -tubulin intensity.
Quantitative PCR. Total RNA was extracted using Aurum Total RNA mini kit
(Bio-Rad) according to the manufacturer’s protocol. The reverse transcription
reaction was performed as previously described (30). Real-time quantitative
PCR assays were carried out on the Bio-Rad MyiQ Real-Time PCR Detection
System using iQ SyBr Green Supermix (Bio-Rad) as the amplification system
with 100 nmol/l primers and 1.5 l template (RT product) in 20-l PCR volume
and annealing temperature of 59°C. Primers sequences were as follows. Rat
and mouse ib1: forward, 5-ATGTCTTCATGAGTGGCCG-3, and reverse,
5-GATTTCAAGGACACAGCTGG-3; human IB1: forward, 5-ATCAGCCTG
GAGTTTGA-3, and reverse, 5-AGGTCCATCTGCAGCATCTC-3; L10E (60S
acidic ribosomal protein P0): forward, 5-ACCTCCTTCTTCCAGGCTTT-3,
and reverse, 5-ACCTCTTTCTTCCAAGCTTT-3; and rat c-Jun: forward, 5-
AGT CTC AGG AGC GGA TCA AG-3, and reverse, 5-CTC TGT CGC AAC CAG
TCA AG-3.
Promoter analysis, plasmids, and short hairpin RNA and small inter-
fering RNA construction. The regulatory regions and promoter analysis of
the human MAPK8IP1 gene were subjected to a computer-assisted search
(http://genomatix.de). To design target-specific short hairpin RNA (shRNA)
directed against IB1 (shIB1), we selected sequences of the type AA(N19) (N,
any nucleotide) from the coding sequence of the rat IB1 mRNA. The selected
small interfering RNA (siRNA) sequence was also submitted to BLAST search
to ensure that it was specific to the target mRNA. Oligonucleotides contained
both the 19-nucleotide sense and 19-nucleotide antisense strands separated
with a short spacer from the reverse complement of the same sequence and
five thymidines as termination signal. The primers used were the following:
sense, 5-GATCCCC CAGCGACTGGATTGACCAG TTCAAGAGA CTGGTCAA
TCCAGTCGCTG TTTTTGGAAA-3, and antisense, 5-AGCTTTTCCAAAAA
CAGCGACTGGATTGACCAG TCTCTTGAA CTGGTCAATCCAGTCGCTG
GGG-3. The complementary target sequences of IB1 and thymidines are
underlined and in bold, respectively. These primers are hybridized and ligated
downstream of the H1-RNA promoter by HindIII/BglII sites of the pSUPER
vector (31). A 19-nucleotide prevalidated siRNA duplex (siIB1) that corre-
sponds to the shIB1 sequence was designed as recommended and was
chemically synthesized by Mycrosynth (Balgach, Switzerland).
Transfection and luciferase assays. The INS-1E cells (105) plated in 24-well
dishes were transiently transfected using Effectene transfection reagent
(Qiagen). After transfection (24 h), the cells were incubated with fresh
medium supplemented or not with 10 mol/l forskolin and 100 mol/l
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FIG. 2. Ex-4 stimulates the expression of IB1. Effects of ex-4 on the levels of IB1 in INS-1E cells exposed to ex-4 used at 100 nmol/l concentration
at indicated times (A), at different indicated concentration for 12 h (B) and in isolated rat islets cultured with 100 nmol/l ex-4 (C) or INS-1E cell
incubated with ex-4 plus 10 ng/ml IL-1 for 16 h (D). The levels of IB1 were assessed by Western blotting. The corresponding quantitation is
depicted below the blots. The values correspond to the ratio in band intensities of IB1 over -tubulin. Data are the means  SE of four
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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isobutylmethylxanthine (IBMX) for 16 h. Then the cells were washed with PBS
and lysed using passive lysis buffer (Promega). Luciferase activities were
measured with 25-l protein extracts solution using the Dual-Luciferase
reporter assay system (Promega). The siRNA duplex was introduced using the
lipofectamine 2000 (Invitrogen) exactly as described by the manufacturer’s
protocol.
Electromobility shift assay. Nuclear protein extracts from the cells were
prepared exactly as described previously (32). The electromobility shift assay
(EMSA) procedure was conducted exactly as previously reported (30). The
sequences of oligonucleotides used are as follows. CreIB1: forward, 5-
TGTGTTACGTTACATT-3, and reverse, 5-AATGTAACGTAACACA-3; CreL2:
forward, 5-GCTCTGAAGTCACTAA-3, and reverse, TTAGTGACTTCAGAGC-
3; CreL3: forward, 5-CCACTGACATCCTCTC-3, and reverse, 5-GAGAGGAT
GTCAGTGG-3; and CreCons: forward, 5-GGACGTAGTCTGACGTCAGCGGA-
3, and reverse, 5-CATCAGACTGCAGTCGCCTCCGA-3. The sequences for
specificity protein-1 (Sp-1) and neuron restrictive silencer element (NRSE)
were those previously described (30).
Protein kinase assay. The preparation of whole-cell protein extracts and the
kinase assays were conducted as previously described (21). Briefly, cell
extracts were incubated for 1 h at room temperature with 1 g glutathione
S-transferase (GST)-Jun (amino acids 1–89) and 10 l glutathione-agarose
beads (Sigma-Aldrich, St-Gallen, Switzerland). Phosphorylation of substrate
proteins was examined after overnight exposure of polyacrylamide gels to
autoradiography; gel quantifications were accomplished by Phosphor-Imager
analysis (Molecular Imager FX; Bio-Rad Laboratories, Basel, Switzerland).
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP)
assays were conducted exactly as previously described (33) with the following
modifications. The anti-CREB1 and anti-CREB2 antibodies were used for
immunoprecipitation. After the reverse cross-linkage, the DNA was precipi-
tated by phenol-chloroform extraction method. Next, we performed the
quantitative PCR to measure the enrichment of CreIB1 sequence by amplifying
5 l DNA using the followings primers: forward, 5-AGGTCTGCAGGGTTT
GTCAT-3, and reverse, 5-CTGTGGTCTGCTGGGGTTAT-3. Amplification of
the sytl4 promoter was used as an internal control: the primers used were
forward, 5-TGGGGGAGGGTATGGTAAAT-3, and reverse, 5-CCTTCTAG
CACTCTGGAAGCA-3.
Apoptosis assay. Apoptosis was determined by scoring cells displaying
pycnotic nuclei visualized with Hoechst 33342 (Invitrogen, Basel, Switzerland)
(21).
B
I/F (hrs) 
IB1
βtubulin
0 2 4 12 16
A
0
0.02
0.04
0.06
0.08
IB
1/
βtu
bu
lin
 (
A
rb
itr
ar
y 
U
ni
t)
**
***
***
c-
Ju
n
m
R
N
A
 le
ve
ls
/L
10
E
(%
 o
f C
tr
l)
0
100
200
300
***
I/F
IL-1β +-
-- +
+
FIG. 3. The effects of ex-4 on IB1 expression is mimicked by cAMP-
raising agents. A: INS-1E cells were cultured with 10 mol/l forskolin
and 100 mol/l IBMX (I/F) at the indicated times. The expression of
IB1 was analyzed by Western blotting. The corresponding quantitation
is depicted below the blots. The values correspond to the ratio in band
intensities of IB1 over -tubulin. Data are the means  SE of four
independent experiments. **P < 0.01, ***P < 0.001. B: The expression
of c-Jun was quantified in isolated rat islets treated with IBMX and
forskolin and IL-1 for 16 h. The levels were normalized against L10E.
Data are the means  SE of five independent experiments. ***P <
0.001.
-
I/F (16h)
IB1
βtubulin
H89 Wort-
0
0.02
0.04
0.06
IB
1/
tu
bu
lin
(A
rb
itr
ar
y 
U
ni
t) *** ***
IB
1/
βtu
bu
lin
 (
A
rb
itr
ar
y 
U
ni
t)
P-PKB
A
-
ex-4 (12h)
H89 Wort-
0
0.02
0.04
0.06 * *
B
IB1
βtubulin
FIG. 4. Effects of the PKA and PI 3-kinase/PKB inhibitors on the IB1
expression. Western blotting analyses were performed to quantify the
IB1 contents of INS-1E cells treated with IBMX and forskolin for 16 h
(A) and ex-4 for 12 h (B), including 10 nmol/l wortmannin or 10 mol/l
H89, PI 3-kinase, and PKA inhibitors, respectively. Immunoblotting
against phospho-PKB (P-PKB) was done to control the inhibitory effect
of wortmaninn on the ex-4–stimulated PKB activation. The results are
representative of three independent experiments. The corresponding
quantitation is depicted below the blots. The values correspond to the
ratio in band intensities of IB1 over -tubulin. Data are the means SE
of four independent experiments. *P < 0.05; ***P < 0.001.
PROTECTIVE EFFECTS OF Ex-4 REQUIRE IB1
1208 DIABETES, VOL. 57, MAY 2008
Data analysis. Data are shown as means  SE. Statistical significance of
differences was calculated either by ANOVA or two-tailed t test for single
comparisons.
RESULTS
Ex-4 interferes with IL-1–mediated JNK signaling
by modulating the expression of IB1. Exposure of
-cells to IL-1 mediates activation of JNK, which in turn
induces phosphorylation of its target transcription factor
c-Jun (26). This is observable between 1 to 16 h after
incubation with IL-1 (22). To determine whether ex-4
could interfere with the JNK pathway, INS-1E cells were
pretreated with ex-4 or the vehicle for 8 h, and thereafter,
the cells were incubated with IL-1 for 16 h. Whole protein
was then extracted from treated cells and incubated with
the c-Jun recombinant. As expected, in vitro kinase assays
showed an increase in c-Jun phosphorylation with extracts
of cells incubated with IL-1 for 16 h (Fig. 1A). To validate
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FIG. 5. Transcriptional regulation of IB1 by
the cAMP/PKA pathway. Analysis of represen-
tative IB1 mRNA levels by real-time PCR from
INS-1E () and rat isolated islets (u) (A) and
human isolated islets (f) (B) incubated with
either ex-4 or 10 mol/l forskolin and 100
mol/l IBMX (I/F) for 16 h. The values ob-
tained in untreated cells were normalized to
100%. The results are the means  SE of three
independent experiments performed in tripli-
cate. **P< 0.01. C: Effects of actinomycin D on
IBMX- and forskolin-stimulated IB1 expres-
sion. INS-1E cells were incubated with IBMX
and forskolin for 8 h in the presence or ab-
sence of 5 g/ml actinomycin D. **P < 0.01. D:
Assessment of IB1 transcriptional activity in
INS-1E cells cultured with IBMX and forskolin
and ex-4. The cells were transiently trans-
fected with a luciferase reporter construct
driven by the 731-bp fragment of the human
MAPK8IP1 promoter (IB1luc). The cells were
exposed to IBMX and forskolin or ex-4 for 16 h
before measuring the luciferase activity. The
data are the means  SE of three independent
experiments. ***P < 0.001. RLU, relative light
units. E: Effect of the PKA inhibitor H89 on the
promoter activity of IB1. INS-1E cells were
transiently transfected with the IB1luc con-
struct and then incubated 24 h later after
transfection with either IBMX and forskolin or
ex-4 for plus or minus the PKA inhibitor H89
(10 mol/l) or wortmannin for 16 h. All results
from transfection experiments are the
means  SE of three independent experiments
performed in triplicate. ***P < 0.001.
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activation of the JNK signaling cascade by IL-1, expres-
sion of the c-Jun gene was then quantified. The transcrip-
tional activity of the promoter of this gene is positively
regulated by JNK (21). Real-time PCR analysis showed a
statistically significant augmentation by two- and threefold
in c-Jun mRNA in INS-1E and rat isolated islet cells,
respectively, cultured with IL-1 for 16 h (Fig. 1B and C).
Both phosphorylation of c-Jun and its expression induced
by IL-1 were efficiently diminished by ex-4 (Fig. 1A–C).
The effect of ex-4 started at 10 nmol/l, but the maximum
efficiency was obtained with 50–100 nmol/l concentration
(Fig. 1A and B). To determine the pathways by which ex-4
inhibits the JNK signaling, INS-1E cells were co-incubated
with wortmannin or H89, two pharmacological inhibitors
of the phosphatidylinositol 3-kinase (PI 3-kinase)/PKB and
PKA pathways, respectively. Quantitative PCR showed
that inhibition of the PI 3-kinase/PKB signaling did not
counteract the inhibitory effects of Ex-4 on the c-jun
expression induced by IL-1 (Fig. 1D). In contrast, treat-
ment of the cells with H89 prevented the inhibitory effects
of ex-4 (Fig. 1D), indicating the requirement of the PKA
activity for inhibition of the JNK signaling achieved in
response to ex-4.
The scaffold protein IB1 has been described as a direct
regulator of the JNK signaling. Overexpressing IB1 or its
JNK-binding domain in -cells prevents activation of c-Jun
stimulated by IL-1 (25,26,34). We then assessed the
possibility that ex-4 might modulate the levels of IB1 to
block JNK-mediated activation of c-Jun. Western blotting
experiments showed higher levels in IB1 contents in
INS-1E cells incubated with 100 nmol/l ex-4 (Fig. 2A).
The rise in IB1 protein levels elicited by ex-4 occurred in
a time-dependent manner reaching a peak at 12–16 h
(Fig. 2A) and was confirmed in isolated pancreatic islets
from rat (Fig. 2C). Induction in the IB1 levels was
observable with 10 nmol/l ex-4 but was further elevated
with 100 nmol/l ex-4 for 12 h (Fig. 2B). In line with
previous reports (22,34), we found that activation of the
JNK signaling by IL-1 was associated with a reduction
in the IB1 contents (Fig. 2D). Western blotting experi-
ments showed that ex-4 efficiently counteracted the
diminution of IB1 elicited by IL-1 (Fig. 2D). Taken
together, these results indicate that ex-4 prevents activ-
ity of JNK by increasing the IB1 levels.
Ex-4 stimulates the expression of IB1 in a transcrip-
tional mechanism requiring the PKA and CREB1
transcription factor. In view of the findings described
above, we sought for a mechanistic explanation of the
augmentation of IB1 elicited by ex-4. Because the latter
regulates the expression of many genes through the cAMP/
PKA pathway, we assessed whether the effect of ex-4
could be mimicked with cAMP-raising agents. Exposure of
INS-1E cells with forskolin and IBMX led to an increase in
IB1 protein levels (Fig. 3A). The increase in IB1 expression
was apparent after a 2-h incubation and was maximal after
12–16 h (Fig. 3A). This result was consistent with an effect
of IBMX and forskolin on JNK activity. Treatment of the
isolated rat islets with IBMX and forskolin prevented
induction of c-jun mRNA mediated by IL-1 (Fig. 3B).
Incubation of INS-1E cells with H89 abolished the action
of ex-4 and IBMX and forskolin on the IB1 expression,
confirming that the effect of ex-4 involves the cAMP/PKA
pathway (Fig. 4A and B). Induction in the IB1 levels
evoked by ex4 was however unaltered in the cells co-
treated with the PI 3-kinase/PKB pathway inhibitor wort-
mannin (Fig. 4B).
We then explored whether ex-4 modulates IB1 content
by enhancing mRNA levels. Real-time PCR analysis
showed an increase in IB1 mRNA in INS-1E and in isolated
pancreatic islets cells from rat and human cultured for
12 h with ex-4 or IBMX and forskolin (Fig. 5A and B).
Treatment of INS-1E cells with actinomycin D, a RNA
synthesis inhibitor, prevented IBMX- and forskolin-medi-
ated induction of IB1 (Fig. 5C), suggesting an effect of the
cAMP pathway on IB1 at the transcriptional level. To test
this hypothesis, a 731-bp fragment of the human IB1
proximal promoter linked to a luciferase gene reporter
(IB1luc) (35) was transfected in INS-1E cells. A high
luciferase activity from the IB1luc construct was detected
in INS-1E cells as previously described (35). We found that
incubation of the cells with IBMX and forskolin or ex-4
generated a twofold increase in the transcriptional activity
of the IB1 promoter (Fig. 5D). To determine whether the
transcriptional induction of IB1 requires the PKA activity,
INS-1E cells were transfected with IB1luc and were
treated with IBMX and forskolin plus or minus the H89 or
wortmannin. Addition of the PKA inhibitor significantly
diminished stimulation of the IB1 promoter activity medi-
ated by IBMX and forskolin or ex-4 (Fig. 5E). Inspection of
the human promoter revealed the presence of a CRE
(CreIB1), which is homologous to the consensus sequence
and conserved between rat and mouse (Table 1). EMSAs
were performed to validate the ability of the CreIB1
sequence to interact with the CREB transcription factors.
The CreIB1 sequence was used as the labeled probe and
incubated with nuclear extracts of INS-1E cells treated
with IBMX and forskolin for 16 h. The binding pattern
obtained was efficiently competed using a 100-fold excess
of the unlabeled CreIB1 and the consensus oligonucleotide
(Fig. 6A). Neither the cold sequences of the IB1 promoter
similar to the CreIB1 sequence (CreL2 and CreL3) nor the
unrelated sequences, including Sp-1 and NRSE, were able
to compete with the binding activity of CreIB1, confirming
the high specificity of the probe/protein interaction (Fig.
6A). Preincubation of nuclear protein extracts with anti-
bodies that recognize CREB1 or CREB2 factors resulted in
a disruption of the CreIB1 pattern only with the CREB1
but not with the CREB2 or hairy and enhancer of split-1
(HES-1) antibodies (negative control) (Fig. 6B). After a
rise in cAMP concentration, CREB transcription factors
are rapidly phosphorylated by PKA (36). Phosphorylation
of CREB increases the ability of the factors to bind to the
target element, thereby converting CREB to a powerful
activator (37). In line with the induction of the CREB
binding activity, we observed an increase in the intensity
of the CreIB1 binding pattern in cells cultured with IBMX
and forskolin or ex-4 for 12 h (Fig. 6C). ChIP followed by
real-time PCR experiments confirmed the in vivo interac-
tion of CREB1 to the endogenous IB1 promoter in insulin-
secreting cells. Enrichment of the PCR product for IB1
TABLE 1
The promoter of IB1 contains a Cre
Species Sequences
Consensus TGACGTCA
CreIB1 Human TTGTGTTACGTTACATTC
Rat GGCTCTGACGTTAGGCA
Mouse CTTTTTTACCTCATCTTG
The sequence was obtained by combining the consensus sequences.
The putative binding elements identified in the promoters are shown
in bold.
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FIG. 6. CREB1 binds to the CRE ele-
ment within the promoter of IB1. A:
Nuclear extracts of INS-1E cells treated
with 10 mol/l forskolin and 100 mol/l
IBMX (I/F) were incubated with the
radioactive probe containing the CreIB1
sequence. In the first lane, the nuclear
extracts were omitted. Where indicated,
the incubation was performed in the
presence of 100-molar excess of unla-
beled oligonucleotides corresponding
to the CRE sequence of the human IB1
promoter (CreIB1), of the Cre consen-
sus sequence (CreCons), or of the two
Cre-like sequences found within the IB1
promoter (CreL2 and CreL3). In the
last two lanes, competition was per-
formed with the binding sequences for
the Sp-1 and RE-1 transcription factors
(NRSE). The radioactive complexes
were analyzed by electrophoresis and
visualized by autoradiography. The po-
sitions of the CREB complex and of the
unbound probe are indicated. B: Before
the addition of the labeled oligonucleo-
tide, the nuclear extracts from INS-1E
cells were preincubated with antibodies
recognizing CREB1 (anti-CREB1), CREB2
(anti-CREB2), and the unrelated factor
HES-1 (anti-HES-1) as negative control.
The positions of CREB1 and of the un-
bound CRE probe are indicated. C:
EMSA was performed with nuclear ex-
tracts from INS-1E cells treated with
IBMX and forskolin or ex-4 for 16 and
12 h, respectively. The results are rep-
resentative of three independent exper-
iments. D: Occupancy of the promoter
of IB1 by CREB1. Formaldehyde cross-
linked chromatin samples from INS-1E
cells incubated with or without IBMX
and forskolin or ex-4 were used for
immunoprecipitation reaction with anti-
CREB1,anti-CREB2andanti-HES-1anti-
bodies as a negative control. As a
control of PCR, DNA aliquots from pre-
immunoprecipitated samples were used
(data not shown). DNA was analyzed by
PCR with specific primers correspond-
ing to IB1. Amplification of the pro-
moter region of sytl4 that do not bind
the CREB factors was used as negative
and internal controls. The data ob-
tained in untreated cells were normal-
ized to 100%. ***P < 0.001. E: INS-1E
cells were transiently transfected with
the promoterless vector pGL3 basic (ba-
sic) () or IB1luc (u). These plasmids
were cotransfected either with an
empty vector or with a plasmid leading
to the overexpression of ICER-. Lucif-
erase activities were measured 2 days
later. The data are expressed as fold
increase over the pGL3basic vector and
are the means  SE of three indepen-
dent experiments. ***P < 0.001.
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promoter was only detected with the use of immunopre-
cipitated DNA with the CREB1 antibody from the cells
exposed to IBMX and forskolin or ex-4 (Fig. 6D). As
observed in Fig. 6B, CREB2 did not associate with IB1
promoter (Fig. 6D). If CREB1 regulates the activity of the
IB1 promoter, the transcriptional activity of IB1luc con-
struct should be silenced by the inducible cAMP early
repressor (ICER). ICER is a member of the CRE modula-
tor family of basic leucine zipper transcription factors that
is thought to serve as a dominant-negative repressor of
cAMP-dependent gene expression (38). Overexpression of
ICER-I (28) reduced the basal and the IBMX and forsko-
lin- or ex-4–stimulated promoter activity of IB1luc (Fig.
6E). In summary, these data reveal that ex-4 upregulates
the expression of IB1 at the promoter levels in a mecha-
nism involving the PKA and the CREB1 transcription
factor.
Silencing in IB1 expression prevents the protective
action of ex-4 against IL-1–induced apoptosis. IB1 is
an important component of pro-survival signaling pathway
in -cells. In this regard, we examined the possibility that
the protective effect of ex-4 on -cells might require IB1.
To test this hypothesis, we used a RNAi strategy to
selectively suppress the expression of IB1. First, we de-
signed a plasmid expressing a specific and efficient se-
quence shRNA directed against IB1. INS-1E cells were
then cotransfected with the HA-tagged IB1 (HA-IB1) and
the plasmid encoding the shIB1. The specificity of the
shRNA-IB1 was tested using a vector encoding HA-tagged
IB1 resistant to the siRNA (HA-IB1-Sir). Mutation was
introduced within the target sequence by changing one
nucleotide in each codon without affecting the primary
sequence of the amino acids. The shRNA-IB1 efficiently
reduced the expression of the exogenous HA-tagged IB1
(Fig. 7A). However neither the mutated IB1 construct, nor
the green fluorescent protein (GFP) (cotransiently ex-
pressed) had their expression modified in the presence of
the shRNA, confirming the specificity of the shRNA-IB1
(Fig. 7A). The effect of the siRNA on the endogenous levels
of IB1 was assessed with a duplex siRNA sequence (siIB1)
corresponding to the shIB1. Western blotting analysis of
extracts from transfected INS-1E cells revealed the effi-
ciency of the siIB1 to diminish the IB1 contents (Fig. 7B).
Reduction in the IB1 levels led to an increase in basal
c-Jun mRNA levels and potentiated the effects of IL-1
(Fig. 7C). However, ex-4 was unable to abolish induction
of c-Jun achieved by IL-1 (Fig. 7C). To establish the
involvement of IB1 in the anti-apoptotic action of ex-4, we
therefore measured the viability of INS-1E cells in which
IB1 was suppressed. As expected, incubation of the cells
with 10 ng/ml IL-1 for 48 h led to a twofold increase in the
rate of apoptosis, whereas the viability of the cells co-
incubated with ex-4 was unchanged compared with con-
trol (Fig. 7D). However, reduction in IB1 contents
potentiated IL-1–induced apoptosis and abolished the
anti-apoptotic action of ex-4, confirming the requirement
of IB1 in the mechanism of action of ex-4 (Fig. 7D).
DISCUSSION
The long-acting GLP-1R agonist ex-4 represents a new
available class of drugs for treatment of type 2 diabetes.
This disease is thought to occur when pancreatic -cells
fail to release sufficient insulin levels to compensate for
insulin resistance in target tissues. Morphometric studies
on postmortem pancreases of people with type 2 diabetes
provide convincing evidence that -cell mass is reduced,
thus explaining in part the -cell failure (39). Genetics and
changes in environmental factors contribute to the -cell
destruction over time. These changes include an increase
in concentration of IL-1, a pro-inflammatory cytokine
implicated in the pathogenesis of type 1 diabetes
(14,15,40). IL-1 has detrimental effects in -cells mainly
through activation of the JNK signaling, which lead to
increased phosphorylation and expression of its target
c-Jun (26,41). In line with this statement, we showed a rise
in JNK activity in the cells exposed to IL-1, which was
concomitant with increased -cells apoptosis. In vitro and
in vivo studies show that one of the major beneficial
properties of ex-4 is the enhancement of -cell mass at
least through inhibition of apoptosis (8–13). In support of
this function, we confirmed that pretreatment of the cells
with ex-4 for several hours completely prevented apopto-
sis induced by IL-1. Herein, we report that this effect of
ex-4 is associated with diminution in phosphorylation and
expression of c-Jun in isolated pancreatic islets and
INS-1E cells challenged with IL-1 for 16 h. Inhibition of
either the PKA or PI 3-kinase/PKB pathway, the two major
pathways through which ex-4 triggers its anti-apoptotic
effects, showed that only PKA is responsible for ex-4–
mediated blocking of the JNK signaling. Incubation of the
cells with IBMX and forskolin, two strong activators of the
cAMP/PKA pathway, mimicked the effects of ex-4 on the
c-Jun expression. Inhibition of PKB did not modulate
c-Jun expression, whereas the use of H89, a pharmacolog-
ical inhibitor of the PKA, also efficiently antagonized the
effects of IBMX and forskolin on the JNK activity. We and
others have previously shown that selective inhibition of
the JNK pathway using the TAT-linked peptide derived
from the JBD of IB1 (JNKi) reduces 50% of the -cells
apoptosis elicited by IL-1, indicating that activation of the
JNK pathway is one of the causes of IL-1–induced
apoptosis (41). In this report, we showed that the full
protection mediated by ex-4 against apoptosis provoked
by IL-1 was associated with an inhibition of the JNK
pathway. Treatment of -cells with a cocktail of cytokines
(IL-1, tumor necrosis factor-, and interferon-) also
leads to apoptosis through activation of JNK (11,42).
However, in that case, ex-4 only confers a partial protec-
tion against apoptosis (11). This situation therefore as-
sumes that inhibition of the JNK pathway is not sufficient
for ex-4 to completely achieve its protective effect. A
previous study reports that -cells challenged with IL-1
alone had unaltered PKB activation (43) whereas phos-
phorylation of PKB is markedly reduced in response to
cytokines. In the latter condition, ex-4 fails to recover the
loss of PKB activation induced by cytokines (11). Thus it
can be assumed that both inhibition of the PKA-dependent
JNK signaling and adequate activation of PKB are needed
for ex-4 to exert a full cytoprotective effect of -cells
against the cocktail of cytokines.
IB1, a scaffold protein that tethers components of the
JNK pathway, is thought to facilitate the activation of JNK
in acute response to various stimuli (44). Data obtained
from different laboratories establish an important function
for IB1 in the control of -cell survival in response to
stressful stimuli. Decreased IB1 expression caused by
sustained exposure of -cells to IL-1 or cocktail of
cytokines, including IL-1, tumor necrosis factor-, and
interferon-, is systematically accompanied by an increase
in JNK-mediated phosphorylation of c-Jun (22,25,34). Con-
sistent with this, we found that reduction in IB1 expres-
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sion in the cells exposed to IL-1 was associated with
more phosphorylated c-Jun and apoptosis. In addition, the
latter phenotype was exacerbated in the cells where the
resting IB1 levels were silenced with the use of the RNAi
approach. Both apoptosis and the JNK activity can be
efficiently overcome by compensating the reduced levels
of IB1 in overexpressing IB1 or overloading -cells with a
JNKi (25,26,41). In this report, we show that the relative
recovering of the IB1 levels after treatment of the cells
with ex-4 for 12–16 h is also sufficient to reduce phosphor-
ylation/expression of c-Jun and to abolish apoptosis elic-
ited in response to IL-1.
The mechanism leading to restored IB1 levels was
deciphered. In fact, incubation of the cells with the PKA
inhibitor H89 prevented the stimulation of the IB1 expres-
sion levels achieved by ex-4. Our data showed that inhibi-
tion of PKB activation does not interfere with the capacity
of ex-4 to stimulate IB1 expression, indicating that PKB is
not required for the effects of ex-4 on the JNK signaling.
Using a combination of approaches, we demonstrated that
ex-4 compensates IL-1–mediated reduction of IB1 by
stimulating the promoter activity of IB1 through the
CREB1 transcription factor. The peak for IB1 induction
was reached at 16 h. After that time, IB1 expression
returned to the level comparable with that observed in
untreated cells (data not shown). This mechanism could
be attributed to the transcription factor ICER. After a
sustained stimulation of the cAMP/PKA pathway, the
transcriptional activation of the CREB factors is followed
by the activity of ICER, a powerful repressor that nega-
tively regulates expression of genes containing a CRE
element (21). In agreement with a regulation of IB1 by
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FIG. 7. Suppression of IB1 impairs the protective effects of ex-4. A: Inhibition of IB1 by RNAi. INS-1E cells were transiently cotransfected with
0.5 () and 1 g () of the plasmids coding shIB1 and wild-type or shRNA-resistant HA-tagged IB1 (HA-IB1 and HA-IB1-Sir, respectively) and
a plasmid coding the GFP as a control of transfection efficiency. Two days later, total protein was extracted and submitted to Western blotting
analysis. B: Inhibition of the endogenous expression of IB1 by a selected siRNA. INS-1E cells were transfected with the siRNA duplex directed
against IB1 (siIB1) or scrambled siRNA (Ctrl). Results on the graph below the blot correspond to the fold changes observed in Western blot band
intensities obtained from lysates of transfected cells with siRNAs. The values correspond to the ratio in band intensities of IB1 over -tubulin.
Data are the means  SE of four independent experiments. **P < 0.01; ***P < 0.001. C and D: Effects of the IB1 silencing in the expression of
c-Jun and apoptosis. INS-1E cells were transfected with siIB1 (f) or control siRNAs (). Thereafter, the cells were preincubated 24 h after
transfection with 100 nmol/l ex-4 for 8 h. The expression of c-Jun mRNA and rate of apoptosis were scored in ex-4–pretreated INS-1E cells
exposed to IL-1 for 16 and 48 h, respectively. The c-Jun levels were normalized against the L10E gene. Data are the means  SE of five
independent experiments. Each experiment was performed three times in triplicate. Results are expressed as means  SE of four independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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ICER, we found that overexpression of ICER-I efficiently
silenced the promoter activity of IB1. Suppression of IB1
expression by RNAi impaired the anti-apoptotic effect of
ex-4. These data provide evidence that IB1 plays a key role
in mediating the effect of ex-4 against apoptosis in a
JNK-dependent manner. According to these data, de-
fects in the GLP-1 signaling are expected to impair
induction of IB1. Interestingly mice with targeted dis-
ruption of the GLP-1R have reduction in pancreatic
-cells mass caused by increased stress-induced apopto-
sis (12). Low plasma levels in GLP-1 have been observed
in human type 2 diabetes (45). Therefore impaired
induction of IB1 could partly account for elevated -cell
apoptosis in diabetes.
Activation of the JNK signaling is partly responsible for
the loss of functional pancreatic islet -cell mass after
grafting. This loss of viability is caused by the pro-
inflammatory cytokines, including IL-1, and the islet
isolation procedure itself with a major loss occurring
shortly after the final purification steps (41,46–48). A
recent report shows that improvement of -cell viability is
associated with a decreased JNK activity both in cultured
rat and human isolated islets (46). Thus, direct inhibition
of the JNK signaling cascade has been proposed as a
strategy to improve the cell viability for transplantation
purpose (46). To this end, we believe that ex-4 or long-
acting analogs mimetics may be used as efficient available
therapeutic drugs. Like IL-1, prolonged exposure of
-cells to high glucose and nonesterified fatty acid con-
centration have devastating effects on -cells and thereby
participate in progression and development of type 2
diabetes. The mechanism responsible for -cell failure
include increased apoptosis that is associated with a rise
in JNK activity (21,49,50). Ex-4 can also protect -cells
against apoptosis provoked by elevated concentrations
of glucose and lipids (8). Thus it is possible that
cytoprotective action of ex-4 against chronic hypergly-
cemia and hyperlipidemia involves inhibition of the JNK
signaling.
This study highlights the potent inhibitory effect of
ex-4–cAMP–PKA system on the JNK activity as a major
mechanism for preventing -cell apoptosis induced by
IL-1. This mechanism largely contributes to the efficiency
of ex-4 and its mimetics analogs in the long-time preser-
vation of -cells against apoptosis in the treatment of type
2 diabetes.
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